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ABSTRACT
 5 Fluorouracil (5FU) chemotherapy is widely used in the treatment of colorectal 
cancer (CRC), and has been the first-choice chemotherapy drug for CRC for many years. 
However, nearly 10% of patients receiving chemotherapy die during the first 30 days of 
treatment. Further, it is estimated that 70% of surviving patients will develop non-specific 
toxicities as a result of chemotherapy treatment. We characterize these toxicities in an 
animal model of chemotherapy treatment and show that perturbations in the gut 
microbiome might be exacerbate the prolonged effects of chemotherapy. A compound 
that could attenuate the multiple non-selective toxicities associated with chemotherapy 
could have great clinical potential. Emodin is a trihydroxy-anthraquinone found in 
several Chinese herbs, including Rheum palmatum and Polygonum multiflorum. Emodin 
has been shown to attenuate the severity of multiple experimental disease models 
including arthritis, liver damage, atherosclerosis, myocardial ischemia, and cancer by 
reducing the inflammatory cascades associated with these conditions. We illustrate that 
emodin is poorly absorbed when given orally or intraperitoneally and is cleared from 
systemic circulation by 12 hours. However, we did discover that emodin is more 
bioavailable in female mice 1 hour after dosing. We also demonstrate that emodin is safe 
in mice when given through the diet for 3 months and does not cause any physiological or 
pathological perturbations. When pairing emodin with 5FU, we were able to attenuate 
functional toxicities associated with chemotherapy and ameliorate the lymphocytopenia 
associated with chronic and acute chemotherapy. Further, we demonstrate that emodin 
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can improve gut resilience to 5FU and reduce aberrations in bacterial spatial 
arrangement. In addition, we examined the ability for emodin to be used as a preventative 
treatment for colorectal and intestinal cancer. We show that emodin treatment reduces 
tumor burden in both the AOM/DSS and Apcmin/+ models of sporadic cancer 
development. In the AOM/DSS model we show that emodin reduces pro-tumorigenic 
M2-type macrophages in the colon. Further, we show that there is amelioration of the 
pro-inflammatory niche that exists in the bone marrow which might contribute to the 
improved survival outcome and quality of life during cancer treatment. The findings 
presented in this document show significant promise for the potential use of emodin as a 




The need for physician-scientists has never been greater. As the world enters the 
next industrial revolution, biomedicine will be at the forefront of the most unprecedented 
discoveries. With new medical technology and an evolving understanding of nature, so 
must come a new approach to medicine.  Chemically derived therapeutic interventions 
will be able to optimize physiological interactions to achieve the maximal result during 
treatment. The goal of this dissertation is to investigate the interaction between three 
characters in medical treatment; the inflammatory response, the gut microbiota, and the 
drug itself. Through the course of my work, I will demonstrate how all three of these 
components of medicine can interact to improve the efficacy, fine tune the 
pharmacokinetics, and reduce non-specific toxicity to idealize the personalized approach 
to medicine. While I know that I am not the only one to propose this approach to 
medicine, I hope these ideas will prove to be fruitful in the evolution of modern medicine 











Figure P1.1 The microbiota-immune-drug axis in the development of personalized 
medicine.  
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INTRODUCTION AND AIMS 
The WHO has reported cancer as the second leading cause of death, accounting 
for nearly 9.6 million deaths worldwide per year. This amounts to nearly 1 in 6 deaths 
being due to cancer. In the United States, the National Cancer Institute estimates that over 
1.7 million new cases of cancer will be diagnosed in 2020 and over 600 thousand people 
will die from the disease. Within this statistic, the American Cancer Society estimated 
that in 2019 there were over 100 thousand new cases of colon cancer and over 40 
thousand new cases of rectal cancer while there were over 51 thousand deaths associated 
to colorectal cancer alone. It is estimated that the average American has a 5% lifetime 
risk of developing colorectal cancer (CRC) with men having a greater mortality rate of 59 
per 100 thousand versus 44 per 100 thousand in women. The incidence of colorectal 
cancer increases with advancing age in both genders, with the highest risk occurring in 
those over 69 years of age. The financial burden of colorectal cancer has had a large 
impact on the current health care system. In 2010, the estimated direct cost of colorectal 
cancer was over $14 billion, with over $11 billion resulting from lost productivity and 
premature death. Thus, colorectal cancer has had, and is continuing, to have a major 
impact on both the population and economy of the United States.1 
5 Fluorouracil (5FU) chemotherapy is widely used in the treatment of CRC and 
has been the first-choice chemotherapy drug for CRC for many years. However, its 
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clinical utility remains hampered by acquired resistance and hematopoietic and 
gastrointestinal toxicities resulting from its non-selectivity. 5FU functions as a 
thymidylate synthase inhibitor with a half-life of approximately 15 min when injected 
intravenously (IV). 
When used in the treatment of CRC, it is estimated that approximately 1% of the 
injected compound reaches the colon to induce a potential anti-tumor effect. This 
translates to a 10-15% success rate in the clinic. Currently, there is no standard 
prescription of 5FU therapy. The most common regimen involves 4 consecutive days of a 
moderate dose with daily monitoring of behavior and phenotypic changes in the patient. 
If the patient is described as well adapted and responsive to the treatment, a fifth day of 
treatment will be given and then will be delivered every other day until the patient begins 
to show symptoms of non-specific toxicity. As such, many side effects are associated 
with 5FU treatment; the most common including fatigue, loss of appetite, and diarrhea, 
all of which can lead to a reduced quality of life. Beyond this, it is estimated that over 7% 
percent of cancer patients treated with chemotherapy die as a result of non-selective 
toxicities rather than the cancer itself. 
Alternative and complementary medicine has been used in many aspects of both 
western and eastern medicine. Attenuating inflammation and disease pathology with 
these compounds is an age-old practice but has recently entered the spotlight in modern 
experimental medicine. Unfortunately, many natural compounds are sold as supplements 
and are therefore at risk for being improperly used. This, however, presents the 
opportunity to investigate the efficacy and applicability of these natural compounds to 
clinical settings as potential primary or complementary therapeutics.  
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Emodin (1,3,8-trihydroxy-6-methylanthraquinone), is a natural anthraquinone that 
has recently entered the spotlight of natural compounds with potential anti-tumor and 
anti-inflammatory properties. Isolated from several Chinese herbs, including Rheum 
palmatum, Polygonum cuspidatum, and Polygonum multiflorum, emodin has been 
regularly used in traditional Chinese medicine. Multiple pre-clinical investigations have 
demonstrated emodin to contain a wide spectrum of pharmacological benefits, including; 
anti-viral, anti-bacterial, anti-allergic, anti-osteoporotic, anti-diabetic, anti-inflammatory, 
neuroprotective, hepatoprotective, and anti-tumorigenic properties. Utilizing these 
potential properties, our ultimate aim is to establish emodin as a safe compound to be 
used as potentially both a primary and complementary therapeutic. 
The overall goal of this proposal is to determine the pre-clinical effectiveness of 
emodin in attenuating the toxicities associated with chemotherapy treatment and the 
potential for emodin to prevent the onset of colorectal cancer. Our central hypothesis is 
that emodin will reduce the inflammation associated with both chemotherapy toxicity and 
colorectal cancer burden through mechanisms involving the inactivation of macrophages 
leading to reduced inflammatory burden, better quality of life, and prolonged survival. 
This hypothesis will be tested in the following three aims: 
Specific Aim #1 will evaluate the effect of 5 fluorouracil chemotherapy on inflammation, 
functional parameters, and gut microbiota. 




Specific Aim #3 will determine the efficacy of dietary emodin on preventing colorectal 
cancer. 
Working Model: Initially, this proposal will examine the overall toxic characteristics of 
5FU chemotherapy both in the absence and presence of colorectal cancer (AIM 1). Next, 
this proposal will investigate the pharmacological properties of natural anthraquinone 
emodin and its ability to be used as a complementary therapeutic to reduce the toxic 
properties associated with 5-FU chemotherapy (AIM 2). Finally, this proposal will also 
evaluate the use emodin to prevent the onset of colorectal cancer (AIM 3). Overall, this 
proposal will provide a comprehensive understanding of 1) the toxicities associated with 
current cancer treatments, 2) the potential use of emodin to reduce toxicities associated 
with current cancer treatments, and 3) the potential for emodin to be used as a dietary 
therapeutic to prevent colorectal cancer. The results of the above described aims will 
serve as an important step for progression of emodin to human trials in addition to 
furthering our understanding of the role of natural anthraquinones in the prevention and 
treatment of colorectal cancer.  
Specific Aim #1 will evaluate the effect of 5 fluorouracil chemotherapy on 
inflammation, functional parameters, and gut microbiota. 
Rationale: It has been previously established that 5FU chemotherapy causes 
severe adverse reactions and non-selective toxicities in cancer patients. Side effects 
include fatigue, loss of appetite, and diarrhea among others, all of which can lead to a 
reduced quality of life and premature death. Identifying strategies to increase efficacy and 
reduce toxicity of chemotherapy are of significant public health importance. Further, 5FU 
has been reported to cause disturbances in the gut microbiome, which can further 
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influence the outcome of cancer therapy. Thus, the goal of this aim is to perform a 
comprehensive analysis of the physiological effects of 5FU therapy on inflammation, 
functional parameters, and gut microbiota.  
Aim 1.1: We will observe the effects of 5FU on local and systemic inflammation 
in non-tumor burdened mice and in the AOM/DSS model of colorectal cancer. 
We will use a low dose regime of 5FU therapy (40 mg/kg) which is most 
comparable to the commonly prescribed dose in clinical medicine.  
Aim 1.2: To observe the effects of 5FU on quality of life, we will employ a 
battery of functional tests to investigate fatigue, muscular strength, and peripheral 
nociception.  
Aim 1.3: We will observe and characterize the changes in the gut microbiome-
immune system using 16S rRNA sequencing and PICRUSt analysis. We will then 
utilize fecal microbial transplantation to characterize the changes in microbial 
composition and their effects on host physiology. 
Specific Aim #2 will determine the effects of dietary emodin on reducing toxicity of 5 
fluorouracil chemotherapy. 
Rationale: Emodin is a natural anthraquinone derivative found in various Chinese 
medicinal herbs. Recent evidence has shown emodin to have many health benefits 
including anti-inflammatory, anti-viral, and anti-bacterial properties among others. In this 
aim we will first characterize the safety and pharmacodynamics of emodin and then use 
emodin as a complementary therapeutic to attenuate the toxicities of 5FU chemotherapy.  
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Aim 2.1: We will perform a standard pharmacokinetics study by giving emodin 
via IP and oral gavage to assay the clearance of emodin in the plasma over time.  
Aim 2.2: To observe the potential long-term effects of emodin, we will feed male 
and female an emodin infused diet for three months.  
Aim 2.3: Emodin will be given 3x/week at a dose of 40 mg/kg complementary to 
our 35 mg/kg 5FU regime and observed at an acute and chronic timepoint to 
observe the potential to ameliorate 5FU-associated toxicities.  
Specific Aim #3 will determine the efficacy of dietary emodin on preventing 
colorectal cancer. 
Rationale: There is emerging evidence that emodin may have anti-tumor 
properties. We will use the AOM/DSS and Apcmin/+ models of colorectal cancer to 
investigate the potential for emodin to be given as a preventative agent to patients at risk 
for developing colorectal cancer.  
Aim 3.1: We will investigate the potential for emodin to reduce the tumor burden 
in both models of CRC when used as a preventative therapeutic.  
Aim 3.2: We will investigate the ability for emodin to reduce the chronic 













REVIEW OF LITERATURE 
2.1 Colorectal Cancer 
The WHO has reported cancer as the second leading cause of death, accounting 
for nearly 9.6 million deaths worldwide per year. The American Cancer Society 
estimated that in 2019 there were over 100 thousand new cases of colon cancer and over 
40 thousand new cases of rectal cancer, while there were over 51 thousand deaths 
associated to colorectal cancer alone. It is estimated that the average American has a 5% 
lifetime risk of developing colorectal cancer (CRC) with men having a greater mortality 
rate of 59 per 100 thousand versus 44 per 100 thousand in women. The incidence of 
colorectal cancer increases with advancing age in both genders, with the highest risk 
occurring in those over 69 years of age. The financial burden of colorectal cancer has had 
a large impact on the current health care system. In 2010, the estimated direct cost of 
colorectal cancer was over $14 billion, with over $11 billion resulting from lost 
productivity and premature death. Thus, colorectal cancer has had, and is continuing, to 
have a major impact on both the population and economy of the United States.1  
Clinical Symptoms of Colorectal Cancer 
Colorectal cancer is a degenerative disease that takes years to develop in humans. 
The incidence of colorectal cancer is suggested to be onset by chronic stress and poor 
lifestyle management, the latter of which is typically a lack of physical activity and poor 
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diet. In the early stages of the disease, symptoms of colorectal cancer may be minimal or 
not present at all. The quantity and severity of symptoms associated with colorectal 
cancer typically accompany the progression of the disease. 
In a clinical setting, symptoms of colorectal cancer are typically broken-down into 
two categories: local and systemic. Local symptoms are those which have a direct effect 
on the colon or rectum. These symptoms include changes in bowel habits, constipation, 
diarrhea, alternating diarrhea and constipation, rectal bleeding or bloody stools, 
abdominal bloating or cramping, incomplete bowel emptying, and narrower stools. 
Systemic symptoms are those that affect the entire body and are typically seen in the later 
stages of the disease. These symptoms typically include unexplained weight loss, 
unexplained loss of appetite, nausea or vomiting, anemia, jaundice, and weakness and 
fatigue. Due to the delayed onset of both local and systemic symptoms past the initial 
onset of the disease, the American Cancer Society recommends that the average 
American should start regular screening at age 45. Typical screening procedures can be 
done either with a sensitive stool-based test or with a physical exam consisting of a 
colonoscopy. Persons in good health are recommended to undergo a colonoscopy every 
10 years or flexible sigmoidoscopy (FSIG) every 5 years.  
The Two-Faced Future of Colorectal Cancer 
The next 50 years will be challenged with a two-faced future of colorectal cancer. 
On the dark side of this face we see the frightening reality that Millennials and Gen Xers 
have twice the incidence of colorectal cancer. A study by Siegel et. al, 2017 reported the 
striking increase in colorectal cancer incidence rates among patients aged 20-39.2 
Although socially, this age group has been shown to be the most active and health 
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conscious group of Americans, the prevalence of preservatives and poor environmental 
health has been attributed to this increase of cancer incidence. This further provides 
rationale to develop a greater understanding of the etiology of colorectal cancer and to 
develop better preventative therapeutics to lower this increasing burden. 
Whereas increased incidence will cause a heavy burden on the healthcare of the 
American people, improved screening and detection methods for colorectal cancer has 
been improving survival rates. This has included improved technological advancements 
in colonoscopy. Colonoscopy is the accepted gold standard for detecting and diagnosing 
colorectal adenomas and cancers. The Third Eye® Retroscope® and Third Eye® 
Panoramic™ are two recently developed colonoscopes that allow for a full 1800 retroflex 
to provide a more complete view of the colonic folds and can improve polyp detection by 
up to 80%.3 Another recent development, pioneered by Check Cap Ltd, has combined X-
ray imaging with microtechnology to improve capture of gastrointestinal images. Check 
Cap’s C-Scan® capsule utilizes a capsule size tablet taken with contrast agent. Over 24-
72 hours the C-Scan capsule will pass through the gastrointestinal system and generate 
3D images of the enteric system which can be assessed by physicians.  
2.2 Models of Studying and Investigating Colorectal Cancer 
There are many models of studying colorectal cancer that are being utilized to 
understand the development, progression, and potential therapies of the disease. Utilizing 
both sexes in multiple models is the gold standard to performing a comprehensive 
investigation of CRC. Cell culture methods have also been utilized, especially for drug 
development, to understand a direct impact of a compound on murine and human cells. 
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Human models are only used in later progressions of drug development, and therefore 
many investigators use rodent and in-vitro models to study colorectal cancer.  
Non-rodent species 
Canine use has become an attractive model for comparative oncology research. 
Similar to rodent models, there are many similarities between canine colorectal cancer 
and the human disease. One of the benefits to canine intestinal cancer models is the onset 
of tumors is more commonly found in the large intestine rather than the small intestine. 
This more closely mimics the descending colon/rectal cancers that are most frequently 
seen in human cases of colorectal cancer.4 Evaluation of clinical cases of canine 
colorectal carcinomas have revelated cytoplasmic and nuclear accumulations of β-
catenin, which further suggests a dysregulation of the WNT signaling pathway as an 
important driver in the onset of colorectal cancer in the canine species.5 Despite the 
similarities between canine and human colorectal cancer, the prevalence in canines is less 
than 1% and therefore severely limits the effectiveness of using this model.4,5  
Sheep are also an effective comparative pathological model of studying colorectal 
cancer due to the similarities of lesions and metastatic behavior with the human disease. 
Despite these similarities, it has been documented that 100% of intestinal 
adenocarcinomas developed in sheep are found in the small intestines. Along with this 
limitation, the unique physiological characteristics of the sheep ruminant fore-stomachs 
has been shown as a significant weakness of this model.4,6 
Orthotopic Tumors 
The transition from in-vitro experiments to in-vivo typically involves implanting a 
tumor in the flank of rodents. The most common models for colorectal cancer are the CT-
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26 cell line, which are native to the BALB/c mouse strain, and the MC38 cell line which 
are native to the C57BL/6 moue strain. Palpable tumors typically develop within 14 days 
and the mice begin to show physiological perturbations associated with cancer. Tumors 
can grow to be large and can account for more than 15% of the animal’s total body 
weight. These models typically mimic the symptoms of tumor burden which include 
increased circulating IL-6 and insulin resistance. These models are primarily used for 
rapid studies and are often incorporated into preliminary understandings of novel 
compounds. The accelerated development of tumors makes the tumor burden less like the 
human disease; but is still accepted as a model of studying colorectal cancer.7 Further, in 
the development of colorectal cancer, it is important to understand that a colorectal tumor 
implanted in the flank of an animal is not in its native hypoxic environment and may 
develop and respond differently to treatments since the tumor is more available to the 
systemic circulation.8,9 
Diet-Induced Rodent Neoplasia Models 
Epidemiological evidence has shown diet as a key modulator to the incidence of 
colorectal cancer in humans.10-12 Several rodent studies have been conducted to examine 
the influence of poor diet on the incidence of colorectal cancer. This diet typically is 
designed to mimic the poor “Western diet” that has become problematic to the current 
health of Americans. In rodent studies, the “Western diet” is designed to increase caloric 
fat intake from 5% to as much as 60%, decrease calcium intake from 0.5% to 0.05%, and 
decrease vitamin D intake to 100 IU/kg from 1,000 IU/kg.4,13 
Feeding of the Western diet for as little as 12 weeks has been shown to induce 
hyperplasia of the colonic crypts in rats and mice.13 Longevity studies have also shown 
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that after 2 years of being fed the Western diet, 70% of mice developed dysplastic crypts 
and small polypoid lesions, most of which were found in the distal colon.14 Another study 
has also shown that a 2-year feeding of a Western diet low in fiber, choline, folate, and 
methionine lead to 25% of C57BL/6 mice to develop intestinal tumors and 
adenocarcinomas. Feeding the Western diet to mice has also been shown to induce a 
transcript profile in normal colonic mucosa that was similar to the pattern loss of the Apc 
allele in Apc138N/+ mice.15 The Western diet model of spontaneous colorectal cancer is an 
attractive model to study the etiology of colorectal cancer, however, the severity of the 
dietary fat intake combined with the time necessary for tumor development do not reflect 
the etiology of human colorectal cancer.  
Chemically Induced Models 
A large variety of chemicals have been shown to have mutagenic properties and 
have been used to controllably induce cancer. 1,2-dimethylhydrazine (DMH) and its 
metabolite azoxymethane (AOM), are the two most commonly use carcinogens to induce 
colorectal cancer in rodents.16 DMH and AOM are alkylating agents that are typically 
injected intraperitoneally or subcutaneously over several weeks to induce tumorigenesis. 
AOM is typically used to produce colorectal polyps and can cause mutations in the K-ras, 
Src/PI3K/Akt, β-catenin, TGF-β, and p53 signaling pathways to drive tumor 
development.17,18 The AOM model can be used on its own or be paired with dietary DSS 
supplementation. DSS is used to induce colitis and systemic inflammation which further 
drives tumor development. This model is useful for studying the gene-gene and gene-
environment interactions that influence the pathophysiology of colorectal cancer. 
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However, it is suggested that this model is not viable due to the little evidence supporting 
the etiology of human colorectal cancer resulting from exposure to alkylating agents.4   
Apcmin/+ 
The Apcmin/+ mouse has been one of the leading models for preclinical colorectal 
and intestinal cancer research over the past 25 years. The phenotype of these mutant mice 
showed severe clinical symptoms of intestinal cancer from the onset of a usually fatal 
case of regenerative anemia attributed to multiple intestinal neoplasms, or “min.” The 
min mouse has a naturally occurring T-to-A nonsense mutation at nucleotide 2,549 of the 
Adenomatous polyposis coli (Apc) gene that pares the Apc protein at the codon 850, this 
predisposes the mice to develop multiple intestinal adenomas.19 The min mutation is 
autosomal dominant, and homozygosity for the mutant allele is embryonic lethal. 
Heterozygous Apcmin/+ typically become anemic by 60 days of age and progress through 
worsening clinical symptoms of intestinal cancer and usually die by 120 days of age.4,19  
The use of the Apcmin/+ mouse model has been widely used to study 
carcinogenesis or to test novel treatments and delivery methods. The Apcmin/+ mouse has 
also been used to study genetic modifications of colorectal cancer risk or Modifiers of 
Min (MoM).4,20 This model, however, leads to the development of polyps primarily in the 
small intestine with few polyps found in the colon. Therefore, it is commonly used as a 






2.3 Treatments for Colorectal Cancer and Non-Specific Toxicities 
The last 60 years has seen great strides for medical technology and has led to an 
improved ability to treat multiple cancers. Since the discovery of DNA replication 
blocking mechanisms of Aminopterin, the predecessor to current treatment methotrexate, 
research into blockading functions of cell growth have been the major focus for the 
development of anti-cancer therapies. As the incidence of different types of cancer 
evolved in the medical community, there was an increased demand of treatment methods. 
Present therapies have seen improved targetability of tumor subtypes and increased early 
detection. As various mechanisms of cancer development and treatment are discovered, 
so paralleled the evolution of chemotherapy treatments. This evolution of treatments has 
further led to treatments focused on drug combinations, delivery techniques, tissue 
specificity, and overcoming drug resistance by carcinomas.21,22 
Common Treatment Regimes 
Chemotherapy is the most widely used treatment of colorectal cancer. 
Specifically, 5 Fluorouracil has been the first-choice chemotherapy drug for CRC for 
many years. 5FU functions as a thymidylate synthase inhibitor and is typically injected 
intravenously (IV). The most common regimen used in clinical settings involves 4 
consecutive days of 5FU treatment with daily monitoring of behavior and phenotypic 
changes in the patient. If the patient is described as well adapted and responsive to the 
treatment on day 5 another single injection will be delivered every other day for 6 days or 
until the patient starts to show symptoms of non-specific toxicity. This regimen is given 
at the discretion of the attending physician and can be prescribed either as an adjuvant 
therapy to a colon resection or as a sole method of treatment.23,24  
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The use of high energy radiation (such as x-rays) or particles to destroy cancer 
cells is more often used in rectal cancer than colon cancers. The use of radiation is 
commonly adjuvant to chemotherapy or surgical resection. When used with surgery, 
radiation is used to kill cancer cells that may have invaded through the colon, posing a 
risk for metastasis after surgery. Because of the risk for causing gut barrier dysfunction, 
radiation is seldomly used in cases where it can be avoided. 
Immunotherapy 
The introduction of immunotherapy has recently revolutionized the understanding 
of biology and medical science and has led to a vast array of targeted therapeutics.25 
Unfortunately, the realm of colorectal cancer has seen little benefits from the 
immunotherapy revolution. In a recent clinical trial, patients treated with Pembrolizumab 
(Keytruda) reported 0% response rate in primary CRC. However, Pembrolizumab did 
gain approval from the FDA in May 2017 for use in patients with unresectable or 
metastatic colon cancer that has tested positive for microsatellite instability-high (MSI-H) 
or deficient mismatch repair (dMMR) and have previously undergone chemotherapy. 
Currently, the use of immunotherapy in metastatic colorectal cancer has proven to be the 
most promising avenue. However, as stated above, the current technology has shown 
little to no promise in the treatment of primary colorectal cancers.26  
Non-Specific Toxicities 
Non-specific toxicities are the major burden associated with current treatments for 
colorectal cancer. As described above, 5FU is the most commonly used chemotherapeutic 
used in the treatment of colorectal cancer. However, its clinical utility remains hampered 
by acquired resistance and hematopoietic and gastrointestinal toxicities. Being the most 
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commonly prescribed chemotherapeutic for colorectal cancer, the majority of literature 
has focused on elucidating the non-specific toxicities associated with 5FU. 5FU functions 
as a thymidylate synthase inhibitor with a half-life of approximately 15 min when 
injected intravenously. When used in the treatment of CRC, it is estimated that 
approximately 1% of the injected compound will reach the colon to induce an anti-tumor 
effect. This translates to a 10-15% success rate in the clinic.27  
As such, many side effects are associated with 5FU treatment, the most common 
including fatigue, loss of appetite, and diarrhea, all of which can lead to a reduced quality 
of life.28 Furthermore, 7.5% of cancer patients treated with chemotherapy die as a result 
of non-selective chemotherapy toxicity rather than the cancer itself.29 One of the most 
potent side effects of 5FU treatment is intestinal mucositis. Mucositis usually appears 
along the entire gastrointestinal tract from mouth to anus and causes general debility.23,30-
32 Mucositis of the intestine is characterized by increased crypt apoptosis and villus 
atrophy, leaving the mucosal tissue open to infection and ulceration.33,34 Several factors 
or genes contributing to the 5FU-induced mucositis have been previously studied; the 
formation of reactive oxygen species (ROS) and the production of pro-inflammatory 
cytokines, such as interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNFα) have 
been implicated in this process.31,33,35 Furthermore, histological evaluation of the small 
intestine indicates obvious villus destruction and inflammation of the crypts.35,36  
Another well-documented side-effect of 5FU is the incidence of cytopenia and 
anemia. Most patients present with severe cytopenia and anemia after treatment with 
5FU. This directly translates to patients becoming immunocompromised and developing 
nosocomial infections which can worsen their condition. Further, anemia results in severe 
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fatigue and weakness which lowers quality of life and the ability to maintain tissue 
homeostasis during treatment periods.  
Finally, many patients present with increased sensitivity to touch and complaints 
of pain. Where this mechanism of toxicity has remained elusive to medical research, 
recent efforts have utilized complementary and alternative therapeutics to blunt these 
responses to provide relief during intense bouts of pain.  
The Future of Treatments in Colorectal Cancer 
Recent advances in medical technology have improved the clinical efficacy of 
diagnosis and early-stage treatment of CRC. However, more needs to be done in the 
respect to treating and preventing colorectal cancer. The future of cancer treatment 
involves a bimodal approach through 1) prevention and 2) physiological 
engineering.12,34,37-43 As our understanding of nature and biomolecular engineering 
improves, so will the ability to design personal therapies to prevent the onset and improve 
current therapeutic interventions. As with the focus of this dissertation, it is important to 
consider multiple aspects of physiology when designing experimental interventions and 
in clinical medicine. 
Phases of Drug Development 
The progression of drug testing requires many pre-clinical and clinical steps that 
are highly regulated by the FDA. The first step in drug development involves the use of 
pre-clinical animal and in-vitro based experiments that show effective and safe delivery 
methods of the proposed compound. After this extensive bout of investigations, the FDA 
can decide whether the drug is reasonably safe for progression to human trials, or to take 
the drug back to formulation. Once in clinical trials the drug is considered an 
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investigational new drug and must pass three phases of clinical testing. These phases are 
overseen by both medical research teams and non-research-based scientists and 
physicians.  
Phase 1 testing is usually conducted in healthy volunteers in an effort to 
determine side effects and to perform necessary human pharmacokinetic analyses. The 
number of participants for this phase is typically between 20 and 80. Phase 2 studies 
begin once the drug has been determined safe for healthy humans. This phase tests a 
variety of patients with certain diseases or conditions and is compared in a controlled 
study against a placebo drug or current form of treatment. In Phase 2, the number of 
participants can be expanded to at most 300 and is usually determined based on the range 
of conditions being investigated. At the end of Phase 2, if a drug has shown evidence of 
effectiveness in a certain population, Phase 3 can begin. Phase 3 is typically aimed at a 
more targeted population and can be initiated as a follow-up study with larger participant 
populations. The number of participants in Phase 3 can be anywhere from a few hundred 
to three thousand. Phase 3 can also be expanded to multiple centers. 
After passing all three phases of human clinical trials, post-market and 
commitment studies are required by a sponsor and are monitored by the FDA. This 
typically allows the drug to enter longevity studies in human participants to determine 
any long-term side effects that may arise from continuous use of the drug. Once passed 
by the FDA, the drug can be submitted as a new compound and within six months can be 
passed and distributed for use in clinical medicine.44  
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Many times, it has been necessary for a drug to undergo a Phase 4 trial. This 
involves recruiting greater numbers of participants to confirm certain findings that might 
have been contradictory or abnormal to previous investigation. Recently, companies such 
as Merk, have initiated Phase 0 studies of new drugs. This involves utilizing a small 
participant pool and performing microdosing of the drug. Microdosing allows for the 
drug to be delivered at a concentration 100X lower than the proposed therapeutic dose. 
Phase 0 also confirm bench-to-bedside translation of compounds to confirm mechanistic 
actions and deem the drug safe for use in greater populations of human participants.  
2.4 Hallmarks of Immunology in Cancer and Cancer Treatments 
The immune niche of a tumor 
With the emergence of immune-based therapies, the immune microenvironment 
has become of significant interest as a primary regulatory mechanism that can determine 
the outcome of anti-cancer treatments. Tumor immune evasion and immune promoting 
factors are two primary hallmarks of cancer contributing to the maintenance of a tumor 
microenvironment.45 Recently, the difference between a “Hot” and “Cold” tumor has 
been highlighted as significant to the prognosis and therapeutic outcome of anti-cancer 
treatments. “Hot” tumors are described as those that contain large amounts of immune 
cells and “cold” tumors are the opposite and do not contain large amounts of immune 
cells.  
The “hot vs. cold” status has been shown to play a significant role in the outcome 
of therapies. A recent article by Newman et. al. 2020 injected unadjuvanted seasonal 
influenza vaccines into melanoma and breast cancer orthotopic tumors effectively 
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changing them into “hot” tumors43. This reduced tumor size by increasing CD8+ T-cells 
and decreasing regulatory B-cells within the tumor. This finding demonstrates that 
turning a tumor from “cold” to “hot” can promote anti-tumor effects and can be utilized 
to improve upon current therapies that may be ineffective. 
Tumor associated macrophages 
A major focus of this dissertation, specifically in Aim 3, will be on tumor 
associated macrophages or TAMs. The presence of TAMs has been shown to play a vital 
role in the outcome and prognosis of many cancers.46 Macrophages are derived from 
monocyte precursors circulating in the blood and are recruited to the tumor by 
chemokines such as MCP-1 and TGFβ.46 Once recruited to the tissue, monocytes will 
mature into macrophages. It is generally understood that the recruitment of macrophages 
to the tumor contribute to the maintenance of the tumor microenvironment and exert pro-
tumoral functions. Pro-tumoral macrophages are characterized as M2-type macrophages, 
which are polarized from exposure to cytokines such as TGFβ and IL-10.47,48 The 
presence of M2-type macrophages in the tumor microenvironment have been shown to 
promote proliferation, invasion and metastasis, angiogenesis, and tissue remodeling.49,50 
There is some evidence suggesting that recruitment of M1-type macrophages through 
increased TNFα, IL1β, and IFNγ might reverse this pro-tumoral environment and cause 
tumor remission. Therefore, therapeutic interventions targeting TAMs and reducing the 
M2-type phenotype within the tumor microenvironment might contribute to improved 
survival and subsequent success of further therapeutic outcome.46,47,50,51  
It is important to establish that there is conflicting literature on macrophage 
phenotype, as defined by expression of cell-surface markers. This conflicting body of 
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literature is primarily derived from the discrepancy in what is defined as a ‘mature 
macrophage’ and the differences in these markers seen from tissue to tissue. For example, 
a review by Bain and Schridde 2018 describes mature macrophages as 
CD64+MHCIIhiCD206+CD163+ cells.52 In addition, they define lamina propria 
macrophages as highly expressing CD11b, CD11c, CD14, and CX3CR1 cells. CD11b is 
widely accepted as a monocyte marker, but where Bain and Schridde do not follow some 
bodies of literature is with addressing the expression of F4/80 and CD68. F4/80 and 
CD68 are two of the most widely cited markers of macrophage expression and are 
commonly used to identify total mature macrophage populations.53-55 Further, we and 
others have previously defined M1-type macrophages as CD11c-expressing cells and 
M2-type macrophages as CD206-expressing cells. CD80, CD86, TLR2, and TLR4 have 
also been suggested to be expressed on M1-type macrophages. Additionally, CD204 and 
CD163 have been suggested to be expressed on M2-type macrophages.  
Whereas there is discrepancy in the expression of markers between tissues, there 
is a common consensus that macrophages are highly plastic cell types that exist on a 
transitionary spectrum that varies from tissue to tissue. In this dissertation, where we 
examine macrophages, we define total macrophages by flow cytometry as 
CD45+CD11b+Ly6C+F4/80+ cells which are then further gated against CD11c and 
CD206. From here where we define CD11c as M1-type and CD206 as M2-type 
macrophages. Where we use tissue gene analysis, we utilize expression of EMR1 (F4/80) 
to describe total macrophage populations and ITGAX (CD11c) and MRC1 (CD206) as 





T-cells function in both a direct and indirect manner in the response to cancer. 
Killer T-cells will attack and kill cancer cells directly and are identified as CD8 positive 
cells. Killer T-cells have been shown to first find cancer cells and can also be stimulated 
to kill cancer cells. Helper T-cells fight cancer indirectly and are identified as CD4 
positive cells. Helper T-cells are known to assist in the communication between the T-
cell receptor (TCR) and with antigen-presenting cells (APCs). The TCR complex and 
CD4 bind to distinct regions of the antigen-presenting MHC Class II molecule. T-Cells 
play a major role in what is known as the cancer-immunity cycle. As cancer cells are 
killed, tumor specific antigens are released and are taken up and presented by APCs. In 
the lymph, these APCs now activate CD4+ T-cells which allows them to specifically 
attack the tumor cells. CAR-T cells are engineered similarly to this process to specifically 
target cancer cells.56-59  
In humans, the count of CD4+ and CD8+ cells have been shown to be directly 
related to clinical outcome and survival. In colon cancer patients, longer disease-free 
survival is correlated with higher CD8+ counts, lower CD4+/CD8+ ratio, and higher 
CD8+/FoxP3+ ratio. Immunoscoring (IS) is an index-based density of CD3+ and CD8+ 
tumor infiltrating lymphocytes (TILs). IS has been shown as a reproducible method from 
predicting survival of patients with advanced CRC. These values indicate that the 
presence of CD8+ cells, measured in the circulation or directly from tumors, is correlated 






Whereas T-cells physically attach to and attack cancer cells, B-cells target them 
indirectly through the production of antibodies. B-cells can play a critical role in cancer 
protection and anti-cancer response. B-cells present in the tumor microenvironment 
secrete antibodies that can directly inflame the tumor parenchyma and cytokines that can 
activate angiogenesis in the vasculature. These responses are capable of inhibiting 
effector cells such as CD8+ T-cells and NK cells. These B-cells are termed B-regulatory 
cells (B-regs) and exists as a heterogenous population that can directly or indirectly 
influence cancer outcome. The specific cytokine release can cause significant influence 
on the tumor microenvironment. For example, IL-10 producing B-regs can exacerbate 
inflammation and support cancer growth by promoting a pro-tumorigenic niche within 
and surrounding the tumor microenvironment.61 
Solid tumors in humans often contain significant B-cell populations. The number 
of tumor-infiltrating B-cells were identified as the second-best predictor of positive 
disease outcome51. Antibodies directed against intracellular can be directly produced by 
B-cells. A study by Mizukami et. al. 2006 showed regression of human lung cancer tissue 
xenotransplanted into SCID mice was associated with higher levels of tumor-resident B-
cell derived IgG in the serum of recipients62. Furthermore, B-cell derived antibodies have 
been shown to bind mouse tumors in an antigen-specific manner and mediate 
complement-dependent lysis59.  
Natural Killer (NK) cells 
Natural Killer cells are lymphocytes that were first identified for their ability to 
attack tumor cells without deliberate immunization of activation. Furthermore, NK cells 
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have also been shown to kill cells that are infected with certain viruses and attack cells 
that lack expression of MHC class I antigens. Recently, the discovery of NK receptors 
and their ligands has uncovered the molecular mechanisms that regulate NK activation 
and function. One of the most documented mechanisms is through IL-12 dependent 
activation of NK cells. IL-12 release is part of a cytokine axis in which myeloid cell-
derived IL-12 triggers lymphoid cell-derived IFNγ production and contributes to 
cytotoxic activation63,64. IL-23 and IL-27 are part of the IL-12 family of cytokines. As 
with IL-12, macrophages and DCs can produce IL-23 and IL-27 upon sensing pathogens 
or their products64,65. 
One of the original models of immunotherapy involved allogenic adoptive 
transfer of NK cells. Unlike T-cells, which can induce autoimmune reactions, NK cells 
appear to be safe when obtained from another person and then injected. Certain ligands 
such as NKG2D (CD314), DNAM1 (CD226), 2B4 (CD244), 4-1BB (CD137), PD1, and 
CTLA4 have been implicated in the activation of NK cells towards tumors. Of these 
ligands, CD314 has been shown to be removed by tumor cells which causes NK cell 
evasion. The most promising therapeutic intervention against this mutation has been the 
use of monoclonal antibodies against the proteolytic cleavage site on the MICA and 
MICB proteins. Preventing this cleavage, in-turn, prevents the shedding of CD314 and 
rendering tumors susceptible to NK attack66.  
Dendritic Cells (CDs) 
Dendritic cells are a heterogenous population of antigen presenting cells that have 
been shown to infiltrate the tumor microenvironment. Where normally, DCs play a 
critical role in the priming and maintenance of local immunity; in the presence of cancer, 
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different subtypes of DCs are recruited to the tumor which can function to either enhance 
or suppress the anti-tumor immune response. There are four primary phenotypes of DCs 
which are associated with the tumor microenvironment: Plasmacytoid DCs (pDCs) which 
function in tolerance induction, Conventional DCs type 1 (cDC1) which function in 
MHC-I cross-presentation, Conventional DCs type 2 (cDC2) which function in MHC-II 
presentation, and Inflammatory DCs (Inf-DCs) or Monocyte-derived DCs (moDCs) 
which function in MHC-I cross-presentation and MHC-II presentation67.  
Death of tumor cells, especially from chemotherapy or radiation, have been 
shown to modulate tumor associated DCs and enhance anti-tumor immunity. Similarly, 
anti-PD1 therapy requires DC-T cell crosstalk and the initiation of anti-tumor CD8+ T 
cell responses by cross-presentation in DCs. DC modulating therapies are currently part 
of a large field of immunotherapy research. Flt3-L treatment has been one of the most 
promising strategies to elicit anti-tumor T-cell immunity. Flt3-L is highly expressed by 
cDC1. Pre-treatment of cDC1 cells with Flt3-L and then subsequent adoptive transfer has 
been shown to enhance efficacy of checkpoint therapy blockade in animal models of 
melanoma and glioblastoma.68 
The actual understanding of the immunoregulatory functions of the tumor 
microenvironment expand past the scope of this review. However, it is well understood 
that certain changes in the tumor microenvironment can promote an anti-tumor niche and 
may be most efficiently achieved by directly or indirectly influencing one or more of the 
above described immune cells. Therefore, therapeutic interventions showing a 




Taken together, the immune system is well-known to regulate and directly impact 
the outcome of cancer onset and therapeutic intervention. Therefore, it is imperative to 1) 
understand the mechanisms of immune function during cancer and 2) to develop 
interventional and preventative therapeutics that can directly ameliorate the inflammatory 
consequences of cancer and the current debilitating therapeutics that are administered 
clinically.  
2.5 Emodin: 1,3,8-trihydroxy-6-methylanthraquinone 
 
Fig 2.1 Emodin (1,3,8-trihydroxy-6-methylanthraquinone) 
Emodin (1,3,8-tryhydroxyanthraquinone) (Fig 2.1) is a natural anthraquinone 
isolated from several Chinese herbs, including Rheum palmatum, Polygonum cuspidatum, 
and Polygonum multiflorum. Multiple pre-clinical investigations have demonstrated 
emodin to contain a wide spectrum of pharmacological benefits, including; antiviral69, 
antibacterial70, anti-allergic71, anti-osteoporotic72, anti-diabetic73, anti-inflammatory74,75, 




Evidence for anti-inflammatory properties 
The primary goal of this proposal is to utilize emodin as a complementary 
therapeutic to attenuate the pro-inflammatory responses to 5FU chemotherapy and 
cancer. Recent evidence utilizing in-vitro investigations or orthotopic tumors have shown 
reduced NF-κB, STAT6, P38 signaling along with reduced IL-6, TNFα, and MCP1 
secretion with emodin. In the presented investigations of this proposal, we will aim to 1) 
confirm these findings in models of 5FU toxicity and colorectal cancer and 2) to discover 
any further mechanisms of action that might contribute to associated benefits of Emodin 
as a primary or complementary therapeutic. 
We will focus primarily, but not exclusively, on the polarization of macrophages 
in the gut. Iwanowycz et al 2016 showed evidence of M1 and M2 bi-directional 
depolarization of macrophages in-vitro.80 A follow-up study by Iwanowycz et al 2016 
confirmed this phenomenon and further showed increased cytotoxic T-cell activation 
leading to reduced orthotopic tumor burden in a model of breast cancer.78 We will 
directly expand on this work utilizing two models of colorectal cancer to confirm the 
anti-tumor potential and build on the literature of immunoregulatory properties of 
emodin. 
Tissue specific effects 
As described above, the benefits of emodin have been extensively demonstrated 
in-vitro. However, these studies have revealed conflicting results about the mechanisms 
of emodin. For example, emodin has been shown to activate P38 MAP Kinase in human 
hepatoblastoma cells81,82 and in osteoblasts72  but has shown decreased activation in non-
small cell lung carcinoma83 and in hepatic stellate cells.84 Further, activation of ERK1/2 
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MAP Kinase has been shown to be increased in non-small cell lung carcinoma85 and 
colorectal cancer cells86 but decreased activation in the amelioration of viral 
myocarditis.69 These discrepancies overshadow the potential in-vivo benefits of emodin 
and provoke further investigations of this promising dietary agent.  
P2X7 Receptor as potential mechanism of action 
The mechanism of action of emodin has yet to be discovered. Recent 
investigations, however, show evidence in-vitro of a mechanism targeting the P2X7 
receptor. The P2X7 receptor is found primarily in the central and peripheral nervous 
systems but also on the surface of microglia, macrophages, and the retina. There is 
evidence that has shown the P2X7 receptor as a pattern recognition receptor for the 
extracellular ATP-mediated apoptotic cell death, regulation of receptor trafficking, mast 
cell degranulation, and pro-inflammatory cascade. A study by Jelassi et al. 2013 
demonstrated emodin was able to reduce breast and non-small cell lung carcinoma cell 
invasion by antagonizing P2X7 receptor mediated ATP-current.79 Further, a study by 
Zhang et al 2019 showed emodin reduced ATP-dependent pancreatic duct cell injury by 
antagonizing the P2X7 receptor.87 
Overall, emodin contains the potential to be used as a complementary and primary 
therapeutic in multiple aspects of cancer treatment. This dissertation will attempt to 
provide vital preclinical evidence in support of this hypothesis in an effort to promote the 
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Emerging evidence suggests that gut microbiota may influence the response to 
chemotherapy. We sought to characterize the effects of 5 fluorouracil (5FU) 
chemotherapy on colon inflammation and functional measures in colorectal cancer (CRC) 
and to further determine whether gut microbiota can influence this response. 50 C57BL/6 
were randomized into four groups; Control+Vehicle (n=10), Control+5FU (n=10), 
AOM/DSS+Vehicle (n=15), and AOM/DSS+5FU (n=15). CRC was induced chemically 
by a single 10 mg/kg injection of azoxymethane (AOM) followed by two cycles (2% and 
1%) of dextran sodium sulfate (DSS). Mice were then treated with 3 cycles of vehicle or 
5FU (cycle 1: 40 mg/kg, cycle 2+3: 20 mg/kg). Functional tests (grip strength and run-to-
fatigue) were performed prior to 5FU treatment (baseline) and at the completion of the 
second cycle of 5FU. Following the third 5FU cycle, mice were euthanized, and the colon 
was evaluated for expression of inflammatory genes using RT-qPCR and stool samples 
were profiled using 16S rRNA sequencing. A second experiment used fecal microbiota 
transplantation from 5FU treated mice to control mice (n=10–15/group) to determine 
whether 5FU associated changes in the microbiota could influence functional measures 
and colon inflammation. 5FU reduced grip strength (p < 0.05) and caused a trending 
decrease in run-to-fatigue performance in cancer mice (p=0.06). Select intestinal 
inflammatory genes were significantly elevated with 5FU treatment and this was further 
exacerbated with cancer (p < 0.05). Microbiota analysis revealed increased dissimilarity 
and alterations in bacterial taxonomy in 5FU and AOM/DSS-treated mice (p < 0.05). 
Fecal transplant from 5FU treated mice reduced functional performance (p < 0.05) and 
altered select colon inflammatory markers (p < 0.05). This study provides evidence of an 
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effect of 5FU on inflammatory responses and functional measures in a mouse model of 
CRC and suggests that gut microbes may play a role in some, but not all, 5FU related 
perturbations. 
3.2 Introduction 
5 Fluorouracil (5FU) chemotherapy is widely used in the treatment of colorectal 
cancer (CRC), and has been the first-choice chemotherapy drug for CRC for many 
years39,88. However, its clinical utility remains hampered by acquired resistance and 
hematopoietic and gastrointestinal toxicities resulting from its non-selectivity30,32. 5FU 
functions as a thymidylate synthase inhibitor with a half-life of approximately 15 min 
when injected intravenously (I.V.)30,89. When used in the treatment of CRC, it is 
estimated that approximately 1% of the injected compound reaches the colon to induce a 
potential anti-tumor effect. This translates to a 10–15% success rate in the clinic27. 
Currently, the common regimen of 5FU therapy involves 4 consecutive days of 5FU 
treatment with daily monitoring of behavior and phenotypic changes in the patient. If the 
patient is described as well adapted and responsive to the treatment on day 5 another 
single injection will be delivered every other day for 6 days or until the patient starts to 
show symptoms of non-specific toxicity23,24. As such, many side effects are associated 
with 5FU treatment, the most common including fatigue, loss of appetite, and diarrhea, 
all of which can lead to a reduced quality of life28. Furthermore, 7.5% of cancer patients 
treated with chemotherapy die as a result of non-selective chemotherapy toxicity rather 
than the cancer itself29. Therefore, identifying methods to better evaluate the associated 




One of the most potent side effects of 5FU treatment is intestinal mucositis. 
Mucositis usually appears along the entire gastrointestinal tract from mouth to anus and 
causes general debility23,30-32. Mucositis of the intestine is characterized by increased 
crypt apoptosis and villus atrophy, leaving the mucosal tissue open to infection and 
ulceration33,34. Several factors or genes contributing to the 5FU-induced mucositis have 
been previously studied; the formation of reactive oxygen species (ROS) and the 
production of pro-inflammatory cytokines, such as interleukin-1β (IL-1β), IL-6, and 
tumor necrosis factor-α (TNFα) have been implicated in this process31,33,35,90. 
Furthermore, histological evaluation of the small intestine indicates obvious villus 
destruction and inflammation of the crypts33,35,36. However, the majority of literature 
explaining 5FU-induced intestinal mucositis fails to utilize a disease model limiting a 
complete understanding of the side effects of 5FU specifically in the context of CRC.  
Gut microbiota have been implicated in 5FU associated toxicity91,92. 5FU leads to 
gut dysbiosis (i.e. an imbalance of gut microbes) and the ensuing inflammation leads to 
exacerbated intestinal mucositis92. Several preclinical studies have reported a drastic shift 
from commensal bacteria (i.e., Bifidobacterium and Lactobacillus spp.) to Escherichia, 
Clostridium, and Enterococcus spp. following even a single intraperitoneal dose of 5-
FU92. Mechanistic support for this relationship is provided by the reduced intestinal 
mucositis and decreased cytokine levels in 5FU treated mice after antibiotic induced 
depletion of microbes92. Understanding the influence of gut microbes on 5FU related 
toxicity may lead to the dentification of targets (i.e. bacteria themselves or pathways that 
they mediate) to reduce side effects of chemotherapy. 
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Using the azoxymethane/dextran sodium sulfate (AOM/DSS) model of CRC, we 
sought to characterize the effects of 5FU on colon inflammation and functional measures 
in CRC and to further determine whether gut microbiota can influence this response. We 
detected a general anti-tumor effect of 5FU in AOM/DSS treated mice; however, side 
effects including mortality, adverse physiological outcomes, mucositis, and colon 
inflammation were evident. Further, we observed significant alterations in gut microbiota 
in the presence of 5FU. Fecal transplantation experiments also were conducted in control 
mice to investigate the potential causality between gut microbiota and 5FU toxicity. Our 




Male C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, 
ME) and were cared for in the animal facility at the University of South Carolina. Mice, 
randomized upon arrival to the animal facility to prevent litter biases in microbiome data, 
were housed five per cage and maintained on a 12:12-h light-dark cycle in a low-stress 
environment (22 °C, 50% humidity, low noise). Mice were kept in a room isolated from 
all other ongoing animal experiments and were handled only by the primary 
investigators. All mice were habituated to the AIN-76A diet prior to any interventions 
and were given food and water ad libitum through the course of the study. All methods 
were in accordance with the American Association for Laboratory Animal Science, and 
the Institutional Animal Care and Usage Committee of the University of South Carolina 
approved all experiments. 
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3.3.2. AOM/DSS protocol and 5FU treatment experiment 1 
In experiment 1 (Fig. 1A), 50 mice were randomly divided into four groups: 
Control+Vehicle (n=10), Control+5FU (n=10), AOM/DSS+Vehicle (n=15), and 
AOM/DSS+5FU (n=15). At 12 wk of age (baseline week 0) mice received either an 
intraperitoneal injection of the carcinogen93, AOM (10 mg/kg) (Sigma, St. Louis, MO), 
diluted in phosphate buffered saline (PBS) (AOM/DSS) or PBS alone (Control). Mice 
receiving the AOM injection were subjected to two cycles of DSS (36–50 kDa) (MP 
Biomedical, Solon, OH)-supplemented water at final concentrations of 2 and 1% at 
weeks 1 and 4, respectively. Each DSS cycle lasted for a 1-wk period. Body weights and 
symptom scores were determined semi-weekly along with food and water measurements. 
Calculation of symptom score was performed as previously described94 , taking into 
account percent body weight loss, stool consistency, and rectal bleeding. Briefly, fresh 
colonic evacuates were smeared onto “Hemoccult” tape to assess severity of diarrhea and 
were tested with developer (Beckman Coulter, Brea, CA) to assess rectal bleeding. 
Bleeding was scored; no positive detection of blood (0), detection of blood but not 
grossly visible (2), and gross visibility of blood (4). Diarrhea was scored; solid cylinder 
(0), soft cylinder and easily spreadable (2), and non-cylindrical or runny (4). Body weight 
was calculated as percent body weight loss; 0–5% (0), 6–10% (1), 11–15% (2), 15–20% 
(3), 20–25% (4), and>25% (5). Scores of all three categories were summed to obtain an 
overall symptom score for each mouse. 
5FU (Sigma Chemical Co., St. Louis, MO) was dissolved in sterile PBS, pH7.4 
and then sterile filtered through a 0.2 μm syringe filter. 5FU was administered in 3 
cycles; cycle 1: 40 mg/kg, cycle 2 and 3: 20 mg/kg via intraperitoneal injection. 5FU was 
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prepared fresh at the beginning of each cycle. Sterile filtered PBS alone was used as the 
vehicle control. Each cycle consisted of 5 consecutive days of injections followed by 9 
days of recovery. The treatment period lasted for 5 weeks and mice were sacrificed 24 hr 
after the final injection of the third cycle. 
3.3.3. Fecal transplantation experiment 2 
For the fecal transplantation experiment (Fig. 1B), 35 mice were randomly 
divided into four groups: Donor Vehicle, Donor 5FU, Recipient Vehicle (Vehicle FMT), 
Recipient 5FU (5FU FMT) (n=5 per Donor group and n=10–15 per Recipient group). 
The Donor 5FU group was injected with 40 mg/kg 5FU for 5 consecutive days as 
described earlier. All Donor mice were sacrificed 9 days after initial injection and a 
mucosal scrape was performed of the distal enteric tract (cecum to anus) to harvest the 
microbiota for fecal transplantation. Fecal materials were suspended in sterile 10% 
glycerol/PBS, allowed to settle by gravity for 10 min, and aliquoted into daily 
requirements for Recipient groups. To perform the FMT study we adopted a protocol by 
Reikvam et al. 201195. Recipient mice were pretreated with the following antibiotic 
cocktail every 12 h for 10 days prior to FMT: Vancomycin (50 mg/kg), Neomycin (100 
mg/kg), Metronidazole (100 mg/kg), and Amphotericin-B (1 mg/kg) via oral gavage 
supplemented with Ampicillin (1 mg/ml) in the drinking water given ad libitum. All 
antibiotics were purchased from ACROS Organics, New Jersey. FMT was administered 






3.3.4. Grip strength assessment 
All experimental mice were utilized to evaluate the effects of 5FU treatment on 
grip strength. Grip strength was measured prior to 5FU administration (week 8) and 
during the recovery period of the second cycle (week 11) in experiment 1 and following 
antibiotic treatment (week 0) and fecal transplantation (week 2) in experiment 2. Briefly, 
holding the mice by the tail, the front and back feet were allowed to grip the grate. Mice 
were then pulled from the grate, generating a force that was measured by the force 
transducer (Aurora Scientific, Ontario, Canada). Five measurements were taken 
consecutively, with 2 min rest between sets until a total of 15 measurements were taken 
for each mouse. The averages of the 15 measurements were used in the data analysis. 
Measurements were performed by the same investigator through the entirety of the study. 
3.3.5. Run-to-fatigue assessment 
To determine the effect of 5FU on fatigability, mice were subjected to a run-to-
fatigue test prior to 5FU administration (week 8) and during the recovery period of the 
second cycle (week 11) in experiment 1 and following antibiotic treatment (week 0) and 
fecal transplantation (week 2) in experiment 2. After 3 consecutive days of habituation 
during the night cycle, mice were subjected to the following run-to fatigue protocol: 15-
min warm-up, 20 m/min for 30 min, and 25 m/min thereafter until fatigue was reached. 
Fatigue was defined as the time at which mice were no longer able or willing to keep up 
with the treadmill despite hand prodding for at least 1 min. All treadmill tests were 
performed during the night cycle by the same two investigators (ATS, BNV) through the 




3.3.6. Tissue collection 
Mice were euthanized by isoflurane overdose 24 h post final injection (cycle 3, 
day 6) in experiment 1 and on day 15 in experiment 2 (Fig. 1A, B). Blood was collected 
from the inferior vena cava and tissues were removed, weighed, and immediately snap-
frozen in liquid nitrogen and stored at −80 °C or fixed in 10% formalin until further 
analysis. Briefly, the colon was carefully dissected distal to the cecum and proximal to 
the anus. Mesentery adipose tissue was removed with forceps. Colons were then flushed 
with PBS, opened longitudinally, and flattened with a cotton swab. In experiment 1, 
colonic polyps were counted under a dissecting microscope and were categorized 
according to size (> 2, 2-1, and<1). For both experiment 1 and 2, a 5-mm piece of the 
distal colon was cut and fixed in 10% buffered formalin (Fisher Scientific, Pittsburg, PA) 
for 24 h for immunohistochemical and morphological analysis. The remaining colon was 
cut in half and snap frozen for RNA analysis. The distal portion of the ileum also was cut 
and fixed in 10% buffered formalin for 24 h for morphological analysis. The liver was 
dissected, and a small portion was fixed in 10% buffered formalin for 24 h, for 
morphological analysis.  
3.3.7. Blood profile 
In both experiment 1 and 2, a complete blood count was performed using the 
VetScan HMT (Abaxis, Union City, CA) for determination of white blood cells (WBCs), 
lymphocytes (LYM), monocytes (MON), neutrophils (NEU), red blood cells (RBCs), 
Hemoglobin (HGB), Hematocrit (HCT), and platelets (PLT). Neutrophil/lymphocyte 
ratio (NLR) was calculated from obtained values. Briefly, whole blood removed from the 
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inferior vena cava was placed in an EDTA microtube and analyzed on the VetScan HMT 
according to the manufacturer’s instructions. 
3.3.8. Hematoxylin and eosin staining & histopathology 
Hematoxylin and eosin staining of the colons, small intestines, and liver were 
performed as previously described96. Colon specimens were characterized according to 
the presence of epithelial neoplasia to: no adenomas/dysplasia (ND), adenomas with low 
grade dysplasia (LGD) adenomas with high-grade dysplasia (HGD) and 
adenocarcinomas. The presence of non-specific colitis also was evaluated in the small 
intestine and the colon (data not shown). Liver specimens were assessed and 
characterized according to the severity of hepatocellular injury: normal, early steatosis 
without inflammation, and acute hepatitis (AHI). All histological analyses were 
performed blindly by a certified pathologist (I.C.). All tissue morphological 
measurements were performed in triplicate and the coefficient of variance was 
determined to be less than 5%. Monocytes/macrophages were observed by positive 
staining of CD68+ (Abcam, ab125212) cells in the colon tissue. 
3.3.9. Gene expression 
Quantification of colonic expression of TNFα, MCP-1, NOS2, IL-6, IL-10, IL-1β, 
IL-4, EMR-1, Ly6G, IFN-γ, and FOXP3, were performed as previously described96. 
Briefly, RNA was extracted using TRIzol reagent (Life Technologies, GIBCO-BRL, 
Carlsbad, CA) and chloroform procedures. Because DSS has been shown to inhibit 
polymerase and reverse transcriptase activity, lithium chloride was used to purify the 
RNA as described in detail by Viennois et al. 201397. RNA sample quality and quantities 
were verified using an Agilent Bioanalyzer and determined to be of good quality based 
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on A260/A280 values (> 1.8) prior to cDNA synthesis using QuantiTect Reverse 
Transcription kit (Qiagen 205313). Quantitative RT-PCR analysis was carried out as per 
the manufacturer’s instructions (Applied Biosystems) using Taq-Man Gene Expression 
Assays. Data were normalized to vehicle treated controls and compared to two reference 
targets (TBP and H2AFV), which were evaluated for expression stability using 
GeNorm98,99.  
3.3.10. Microbiome analysis 
All Microbiome analysis and sequencing was performed by the University of 
North Carolina Microbiome Core. Fecal evacuates were collected from each mouse at the 
conclusion of the study and were chosen at random for 16S rRNA sequencing, at least 
one sample from each cage was used to prevent a cage effect in the data. A final 
n=5/group was obtained and used for 16S rRNA sequencing. DNA was isolated from 
fecal evacuates homogenized with bead-beating using the Qiagen Qiamp Fast DNA Stool 
Mini Kit (Qiagen #51604) and was used for 16S rRNA gene targeted sequencing using 
the V4 region on an Illumina MiSeq sequencer100,101. Amplification of the 16S rRNA V4 
hypervariable region was carried out using the 16S V4 515F forward (5′ TCGTCGGCAG 
CGTCAGATGTGTATAAGAGACAGGTGCCAGCMGCCGCGGTAA 3′) and V4 
806R reverse primer (5′ GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGGAC 
TACHVGGGTWTCTAAT 3′) with added Illumina adapter overhang nucleotide 
sequences. The PCR conditions used were initial denaturing step at 95 °C for 3 min, 
followed by a cycling of denaturing of 95 °C for 30 s, annealing at 55 °C for 30 s and a 
30 s extension at 72 °C (25 cycles), a 5 min extension at 72 °C and a final hold at 4 °C. 
Each 16S amplicon was purified using the AMPure XP reagent (Beckman Coulter, 
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Indianapolis, IN). In the next step each sample was amplified using a limited cycle PCR 
program, adding Illumina sequencing adapters and dual index barcodes (index 1(i7) and 
index 2(i5)) (Illumina, San Diego, CA) to the amplicon target. The thermal profile for the 
amplification of each sample had an initial denaturing step at 95 °C for 3 min, followed 
by a denaturing cycle of 95 °C for 30 s, annealing at 55 °C for 30 s and a 30 s extension 
at 72 °C (8 cycles), a 5 min extension at 72 °C and a final hold at 4 °C. The final libraries 
were again purified using the AMPure XP reagent (Beckman Coulter), quantified and 
normalized prior to pooling. The DNA library pool was then denatured with NaOH, 
diluted with hybridization buffer and heat denatured before loading on the MiSeq reagent 
cartridge (Illumina) and on the MiSeq instrument (Illumina). 
Automated cluster generation and paired–end sequencing with dual reads were 
performed according to the manufacturer’s instructions. Multiplexed paired-end fastq 
files were produced from the sequencing results of the Illumina MiSeq using the Illumina 
software configure BclToFastq. The paired-end fastq files were joined into a single 
multiplexed, single-end fastq using the software tool fastq-join. Demultiplexing and 
quality filtering was performed on the joined results. Quality analysis reports were 
produced using the FastQC software. Bioinformatics analysis of bacterial 16S amplicon 
sequencing data was conducted using the Quantitative Insights Into Microbial Ecology 
(QIIME) software102. Operational taxonomic units (OTUs), an operational definition used 
to classify groups of closely related individuals103, were picked from the quality filtered 
results using pick_de_novo_otus.py. Chimeric sequences were detected and removed 
using ChimeraSlayer. Alpha diversity and beta diversity analysis were performed on the 
data set using the QIIME routines: alpha_rarefaction.py and beta_diversity_-
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through_plots.py, respectively. Summary reports of taxonomic assignment by sample and 
all categories were produced using QIIME summarize_taxa_through_plots.py and 
summarize_otu_by_cat.py103. Samples were rarefied at 10,000 reads/sample. FastTree2 
(Price MN, Dehal PS, Arkin AP FastTree 2- approximately maximum-likelihood tress for 
large alignments) to build the phylogenetic tree. Finally, we used an open reference 
method for OTU picking. Phylogenetic Investigation of Communities by Reconstruction 
of Unobserved States (PICRUSt) was used to predict the functional gene content in the 
fecal microbiota based on taxonomy obtained from the Greengenes reference database. 
PICRUSt and LefSe were performed online in the Galaxy workflow framework. 
3.3.11. Statistical analyses 
All data were analyzed using commercial software (SigmaStat, SPSS, Chicago, 
IL). All outcomes were analyzed using a two-way ANOVA (disease×treatment), three-
way ANOVA (disease×treatment×time) or by a Two-Tailed Student’s T-Test where only 
two groups were compared. A Student-Newman-Keuls test was used for all post-hoc 
analyses. Survival curve analysis was conducted by Log-rank (Mantel-Cox) test. Pearson 
correlations were used to test the relationship between microbiota and colonic gene 
expression. Any data that were not normally distributed or did not display equal variance 
were logarithmically transformed so that those criteria were met. Statistical significance 








3.4.1. Experiment 1: 5FU causes adverse physiological effects, increases colon 
inflammation, and alters gut microbiome profile 
3.4.1.1. 5FU reduces tumor burden but decreases survival in AOM/DSS mice 
As expected, there was a main effect of AOM/DSS on body weight loss during 
the DSS administration (weeks 0–8) (p < 0.05) but not during the 5FU treatment period 
(weeks 8–13). Three cycles of 5FU (weeks 8–13) caused noticeable weight loss in both 
control and AOM/DSS mice but this did not reach statistical significance. However, there 
was a significant interaction detected beginning at week 9; within AOM/DSS, 5FU 
treated mice experienced greater weight loss than AOM/DSS alone (2A, B, p < 0.05). 
Consistent with this, a Mentel-Cox test indicated significant survival risk in 
AOM/DSS+5FU mice compared to all other groups (Fig. 2C, p < 0.05). As expected, a 
main effect of AOM/DSS on severity of symptoms was detected during DSS 
administration as well as during the duration of the 5FU treatment (Fig. 2D, p < 0.05). 
Similarly, at weeks 9–13 (beginning 1 week after 5FU treatment) a main effect of 5FU 
was detected for symptom score (Fig. 2D, p < 0.05). Further, there was a significant 
interaction at weeks 10–11; AOM/DSS+5FU exhibited greater symptom scores than 
AOM/DSS alone. At necropsy, there was no main effect of AOM/DSS or 5FU in liver 
weight; however, a significant interaction was detected within AOM/DSS mice where 
5FU significantly increased liver weight compared to AOM/DSS alone (Fig. 2E, p < 
0.05). As expected, a main effect of AOM/DSS was detected for spleen weight with 
AOM/DSS groups having significantly greater weight (Fig. 2F, p < 0.05) but there was 
no effect of 5FU and no interaction. Both AOM/DSS and 5FU reduced the total weight of 
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the epididymal fat pad (Fig. 2G, p < 0.05) but there was no significant interaction. 
Similarly, a main effect of 5FU was detected in mesenteric fat pad mass with 5FU 
resulting in overall lower weight (Fig. 2H, p < 0.05). A trending decrease in total polyp 
number (Fig. 2I, p=0.18) and a significant decrease in large polyp number (Fig. 2J) (p < 
0.05) was recorded in AOM/DSS+5FU mice compared to AOM/DSS alone. Consistent 
with this, histological analysis of the colonic polyps in AOM/DSS mice treated with 5FU, 
revealed less adenomas with adenocarcinoma and more low-grade dysplasia (Fig. 2K,L) 
compared to AOM/DSS alone. 
3.4.1.2. Nonspecific toxicity of 5FU destroys intestinal tissue morphology and induces 
hepatotoxicity 
 
To observe some of the most commonly associated side effects of chemotherapy, 
we analyzed the small intestine and liver tissue. Histological analysis revealed a main 
effect of 5FU in shortening of the length/atrophy of the villi in small intestine (Fig. 3A, 
B, p < 0.05). Histology of the livers revealed acute hepatitis in 80% of the AOM/DSS 
mice treated with 5FU and in 90% of the cases the presence of necrosis accompanied by 
the formation of abscesses (Fig. 3C, D); findings compatible with liver toxicity. 
3.4.1.3. 5FU alters blood profile differently in the presence of tumor burden 
A main effect of both 5FU and AOM/DSS was detected in LYM, RBC, HGB, 
HCT, and PLT counts (Table 1, p < 0.05); 5FU treatment decreased LYM, RBC, HGB, 
HCT but increased PLT whereas AOM/DSS treated mice exhibited increased LYM but 
decreased RBC, HGB, HCT and PLT (Table 1, p < 0.05). Further, there was a significant 
interaction detected within AOM/DSS; 5FU treated mice presented with greater WBC, 
MON, NEU counts, and NLR (Table 1, p < 0.05) compared to AOM/DSS alone. 
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3.4.1.4. 5FU alters the immune profile of the colon.  
There was a significant main effect of both 5FU and AOM/DSS in mRNA 
expression of inflammatory cytokines TNFα and NOS2 (Fig. 4, p < 0.05). Further, a main 
effect of AOM/DSS was detected in mRNA expression of inflammatory cytokine IFNγ 
and macrophage marker EMR1. Interestingly, a significant interaction was detected 
within AOM/DSS where AOM/DSS mice treated with 5FU showed increased mRNA 
expression of inflammatory cytokines and chemokines MCP-1, IL6, IL1β, IL10 and the 
regulatory T-cell marker FOXP3 (Fig. 4, p < 0.05) compared to AOM/DSS alone. There 
was no significant difference in IL4 expression between any groups (Fig. 4). 
3.4.1.5. 5FU affects functional measures of fatigue 
To evaluate the effects of 5FU on peripheral muscle fatigue we utilized grip 
strength testing (measured as absolute strength in N and relative N/Kg body weight). No 
significant differences between groups were detected in relative grip strength (N/Kg); 
however, analysis of absolute strength indicates a significant interaction within 
AOM/DSS treatment in which AOM/DSS mice treated with 5FU exhibited a significant 
decrease in strength (Fig. 5A, B, p < 0.05) compared to AOM/DSS alone. To measure the 
effect of 5FU on fatigability, mice were challenged with a run-to-fatigue test. Given that 
there were no differences in absolute values at baseline between any of the groups, the 
data is presented as percent performance change (Fig. 5C). No significant main effects 
were detected; however, AOM/DSS mice treated with 5FU showed a strong trend for a 
decreased overall performance compared to AOM/DSS alone with a majority (7/9) of 




3.4.1.6. 5FU treatment alters gut microbiota and correlates with colonic gene expression 
Recent investigations have indicated that 5FU significantly alters the gut 
microbiota in both the colon and small intestine. Further, alterations in gut microbiota 
composition may have detrimental effects on immune function in the gut. To focus our 
investigation on the colon microenvironment we performed 16S rRNA sequencing on 
fecal pellets collected during euthanasia (the full analysis will be available upon request 
to the corresponding author). A Shannon plot and total sequences per sample figures were 
generated to demonstrate differences in community richness and evenness to estimate 
within-community diversity (alpha-diversity) (Fig. 6A, B). Results of the alpha-diversity 
plots indicate that three cycles of 5FU did not necessarily alter microbiota diversity in 
control mice but did alter the richness and evenness in AOM/DSS mice (Fig. 6A, B). 
Unweighted UniFrac PCoA analysis demonstrated that there is a difference in beta-
diversity across groups at the OTU level (Fig. 6C). A two-way ANOVA was performed 
to determine main effects and interactions among phyla and class. AOM/DSS increased 
the relative abundance of OTUs in Proteobacteria and Verrucomicrobia (Fig. 6D, p < 
0.05) but decreased it in Actinobacteria, Bacteroidetes, and Tenericutes (Fig. 6D, p < 
0.05) whereas 5FU increased the relative abundance of OTUs in the Actinobacteria and 
Verrucomicrobia phyla (Fig. 6D, p < 0.05). Surprisingly, there were no main effects in 
the relative abundance of OTUs of the Firmicutes phylum. Interactions were evident 
within AOM/DSS and 5FU; within AOM/DSS, 5FU decreased the relative abundance of 
OTUs in the Firmicutes phylum compared to AOM/DSS alone (Fig. 6D, p < 0.05) and 
within 5FU, AOM/DSS had significantly less relative abundance of OTUs of 
Actinobacteria compared to 5FU alone (Fig. 6D, p < 0.05). Interestingly, the 
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aforementioned differences were seen in a similar fashion at the class level. A main effect 
of AOM/DSS was detected for decreased relative abundance of Actinobacteria, 
Bacteroidia, Erysipelotrichi, Deltaproteobacteria, and Mollicutes and increased 
abundance of Betaproteobacteria and Verrucomicrobia classes (Fig. 6E, p < 0.05). 
Further, a main effect of 5FU was detected in which the relative abundance of OTUs 
were decreased in the classes Coriobacteria and Deltaproteobacteria and increased in the 
Actinobacteria, Bacilli, Betaproteobacteria, and Verrucomicrobia classes (Fig. 6E, p < 
0.05). There was no significance differences detected in the class Clostridia. A significant 
interaction was found within 5FU in which AOM/DSS mice had significantly greater 
abundance of OTUs of Actinobacteria compared to 5FU alone whereas 5FU resulted in a 
decrease in Bacteroidia in the absence of AOM/DSS (Fig. 6E, p < 0.05). 
To observe the potential relationship between gut microbiota changes and colon 
gene expression we performed Pearson correlations on three of the most influenced 
microbial phyla that relate to inflammation and cancer outcome; Bacteroidetes, 
Proteobacteria, and Verrucomicrobia. Six genes; TNFα (r=0.788, p < 0.01), MCP-1 
(r=0.588, p < 0.01), NOS2 (r=0.679, p < 0.001), IL6 (r=0.671, p < 0.01), IL1b (r=0.516p 
< 0.05), and FOXP3 (r=0.535, p < 0.05) were positively correlated with Verrucomicrobia 
abundance (Fig. S1A–F). Similarly, eight genes; TNFα (r=0.528, p < 0.05), MCP-1 
(r=0.717, p < 0.01), IL6 (r=0.685, p < 0.01), IFNγ (r=0.582, p < 0.01), IL1β (r=0.742, p < 
0.01), IL10 (r=0.647, p < 0.01), FOXP3 (r=0.717, p < 0.01), and NOS2 (r=0.624, p < 
0.01) were positively correlated with Proteobacteria abundance (Fig. S1G–N). Lastly, 
three genes; IL10 (r=−0.616p < 0.01), IL6 (r=−0.476, p < 0.05), and FOXP3 (r=−0.680, p 
< 0.01) were negatively correlated with Bacteroidetes abundance (Fig. S1O–Q). 
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3.4.1.7. Metagenomic PICRUSt analysis indicates functional consequences of altered 
microbiota. 
 
To investigate the functional consequences of the taxonomic changes in gut 
microbial composition, we performed PICRUSt metagenomic analysis to generate a 
functional profile of the microbial communities investigated. The full analysis will be 
available upon request to the corresponding author. We present here the most interesting 
of the findings (Fig. S2A–D). We detected a main effect of 5FU and AOM/DSS in 
predicted expression of nitrate reductase subunits (alpha, beta, gamma, and delta), [citrate 
(pro-3S)-lyase] ligase and [protein-PII] uridylyltransferase (Fig. S2A, p < 0.05), and 
acylphosphatase (Fig. S2C, p < 0.05). Similarly, there is a main effect of AOM/DSS in 
predicted expression of 5′nucleotidase (Fig. S2A, p < 0.05) and a main effect of 5FU on 
fumarate hydratase expression (Fig. S2D, p < 0.05). There were no significant 
interactions for the aforementioned outcomes. However, a significant interaction was 
detected for beta-mannosidase within 5FU; 5FU alone increased beta-mannosidase but it 
was significantly decreased in AOM/DSS mice treated with 5FU (Fig. S2B, p < 0.05). 
3.4.2. Experiment 2: fecal transplantation of 5FU-disturbed microbiota alters host 
physiology 
 
3.4.2.1. Fecal transplantation affects functional measures of fatigue 
To elucidate the role of the gut microbiota on the adverse side-effects associated 
with 5FU treatment we performed fecal transplantation studies in control mice (Fig. 1B). 
No body weight or organ weight difference was detected between the two groups 
(Vehicle FMT and 5FU FMT) (Fig. 7A–F). All mice were challenged to the same fatigue 
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tests used in experiment 1. A significant decrease in absolute grip strength (Fig. 7G, p < 
0.05) and a trending decrease in relative grip strength (Fig. 7H, p=0.06) was detected in 
mice treated with 5FU FMT compared to vehicle control. In the run-to-fatigue test, a 
trending decrease (Fig. 7 I, p=0.07) in performance was recorded in 5FU mice compared 
to control. Similar to Experiment 1, we noticed a large number (6/15) of mice with 
negative performance changes following 5FU FMT. 
3.4.2.2. Fecal transplantation manifests a unique blood profile 
Upon analysis of the blood profile, we noticed a significant increase in WBC, 
MON, and LYM counts in 5FU FMT mice vs Vehicle FMT controls (Table 2, p < 0.05). 
However, no differences in NEU and RBC counts were detected (Table 2). The increase 
in lymphocyte count contributed to a trending decrease in NLR in 5FU FMT mice 
compared to Vehicle FMT controls (Table 2, p=0.07).  
3.4.2.3. 5FU fecal microbial transplantation reduces macrophage populations in the 
colon 
 
To further understand the potential contribution of gut microbiota on 
inflammatory responses following 5FU treatment, we performed gene expression analysis 
on the colon tissue. Contrary to our hypothesis, we found a decreased expression of 
MCP-1, IL10, and EMR1 in 5FU FMT mice compared to Vehicle FMT controls (Fig. 
8A, p < 0.05). A trending decrease in IL1β (p=0.08) also was detected with no 
differences in TNFα, NOS2, IL4, and Ly6G expression (Fig. 8A). Investigating the 
morphology of the colon tissue, we did not notice any histological differences between 
Vehicle FMT and 5FU FMT mice (Fig. 8B). The gene expression data explained above 
indicate a decreased macrophage population in 5FU FMT mice relative to Vehicle FMT 
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controls. To confirm this finding, we performed immunohistochemical analysis of 
CD68+ cells present in the colons (Fig. 8C). Although we did not directly quantify, 
observation suggests fewer CD68+ positive cells in the lamina propria and epithelial 
layers in 5FU FMT mice. 
3.5 Discussion 
5FU chemotherapy is widely used in the treatment of CRC. However, side effects 
including fatigue, loss of appetite, and diarrhea, all of which can lead to a reduced quality 
of life, are common. Emerging evidence suggests that the gut microbiota may play a role 
in this response. In the current study, we sought to characterize the effects of 5FU on 
colon inflammation and functional measures in CRC and to further determine whether 
gut microbiota can influence this response. Despite a general anti-tumor effect of 5FU, 
we document findings of non-selective toxicity in intestinal and liver tissue that which 
are associated with reduced functional performance and decreased survival. Select 
intestinal inflammatory genes were significantly elevated with 5FU treatment and this 
was further exacerbated with cancer. Both 5FU and AOM/DSS treatment result in 
significant alterations in gut microbiota and predicted functional parameters. Finally, 
using fecal transplantation we demonstrate that a 5FU altered microbiome influences the 
systemic and colonic immune environment and can impact functional parameters. 
Our findings indicate that a clinically relevant chemotherapy regimen has general 
anti-tumor effects in the AOM/DSS model of CRC. This is consistent with previous 
reports of a beneficial effect of 5FU in intestinal tumorigenesis in the Apcmin/+ mice 
model where a 60–80% reduction in polyps was reported104. Despite these benefits 
however, our data indicates that 5FU reduces body weight, exacerbates symptom severity 
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score, increases liver weight, and decreases epididymal fat mass, consistent with a 
decrease in survival. These results are not surprising given the well documented toxicities 
resulting from 5FU non-selectivity30,32. The manifestations of 5FU induced toxicity have 
been mainly attributed to ‘mucositis’ or the disruption of the mucosal barrier35,105. We 
confirm this damaging mechanism as we report a main effect of 5FU treatment on 
reducing villus length in the distal ilium. Further complications of chemotherapy in CRC 
include progressive liver failure leading to premature death36,105,106. Our results are 
consistent with this as the majority of AOM/DSS mic treated with 5FU presented with 
acute necrotizing inflammation with abscesses in the liver. These histological findings are 
indicative of an immune response against a bacterial infection107,108, evidence that can be 
associated with the presence of leaky gut syndrome; however, further investigation would 
be needed to confirm this finding. Other studies have reported similar results using short, 
high-dosage treatment regimens (Chang et al., 2012; Li et al., 2017) but have utilized 
non-diseased mouse models33,91. Our findings suggest that the chemotherapy regimen 
administered in this experiment, using a mouse model of CRC, is effective in replicating 
the clinical outcome of 5FU treatment. 
Given 5FU’s well documented effects on blood parameters, we used a diverse 
blood panel analysis to specifically investigate its effects on circulating immune cells and 
factors contributing to chronic anemia in the context of CRC. Consistent with clinical and 
experimental literature, we observe decreased circulating immune cells and indications of 
severe anemia with 5FU treatment and in the presence of cancer.35,37 As expected, the 
combined treatment of 5FU and AOM/DSS had worsening effects on anemia including 
RBCs, HCT and HGB. Interestingly, however, where 5FU seemingly causes significant 
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immune cell death in a healthy physiological state, it appears that the already altered 
physiology caused by the AOM/DSS model of tumor burden increased the systemic 
immune response when combined with 5FU. This specifically caused an increase in 
neutrophils and monocytes, but not lymphocytes. The mechanism for this increase in 
circulating innate immune cells is unclear and warrants further investigation.  
ROS produced following initiation of 5FU-related mucositis induces tissue injury 
and triggers a cascade of inflammatory pathways including nuclear factor kappa-B (NF-
κB) activation. Once activated by 5FU, NF-κB induces gene expression and production 
of pro-inflammatory cytokines, which, in turn, lead to tissue injury and apoptosis.109 In 
addition, CRC itself leads to significant colon inflammation as we have previously 
reported.110 Therefore, it is possible that colon-specific inflammation may be exacerbated 
following treatment of 5FU in CRC leading to worsening symptoms and poor prognosis. 
Thus, we next examined the effects of 5FU on colon inflammation in the context of CRC. 
As hypothesized, both 5FU and AOM/DSS lead to an increase in select inflammatory 
mediators with a greater degree of inflammation noted in AOM/DSS mice treated with 
5FU. As such, it is possible that this ‘inflammatory cytokine storm’ may explain, at least 
in part, the increased mortality in AOM/DSS mice treated with 5FU. 
To establish the functional deficits associated with chronic 5FU treatment, we 
performed a grip strength and run-to-fatigue test. AOM/DSS mice treated with three 
cycles of 5FU significantly reduced absolute grip strength and there was a strong trend 
towards a decreased run-to-fatigue time. This was consistent with findings of a previous 
study by our group that characterized the chronic fatigue of 5FU treatment.111 The 
mechanisms responsible for 5FU-related fatigue in cancer patients have not yet been fully 
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elucidated. However, several hypotheses have been postulated and include: central 
serotonin dysregulation, hypothalamus-pituitary-adrenal axis dysfunction, circadian 
disruption, depression, anemia, and central and peripheral inflammation.112,113 Arguably, 
the strongest of these are inflammation and anemia. Our data supports these hypotheses 
given the increase in anemia related outcomes and inflammation in AOM/DSS mice 
treated with 5FU – mice with the greatest performance deficits. 
Recent investigations have implicated a direct role of gut microbiota in the 
development and treatment of CRC. Therefore, we next examined the effects of 5FU on 
the gut microbiota profile. Others have reported differences in gut microbiota following 
5FU treatment in non-cancer mice.91 However, to our knowledge this is the first report of 
a change in microbiota profile when 5FU is administered in the presence of CRC in an 
experimental mouse model; specifically, we note a decrease in alpha diversity. We focus 
our discussion on the most important and novel findings of the post-hoc analysis of 
bacterial phyla. We saw a decrease in abundance of Firmicutes phylum in AOM/DSS 
mice treated with 5FU but not in AOM/DSS alone. The Firmicutes represent one of the 
most abundant phyla of the gut microbiota and are important for short-chain fatty acid 
production and maintenance of gut homeostasis.91,114 In-fact decreases in Firmicutes have 
previously been associated with inflammatory bowel disease and CRC.114,115 This 
suggests a possible role of chemotherapeutics in altering the gut microbiota in the 
presence of CRC in a manner that exacerbates gut dysbiosis and may contribute to a 
worse prognosis following chemotherapy treatments. Further, both 5FU treatment and 
AOM/DSS treatment increased relative abundance of Verrucomicrobia. This is not 
surprising given that the Verrucomicrobia phylum is suggested to be directly related to 
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inflammation in the colon.40,116,117 The increase in Proteobacteria phylum with 
AOM/DSS appeared to result from increased Betaproteobacteria. This is consistent with 
findings in human fecal samples in which Betaproteobacteria were found to be increased 
in patients with CRC.118 Our findings of a decrease in Bacteroidetes in AOM/DSS treated 
mice are consistent with some reports of lower levels of Bacteroidetes being linked to 
increased cancer risk.115 The strong correlations detected between the above-mentioned 
phyla and colon inflammatory mediators suggest a potential link between gut microbes 
and the exacerbated inflammation in AOM/DSS mice treated with 5FU. If 
Verrucomicrobia and Proteobacteria are indeed playing a role in the creation of an 
‘inflammatory cytokine storm,’ selected targeting of these phyla may help lower the 
adverse toxicities common to 5FU treatment. Further, PICRUSt analysis of OTUs 
indicates significant changes in predicted genes involved in environmental processing 
and cellular processes. From these predicted changes it can be suggested that alterations 
in the gut microbiota may affect key processes outside the gut that may be contributing to 
the exacerbated disease state in AOM/DSS mice treated with 5FU. 
While our gut microbiota findings are consistent with some of the previously 
reported literature for both 5FU and CRC, it is important to note that inconsistencies also 
exist. For example, a recent study by Li et al. (2017), reported decreased Firmicutes and 
Proteobacteria, increased Bacteroidetes, and no significant change in Verrucomicrobia 
following 5FU treatment in a cancer-free model91, whereas we saw increases in 
Verrucomicrobia and Actinobacteria with no changes in the other phyla. However, only 3 
consecutive injections of 5FU (50 mg/kg) were used by Li et al. (2017), whereas we 
employed a cycled regime with the aim of investigating chronic effects of 5FU treatment. 
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These differences in treatment regime likely contributed to the disparities in findings 
across studies. Further, some of these differences may stem from our utilization of the 
AIN-76A purified diet instead of standard chow and randomization of the mice upon 
arrival to the facility to prevent maternal bias in fecal analysis.116 Similarly, while we 
report here a decrease in Bacteroidetes with AOM/DSS, it should be noted that reports of 
increases also have been reported in CRC119 indicating inconsistencies in the literature. 
Culminating from the differences in the gut microenvironment of 5FU treated 
mice, we next sought to determine whether gut microbes may be responsible for some of 
the side effects associated with 5FU. Thus, we designed an experiment utilizing gut 
microbiota depletion followed by subsequent engraftment by either Vehicle FMT or 5FU 
FMT (Fig. 1B).95 An absence of body weight and organ weight changes from fecal 
transplantation was contrary to our hypothesis and the findings of Li et al. (2017), which 
showed a significant decrease in body weight following transplantation of feces from 
5FU treated mice.91 As noted above, differences in the study design may have contributed 
to the disparities among findings. Interestingly, however, we did find a decrease in 
muscle strength and run-to-fatigue times following engraftment of 5FU FMT that is 
consistent with the findings in Experiment 1. To our knowledge this is the first report of a 
direct relationship between 5FU, gut microbes, and performance deficits and probes the 
determination of the exact microbes that may be contributing to this response. 
We next examined the effects of engraftment by either Vehicle FMT or 5FU FMT 
on circulating and colonic immune responses. Performing the same diverse blood panel 
as Experiment 1, we observe an increased number of circulating immune cells (WBC, 
LYM, MON) in 5FU FMT mice engrafted with 5FU treated feces, a finding contrary to 
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the results of direct 5FU treatment in Experiment 1. Others have reported effects of gut 
bacteria on circulating immune cells.57 However, to our knowledge this is the first report 
of a 5FU influenced gut microbiome on circulating immune cells. Fecal Microbial 
Transplantation of microbes from mice treated with 5FU (5FU FMT) to non-diseased 
(Control) mice specifically reduced the MCP-1 and EMR1 gene expression in the colon 
but Ly6G was unaltered. This indicates that the engrafted microbiome may be causing a 
reduction specifically in the macrophage population in the colon but not in neutrophils. 
This was consistent with a notable reduction in CD68+ cells in the colon. This finding 
was further supported by a decreased expression of IL-10 and a trending decrease in IL-
1β, cytokines that are known to be released from macrophages.111 This suggests that the 
altered microbial composition resulting from 5FU treatment may, in-itself, be eliciting an 
anti-inflammatory response independent of 5FU, where cellular damage from 5FU is 
most likely contributing to the proinflammatory response reported in Experiment 1. 
Although requiring further investigation, this would explain the correlations of certain 
bacteria to both pro- and anti-inflammatory markers in the colon tissue in Experiment 1. 
Taken together, these data suggest that transfer of 5FU treated feces leads to an increased 
production of circulating immune cells including monocytes; yet appears to reduce 
macrophages in the colon. However, the exact microbes that are driving this response 
cannot be determined from the current study. 
The novel findings from this study implicate that 1) the immune response to 
cancer therapy may be regulated by gut microbiota and 2) gut microbiota may influence 
functional outcomes following cancer therapy. This suggests that gut microbiota may 
serve as a potential therapeutic target for manipulating immune responses and improving 
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quality of life outcomes during cancer therapy. It is certainly possible, and even likely, 
that some microbes may confer beneficial effects in this model whereas others may have 
detrimental effects. Thus, future preclinical studies should determine the exact microbes 
that are responsible for the aforementioned effects so that therapeutics can be developed. 
Administration of antibiotics and FMT are viable options for manipulating gut microbiota 
during cancer therapy and could be implemented in the clinic. 
In summary, this study examined the functional and physiological effects of 5FU 
in the context of CRC. Despite a general anti-tumor effect of 5FU, we report findings of 
non-selective toxicity in intestinal and liver tissue that are associated with reduced 
functional performance and decreased survival. The side effects of 5FU in CRC were 
associated with alterations in gut bacteria and functional pathways. Finally, using fecal 
transplantation we demonstrate that a 5FU altered microbiome can influence the systemic 
and colonic immune environment and can impact functional parameters. However, 
further studies are necessary to determine the exact bacterial populations that are 
responsible for these effects and whether gut bacteria can be targeted for reducing side 
effects associated with chemotherapy. 
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3.7 Figures & Legends 
 
Figure 3.1. Study Design for experiment 1 and experiment 2. A. Experiment 1 design 








Figure 3.2. 5FU reduces tumor burden but decreases survival in AOM/DSS mice. A. 
Gross body weight. B. Percent body weight change. C. Survival curve. D. Symptom 
score. * Indicates statistical significance (p < 0.05) for AOM/DSS+5FU group vs. all 
groups, # indicates statistical significance (p < 0.05) for Control+5FU vs. 
Control+Vehicle from 3-way ANOVA. E-H. Liver, spleen, epididymal fat, and 
mesenteric fat, weights at euthanization. Groups not containing the same letters (a, b, ab) 
indicate statistical significance between groups (p < 0.05) from two-way ANOVA, n=9–
13/group. I. Total Polyp count. J. Polyp size. K. Dysplasia characterization. L. 
Representative H&E staining of distal colon specimens at 4X, insets are 20X. * Indicates 





Figure 3.3. Nonspecific toxicity of 5FU in distal ileum and liver tissue. A. 
Representative H&E staining of distal ileum specimens at 4X, insets are 20X. B. 
Measurement of villus length in small intestine. Groups not containing the same letters 
(a, b) indicate statistical significance between groups (p < 0.05) from two-way ANOVA. 
C. Representative H&E staining of liver tissue specimens at 4X, insets are 20X. D. 







Table 3.1. 5FU alters blood profile in AOM/DSS mice different from control. White blood cells (WBC), Lymphocytes (LYM), 
Monocytes (MON), Neutrophils (NEU), Neutrophil:Lymphocyte Ratio (NLR), Red Blood Cells (RBC), Hemoglobin (HGB), and 
Hematocrit (HCT). Groups not containing the same letters (a,b,c,d) indicate statistical significance between groups (p < 0.05) from 






































































































Figure 3.4. 5FU alters the immune profile of the colon. A. qPCR analysis of TNFα, 
MCP-1, NOS2, IL6, IFNg, IL1b, IL10, IL4, FOXP3 genes. Data were normalized to 
vehicle treated controls and compared to two reference targets (TBP and H2AFV), which 
were evaluated for expression stability using GeNorm. Groups not containing the 
same letters (a–d) indicates statistical significance between groups (p < 0.05) from two-
way ANOVA, n=9–13/group. 
 
 
Figure 3.5. 5FU affects functional measures of fatigue. A. Relative grip strength 
measured in newtons/kilogram (N/kg). B. Absolute grip strength measured in newtons 
(N). C. Percent performance change in run-to-fatigue test from pre-5FU treatment to 
post-5FU treatment. Groups not containing the same letters (a, b) indicates 








Figure 3.6. 5FU alters gut microbial profile. A. Shannon plot of alpha-diversity in 
microbial communities. B. Total sequences per sample by Shannon rarefaction. C. 
Unweighted UniFrac Principle Coordinate Analysis (PCoA) of beta-diversity in 
microbial communities. D. Percent abundance of microbial phyla. E. Percent abundance 
of microbial class, n=5/group. 
 
Figure 3.7. Fecal Transplantation of 5FU altered microbiome does not alter body 
weight but does affect functional measures of fatigue. A. Gross body weight. B. 
Percent body weight change. C-F. Liver, spleen, epididymal fat, and mesenteric fat, 
weights at euthanization. G. Relative grip strength measured in newtons/kilogram (N/kg). 
H. Absolute grip strength measured in newtons (N). I. Characterization of performance 
changes in run-to-fatigue test. J. Percent performance change in run-to-fatigue test from 
pre-5FU treatment to post-5FU treatment. * Indicates statistical significance between 







Table 3.2 5FU FMT manifests a unique blood profile. White blood cells (WBC), Lymphocytes (LYM), Monocytes (MON), 
Neutrophils (NEU), Neutrophil:Lymphocyte Ratio (NLR), Red Blood Cells (RBC), Hemoglobin (HGB), and Hematocrit (HCT). * 
































































Figure 3.8. 5FU alters macrophage population in the colon lamina propria and is 
replicated with fecal transplantation. A. qPCR analysis of TNFα, MCP-1, NOS2, IL1b, 
IL10, IL4, Ly6G, and EMR1 genes in fecal transplantation mice. B, C. Representative 
H&E staining and CD68+ staining, respectively, in distal colons of fecal 
transplantation mice. Arrows indicate examples of positive staining. * Indicates statistical 






























3.8 Supplemental Material 
 
 
Supplementary Figure S3.1. Verrucomicrobia, Proteobacteria, and Bacteroidetes 
phyla correlate with key markers of inflammation in the colon. Pearson correlation 
coefficients (r) are shown for Verrucomicrobia to colon gene expression of A. TNFα B. 
MCP1 C. NOS2 D. IL6 E. IL1b and F. FOXP3 with the associated p-values. Pearson 
correlation coefficients (r) are shown for Proteobacteria to colon gene expression of G. 
TNFα H. MCP1 I. IL6 J. IFNg K. IL1b L. NOS2 M. FOXP3 and N. IL10 with the 
associated p-values. Pearson correlation coefficients (r) are shown for Bacteroidetes to 




Supplementary Figure S3.2. Select PICRUSt analysis results indicating altered 
functional consequences of 5FU treatment. A. Select markers of environmental 
information processing. B. Select marker of cellular processes. C. Select marker of 
xenobiotic degradation. D. Select marker involved in development of human diseases. 






























Background: Emodin, a natural anthraquinone, has shown potential as an effective 
therapeutic agent in the treatment of many diseases including cancer. However, its 
clinical development is hindered by uncertainties surrounding its potential toxicity. The 
primary purpose of this study was to uncover any potential toxic properties of emodin in 
mice at doses that have been shown to have efficacy in our cancer studies. In addition, we 
sought to assess the time course of emodin clearance when administered both 
intraperitoneally (I.P.) and orally (P.O.) in order to begin to establish effective dosing 
intervals. Methods: We performed a subchronic (12 week) toxicity study using 3 
different doses of emodin (~20 mg/kg, 40 mg/kg, and 80 mg/kg) infused into the AIN-
76A diet of male and female mice (n=5/group/sex). Body weight and composition were 
assessed following the 12-week feeding regime. Tissues were harvested and assessed for 
gross pathological changes and blood was collected for a complete blood count and 
evaluation of ALT and creatinine. For the pharmacokinetic study, emodin was delivered 
intraperitoneally I.P. or P.O. at 20 mg/kg or 40 mg/kg doses to male and female mice 
(n=4/group/sex/time-point) and circulating levels of emodin were determined at 1, 4 and 
12 hrs following administration via LC-MS/MS analysis. Results: We found that 12 
weeks of low (20 mg/kg), medium (40 mg/kg), or high (80 mg/kg) emodin feeding did 
not cause pathophysiological perturbations in major organs. We also found that 
glucuronidated emodin peaks at 1hr for both I.P. and P.O. administered emodin and is 
eliminated by 12 hr. Interestingly, female mice appear to metabolize emodin at a faster 
rate than male mice as evidenced by greater levels of glucuronidated emodin at the 1hr 




(20 mg/kg I.P.). Conclusions: In summary, our studies establish that 1) emodin is safe 
for use in both male and female mice when given at 20, 40, and 80 mg/kg doses for 12 
weeks and 2) sex differences should be considered when establishing dosing intervals for 
emodin treatment.  
4.2 Background 
Emodin (1,3,8-trihydroxy-6-methylanthraquinone) (Fig 1A) is a natural 
anthraquinone isolated from several Chinese herbs, including Rheum palmatum, 
Polygonum cuspidatum, and Polygonum multiflorum. Pre-clinical investigations have 
demonstrated emodin to contain a wide spectrum of pharmacological benefits, including; 
anti-viral69, anti-bacterial70, anti-allergic71, anti-osteoporotic72, anti-diabetic73,85, anti-
inflammatory74,75,80,120, neuroprotective76, hepatoprotective77, and anti-
tumorigenic78,79,86,121-123 properties (Supplemental Table 1). In fact, studies by our group 
have shown that emodin is effective at reducing mammary tumorigenesis given its 
actions on macrophages.78,122  Both the National Cancer Institute (NCI) and the National 
Center for Complementary and Integrative Health (NCCIH) recognize the importance of 
evidence-based complementary medicine modalities that may be integrated as part of 
standard cancer care for all patients across the cancer continuum. However, further 
development of emodin as an effective anti-cancer agent is hindered by uncertainties 
surrounding its potential toxicity.    
Evaluation of the safety of dietary compounds is paramount to their clinical 
development.  Several studies have reported side effects of emodin that may preclude its 
development beyond pre-clinical studies. For instance, it has been suggested that emodin 




mutagenicity in certain strains of bacteria.124,125 There also are reports of hepatotoxic 
effects of emodin depending on the dose. 126-130 Further, at very high doses (1-3 g/kg/d 
for mice), emodin has been shown to have laxative effects leading to melanosis.125,131 
While the number of negative reports is arguably balanced by the number of studies 
reporting no side-effects, uncertainties remain and have hampered enthusiasm for further 
development of this promising dietary agent.    
Given the potential toxicity associated with emodin along with our efforts in the 
development of emodin as a complementary cancer therapy, we performed a sub-chronic 
toxicity study of emodin as a first step to clinical translation. We subjected mice to an 
emodin infused diet of three different concentrations (~20 mg/kg, 40 mg/kg and 80 
mg/kg) – similar doses that we have used in our efficacy studies – for 12 weeks to 
monitor any potential toxic effects that emodin may have. In addition, we performed a 
pharmacokinetic study to evaluate the time course of emodin clearance from the 
circulation when given via two different routes of administration, intraperitoneally (I.P.) 
and orally (P.O.). To ensure that we are not limiting translational relevance, both male 
and female mice were used in both the toxicity and pharmacokinetic studies.   
4.3 Methods 
4.3.1 Animals 
Male and female C57BL/6J mice were purchased from Jackson Laboratories (Bar 
Harbor, ME) and were cared for in the animal facility at the University of South Carolina 
School of Medicine. Mice (n=4-5/group/sex/experiment) were randomized upon arrival 
to the animal facility to prevent litter biases and were housed 4-5 per cage and maintained 




noise). Mice were handled only by the primary investigator (ATS). All mice were 
habituated for 6 weeks to the AIN-76A diet prior to any interventions and were given 
food and water ad libitum through the course of the study. All methods were performed 
in accordance with the American Association for Laboratory Animal Science and the 
Institutional Animal Care and Usage Committee at the University of South Carolina.  
4.3.2 Emodin 
Emodin was purchased from Nanjing Zelang Medical Technology Co., Ltd, 
(Nanjing, China). Emodin was independently analyzed by the Mass Spectrometry Center 
at the University of South Carolina prior to the initiation of the experimental study. 
Liquid Chromatography -Ultraviolet-Mass Spectrometry (LC-UV-MS) and Nuclear 
Magnetic Resonance (NMR) was performed to confirm the purity and molecular 
structure of emodin (Fig 1A). 
4.3.3 Emodin dosing and time course analysis for pharmacokinetic studies 
 Emodin was delivered intraperitoneally (I.P.) or by oral gavage (P.O.) at 20 
mg/kg or 40 mg/kg doses. For the I.P. study, emodin, dissolved in DMSO was made in a 
large batch, aliquoted, and stored at -200C until used for injections. It was subsequently 
diluted in PBS (1% DMSO) and administered to mice I.P. at doses of 20 mg/kg (0.5 
mg/mL) or 40 mg/kg (1 mg/mL). To deliver emodin P.O., we utilized a 20G 30-mm 
flexible plastic tubal oral gavage needle (Instech, #FTP-20). To prevent aspiration of the 
emodin bolus, mice were briefly anesthetized with 2% isoflurane prior to gavage and held 
upright until consciousness was regained. Emodin was prepared fresh on the day of 
administration. Briefly, emodin was mixed in pure propylene glycol (VWR, #97061) for 




delivered to mice at 20 mg/kg (6mg/mL) and 40 mg/kg (12mg/mL) doses. We used 1% 
DMSO in PBS (I.P.) or pure propylene glycol (P.O.) for vehicle controls. 
 Plasma emodin content was analyzed at three specific time points (t=1hr, 4hr, and 
12hr) after treating male and female WT C57BL/6J mice I.P. or P.O. Emodin was given 
at 20 mg/kg or 40 mg/kg; n=4 mice were used per dosage, per timepoint, and per sex. 
Vehicle treated mice were used to analyze empty plasma extracts.  
4.3.4 Solid Phase Extraction and LC-MS/MS Analysis 
 Whole blood was collected in EDTA coated tubes from the inferior vena cava and 
centrifuged at 4,000 RPM for 10 min. Plasma was aliquoted and stored at -200C until 
solid phase extractions. For free emodin quantification, 50 μl plasma was mixed with 
equal 0.2M sodium acetate buffer with 1% ascorbic acid (pH 5.0). For emodin 
glucuronide quantification, 50 μl plasma was mixed with half volume of 0.2M sodium 
acetate buffer with 1% ascorbic acid and 1000 units of β-glucuronidase (Millipore Sigma 
#G2174). D4-emodin (1 ng/μl) was used as an internal standard (Santa Cruz #218302). 
Both tubes were then incubated at 370C for 2hr. After incubation, the mixture was 
extracted with 600 μl ethyl acetate three times. The ethyl acetate layer was evaporated 
under N2 gas to dryness and reconstituted in 5% ammonia water. Solid phase extraction 
was performed using a vacuum manifold (Supelco #SU57250-U) with Oasis MCX 
cartridges (Fisher #186000254) and was eluted with 3 mL 5% formic acid-methanol. 
After elution, the eluent was evaporated under N2 gas to dryness and reconstituted in 400 




Emodin samples were analyzed and quantified by LC-MS/MS using electrospray 
ionization in negative ion mode. Chromatorgraphic separation was performed on a 
Waters Acquity UPLC system using a binary solvent gradient. Solvent A was water 
containing 0.1% formic acid and solvent B was methanol. The LC column was a Waters 
XBridge C18 reversed phase column (2.1mm X 100mm containing 3.5um particles) 
running at a flow rate of 0.2 mL/min. The solvent gradient started at 50%B, ramped to 
95%B over 10 minutes and was maintained at 95%B until 14 minutes. The gradient then 
returned to initial conditions. The mass spectrometer was a Waters Premier XE triple 
quadrupole instrument. Data was collected in multiple reaction monitoring (MRM) mode. 
Two precursor/product ion pairs were monitored; one pair for emodin (269 daltons > 225 
daltons) and one pair for the internal standard deuterium labeled emodin (273 daltons > 
229 daltons). According to the standard curve of emodin in 5% ammonia methanol, the 
concentration of emodin was calculated relative to the D4-emodin internal standard. Total 
emodin was measured from the tube containing the β-glucuronidase, free emodin was 
measured from the tube without β-glucuronidase, and glucuronidated emodin was 
calculated as the difference between total emodin and free emodin.  
4.3.5 Emodin diets for sub-chronic toxicity study 
We analyzed the effect of emodin feeding over a 12-week period. Emodin was 
infused into the AIN-76A diet at three different concentrations; 170 mg/kg, 340 mg/kg, 
and 680 mg/kg (BioServ, Frenchtown, NJ). These concentrations were based on our 
established average food intake of C57BL/6 mice and translate to a daily ingested dose 
per body weight of ~20 mg/kg, 40 mg/kg, and 80 mg/kg, respectively. Therefore, we 




mg/kg, and 80 mg/kg. Mice were purchased at 4 weeks of age, kept on AIN-76A diet 
until 10 weeks of age, and then separated into experimental groups and started on their 
respective diets. Mice were maintained on their treatment diets for 12 weeks and were 
given food and water ad libitum.  
4.3.6 Body weights and body composition 
 Body weight, food, and water consumption were monitored on a weekly basis 
throughout the study. Body composition was assessed after 12 weeks of emodin diet 
using dual-energy X-ray absorptiometry (DEXA) (Lunar PIXImus, Madison, WI). 
Briefly, mice were placed under gas anesthesia (isoflurane, 2%) and were assessed for 
bone mineral density (BMD), lean mass, fat mass, and body fat percentage. Lean mass 
(%) was calculated as percent lean weight and bone mineral content (BMC) of total body 
weight.  
4.3.7 Tissue Collection 
After 12 weeks of dietary treatment, mice were euthanized by isoflurane overdose 
following a 4 hour fast, blood was collected from the inferior vena cava and placed in 
EDTA coated lavender top tubes for plasma collection and blood panel analysis. The 
following tissues were harvested and fixed overnight in 10% neutral buffered formalin 
and subsequently embedded in paraffin; spleen, liver, kidney, heart, colon, and ileum. 
Colon and ileum were cleaned with PBS and swiss rolled prior to fixation. Liver, 
epididymal fat, mesenteric fat, and spleen weight were determined from freshly excised 
tissue prior to fixation. Colon, entire small intestine, and tibial length were also measured 




4.3.8 Blood Panel Analysis  
 A complete blood panel analysis was performed using the VetScan HMT (Abaxis, 
Union City, CA) for determination of white blood cells (WBC), lymphocytes (LYM), 
monocytes (MON), neutrophils (NEU), platelets (PLT), red blood cells (RBC), 
hematocrit (HCT), and hemoglobin (Hb). Neutrophil/lymphocyte ratio (NLR) was 
calculated from obtained values. 
4.3.9 Plasma Markers of Toxicity 
 Plasma was analyzed for common markers of major organ toxicity/physiological 
impairment including ALT (Cayman Chemical, 700260) and creatinine (Cayman 
Chemical, 700460) and according to manufacturer’s instructions. 
4.3.10 Histopathology Analysis 
 All tissues collected were stained with hematoxylin and eosin (H&E) as 
previously described.132 To analyze the presence of fibrosis, trichrome staining was 
performed in heart, liver, kidney, and spleen as previously described.133  Goblet cells 
were identified in the colon and small intestine by Alcian blue staining and 
counterstained by nuclear fast red as previously described.94 All histopathological 










4.4.1 There is no difference in bioavailability of emodin when given I.P. vs P.O. but it 
is more bioavailable in female mice. 
 We measured the concentrations of free emodin and glucuronidated emodin in 
plasma of mice given emodin via I.P. or P.O. at 20 or 40 mg/kg doses and at t=1, 4, or 12 
hrs (n=4/timepoint/sex; Fig 4.1B-E). The majority of emodin detected in each sample was 
glucuronidated while free emodin was scarcely found at all time points following both 
I.P. and P.O. routes of administration. The highest point of emodin detection was at the 
t=1hr time point and was at approximately 50% concentration at t=4hr and was 
completely eliminated at t=12hrs. Interestingly, we found that female mice had greater 
concentrations of glucuronidated emodin at t=1hr in all doses and routes except for the 20 
mg/kg dose given P.O. (Fig 4.1B-E, p<0.05) and at t=4hr only in mice given the 20 
mg/kg dose by I.P. (Fig 4.1B, p<0.05). Overall, there was no difference between I.P. and 
P.O. administration at any of the timepoints tested. 
4.4.2 12-week emodin feeding does not present phenotypic toxicities in mice. 
 We fed male (n=5/group) and female (n=5/group) mice a purified diet (AIN-76A) 
infused with three different concentrations of emodin. In statistical analysis, male and 
female mice were combined. After 12 weeks of feeding, emodin dose did not affect body 
weight compared to control mice (AIN-76A fed) (Fig 4.2A). Similarly, body composition 
analysis did not show any differences in lean mass (%) or body fat (%) (Table 4.1) for 
any of the emodin doses versus the control group. Further, there was no difference in 
organ weight (liver, spleen, mesenteric fat, epididymal fat) or length (colon length, small 




4.4.3 Spleen and blood analyses do not indicate inflammatory responses to emodin 
feeding. 
 To assess the sub-chronic effect of emodin on circulating immune cells we 
performed a comprehensive blood panel analysis. Table 4.2 indicates that there was no 
effect of emodin at any dose on circulating immune cells. To further investigate the 
potential toxicity of emodin on the immune system, we performed H&E staining on 
spleen biopsies. There were no histological changes of red or white pulp and there 
appears to be no indication of blood flow blockage or fibrosis (Fig 4.3A).  
4.4.4 Liver, Kidney, and Heart do not present with any noticeable toxicities after 12-
wk emodin feeding. 
 
4.4.4.1 Emodin feeding does not cause liver toxicity 
 To investigate the potential toxicity of emodin to the liver we performed H&E 
and trichrome staining. There were no indications of fibrosis or NASH in any of the mice 
fed emodin diets (Fig 4.4A,B). To confirm our findings, we measured ALT levels in 
plasma. We found that there were no elevated plasma ALT levels following any dose of 
emodin (Fig 4.4C). 
4.4.4.2 Emodin feeding does not cause kidney toxicity 
 To investigate the potential toxicity of emodin to the kidneys we performed H&E 
and trichrome staining. There were very few indications (<5%) of isolated tubular ectasia 
and sloughed cells in tubular lumens in addition to an absence of inflammation (Fig 
4.5A). To test the function of the kidneys we measured creatinine levels in plasma. 
Plasma creatinine levels were in normal range, lower that 5mg/dl in any of the mice 





4.4.4.3 Emodin feeding does not cause noticeable toxicity to the cardiovascular system. 
To investigate the potential toxicity of emodin to the cardiovascular system, we 
performed H&E and trichrome staining on heart muscle (Fig 4.6A,B). There was no 
indication of architectural change of the tissue or fibrosis in cardiac tissue. Further, we 
did not observe any indications of atrial or ventricular hypertrophy. 
4.4.5 Small intestine and colon analysis do not indicate GI toxicity after 12-wks of 
emodin feeding. 
 To assess potential gastrointestinal toxicities of sub-chronic emodin feeding, we 
performed histopathological analysis on small intestine (Fig 4.7A) and colon tissue (Fig 
4.7B,C). H&E staining did not indicate any significant dysplasia in either the small 
intestine (Fig 4.7A) or colon (Fig 4.7B). We furthered stained colon biopsies with Alcian 
blue to assess goblet cell integrity. Alcian blue staining did not show any significant 
differences in goblet cell count or morphology in the colon (Fig 4.7C). 
4.5 Discussion 
Emodin (Fig 4.1A), a natural anthraquinone, has shown many potential health 
benefits in pre-clinical models. In fact, we have reported that emodin is effective at 
reducing tumorigenesis given its actions on macrophages.78,122 However, further 
development of emodin as an effective anti-cancer agent is hindered by uncertainties 
surrounding its potential toxicity. The primary purpose of this study was to uncover any 
potential toxic properties of emodin in mice using doses that we have found to have 
efficacy in our cancer studies.78,122 In addition, we sought to assess the time course of 
emodin clearance when administered both I.P. and P.O. in order to begin to establish 




or high (80 mg/kg) emodin feeding does not cause pathophysiological perturbations in 
major organ systems. We also found that glucuronidated emodin peaks at 1hr for both I.P. 
and P.O. administered emodin and is eliminated by 12 hr.   
Despite inconsistencies in the literature, previous investigations have shown that 
emodin is typically cleared by 12 hr after injection/ingestion.77,122,134 We show in the 
present study that emodin is rapidly metabolized to its glucuronidated form, peaking at 1 
hr, and is completely cleared by 12 hr when given both I.P. and P.O. Further, we confirm 
that the parent free emodin is undetectable after 1 hr, even at higher doses. Some of the 
inconsistences in the literature are likely due to the varying vehicles used. It is important 
to note that emodin is not soluble solely in PBS or water and must have an alcohol-based 
solvent to dissolve. Several previous studies have reported using saline or PBS only as a 
vehicle,70,73,121,135 which is likely to result in delivery of a non-homogenous solution, and 
presumably inconsistent pharmacokinetic data. We aimed to deliver a homogenous 
solution of emodin to improve our consistency of plasma analysis. Thus, emodin was 
dissolved in pure DMSO for the I.P. study and in propylene glycol for the P.O. study. 
Our findings are supported by previously published work.77,122,134,136  For example, a 
study by Shia et al., 2010 utilized a similar solvent to propylene glycol (PEG 400) and 
showed comparable results using male Sprague-Dawley rats.136 While we report peak 
levels of emodin at 1 hr post administration for both the I.P. and P.O. studies, it is 
important to note that our assessment was limited to 1 hr, 4 hr and 12 hr time-points. 
Thus, it is certainly possible that emodin may have peaked prior to, or following, the 1 hr 
time-point. Evaluation of additional time-points is necessary to fully determine the timing 




 Of further interest with the pharmacokinetic findings is the indication that 
females have almost double the amount of glucuronidated emodin in the circulation at 1 
hr following injection/gavage. When given I.P., this difference remains at the 4 hr time-
point (only significant in the 20 mg/kg dose), but not in mice given emodin via P.O.  This 
finding is consistent with Liu et al., (2010) that showed in an ex vivo experiment that 
emodin is absorbed and metabolized at a faster rate in females vs. males.75 Although the 
clearance of emodin is comparable between males and females, it is important to note this 
difference in pharmacokinetics between males and females so that appropriate dosing can 
be implemented during the transition to clinical investigations.  
Given the potential toxicity associated with emodin along with our efforts in the 
development of emodin as a complementary cancer therapy we performed a sub-chronic 
toxicity study of emodin as a first-step to clinical translation. We subjected mice to an 
emodin infused diet of three different concentrations (~20 mg/kg, 40 mg/kg and 80 
mg/kg) – similar doses that we have used in our efficacy studies - for 12 wks to observe 
any potential toxic effects that emodin may have. Emodin did not impact body weight or 
body composition in the current study. Further, there was no effect of emodin on major 
organs. It should be noted that others have reported beneficial effects of emodin on 
metabolic disorders including a reduction in body weight; however, unlike the current 
study, these effects were documented in the settings of diet-induced obesity. 137,138    
There is some suggestion that emodin may have mutagenic properties given the 
documented reports of genotoxicity and mutagenicity in certain strains of bacteria.124,125 
However, a two-year genetic toxicology and carcinogenesis study conducted by the 




activity for emodin in female mice and equivocal evidence in male mice given a low 
incidence of renal tubule adenoma and carcinoma (1 mouse in each of 35 mg/kg and 70 
mg/kg groups of 10) following a two year feeding study.139 Only in doses of 170 mg/kg 
and higher were significant toxicities noticed in this study.139 Together with other 
assessments of emodin from carcinogenicity studies, evidence does not support a 
genotoxic risk of emodin to humans.124,125,131  In fact, there are a number of recent reports 
that indicate anti-tumor effects of emodin including studies by our group.78,122 This is 
further supported by the current study; we show that emodin, when given at doses of 20, 
40, and 80 mg/kg for 12 wks, does not appear to have mutagenic properties.  
There also are some reports of hepatotoxic effects of emodin while other studies 
report hepatoprotection.126-130 Based on a review of the literature it is likely that emodin 
has bidirectional potential, both liver protection126,127 and hepatoxicity126-130 depending on 
the dose. In our study, we found no hepatoxicity with daily emodin treatment for 12 wks 
and this was supported by no elevation in plasma ALT levels. Similarly, there are some 
indications that emodin, or foods containing emodin, may cause kidney toxicity140 while 
other reports document that emodin may actually serve as a therapeutic for kidney 
injury.141  We found no evidence of nephrotoxicity in the current study nor did we see 
elevated plasma creatinine levels following emodin treatment. Further, emodin has been 
shown to have laxative effects leading to melanosis, but only at very high doses, for 
example, 1-3 g/kg/d for mice.125,131 Thus, it is not surprising that we did not find any 
laxative effects following administration of emodin in the 20-80 mg/kg dose range. Nor 




emodin have not been documented in the spleen or heart, at least to our knowledge, we 
assessed these tissues and report no toxic effects. 
4.6 Conclusion 
In summary, we show that the pharmacokinetics of emodin does not differ 
significantly between the peritoneal and oral routes of administration.  However, there are 
sex differences in the pharmacokinetics of emodin with female mice having higher levels 
of metabolized emodin that should be considered during the transition to clinical 
investigations. Further, we confirm that emodin is a safe compound to be used in both 
male and female mice when given at 20, 40, and 80 mg/kg doses for 12 wks.  
4.7 Figures & Legends 
Figure 4.1. Emodin is rapidly glucuronidated when given I.P. and P.O. and is more 
bioavailable in females. A. Chemical structure of emodin (PubChem CID: 3220). B-E. 
Total, glucuronidated, and free emdoin bioavailability in male and female mice 1hr, 4hr, 
and 12hr after given I.P at B) 20 mg/kg and C) 40 mg/kg and P.O. at D) 20 mg/kg and E) 
40 mg/kg. n=3-4/dose/timepoint/sex. * indicates statistical significance (p<0.05) between 
sexes of total emodin. # indicates statistical significance (p<0.05) between sexes of 





Figure 4.2. 12-week emodin feeding does not present phenotypic changes in male 








Table 4.1. Male and female mice fed emodin for 12-weeks do not show differences in body composition and major organ 
weight. Lean mass and body fat percentage (%) were measured using DEXA scan. Liver, spleen, mesenteric fat, and epididymal fat 
were measured in milligrams (mg). Tibial length was measured in millimeters (mm). Colon length and small intestine (SI) length were 













































































































Table 4.2. Male and female mice fed emodin for 12-weeks do not show changes in CBC counts. White blood cells (WBC), 
lymphocytes (LYM), monocytes (MON), neutrophils (NEU), neutrophil:lymphoctye ration (NLR), red blood cells (RBC), hemoglobin 






































































































Figure 4.3. 12-week emodin feeding does not present histological changes in spleen. 
A. Representative 10X and 40X (insets) images of male and female spleens stained with 
H&E. n=5/group. 
 
Figure 4.4. 12-week emodin feeding does not cause liver toxicity. A. Representative 
H&E stains of livers imaged at 10X and 40X (insets). B. Representative trichrome stains 
of livers imaged at 10X and 40X (insets). C. Plasma ALT activity measured in units/mL 





Figure 4.5. 12-week emodin feeding does not cause kidney toxicity. A. Representative 
H&E stains of kidneys imaged at 10X and 40X (insets). B. Plasma creatinine measured in 
milligrams/deciliters (mg/dl) of plasma. Dashed line indeicates critical toxic levels 
(5mg/dl). n=5/group. 
 
Figure 4.6. 12-week emodin feeding does not cause cardiotoxicity. A. Representative 
H&E stains of cardiac tissue imaged at 10X and 40X (insets). B. Representative 





Figure 4.7 12-week emodin feeding does not cause GI toxicity. A. Representative 
H&E stains of swiss rolled small intestines imaged at 10X and 40X (insets). B. 
Representative H&E stains of swiss rolled colons imaged at 10X and 40X (insets). C. 








4.8 Supplemental Material 
Supplementary Table 4.1.  Emodin Review.  Assessment of studies examining the potential therapeutic properties of emodin in 
various models of pathology. Studies that examined more than one dose of emodin or time point were treated as separate experiments 
when totaling each respective outcome.  ↔ = No Change, ↓ = Decrease, ↑ = Increase, N/A = Not Assessed, HFD = High Fat Diet. 
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THE EFFECT OF ANTHRAQUINONE EMODIN ON SURVIVAL, 























Emodin, a natural anthraquinone, has been shown to have anti-inflammatory properties 
and may be effective to ameliorate off-target toxicities of 5FU chemotherapy. We 
evaluated chronic (n=5-20/group) and acute (n=20/group/sex) interventions to 5FU. 
Emodin improved run-to-fatigue time both acutely and chronically but only improved 
grip strength and peripheral nociception sensitivity chronically. Acutely, emodin reduced 
small intestine IL10, Mrc1, and Ly6G while reducing NOS2, TNFα, and Ly6G and 
increasing Mrc1 chronically. In the colon, emodin did not cause significant alterations in 
inflammatory gene expression but reduced NOS2 and Muc5ac chronically. Acutely, male 
mice retained circulating lymphocytes with increased emodin dosage. Further, emodin 
improved cell cycling in bone marrow increasing S and G2/M phase cells. Utilizing 16S 
rRNA FISH, 5FU caused pockets of mucus disruption, gut barrier damage, and 
alterations in bacterial spatial arrangement, which were mitigated with emodin. Taken 
together, emodin treatment may contribute to improved hematopoietic integrity and GI 
health by reducing damaging inflammation, which may improve overall quality of life. 
5.2 Introduction 
Synthetic chemotherapeutics such as antimetabolites, anthracyclines, and taxanes 
have improved the overall efficacy of cancer treatment regimens but present significant 
risk to the patient both during and after treatment29,88,142. Chemotherapy treatment has 
approximately a 12% success rate clinically. However, nearly 10% of patients receiving 
chemotherapy die during the first 30 days of treatment. Further, it is estimated that 70% 
of surviving patients will develop non-specific toxicities as a result of chemotherapy 




complementary treatments to attenuate the toxicity of chemotherapeutics giving the 
patient a better quality of life during treatment. We, and others, have previously 
characterized hallmark characteristics of 5FU toxicity32,35,111,132,142. Most notably the 
presence of intestinal mucositis and lymphocytopenia contributes to the reduced survival 
and quality of life associated with 5FU23,33,91,142. These characteristics are closely 
monitored clinically and can be limiting to the success of interventional therapies39,143. 
Therefore, amelioration of these symptoms might improve 5FU outcome. 
 There has been a recent upsurge in the clinical utilization of herb-derived 
compounds due to evidence of multiple health benefits attributed to continual use with 
these compounds. A compound that could attenuate the multiple non-selective toxicities 
associated with chemotherapy could have great clinical potential. Emodin is a trihydroxy-
anthraquinone found in several Chinese herbs, including Rheum palmatum and 
Polygonum multiflorum144,145. Emodin has been shown to attenuate the severity of 
multiple experimental disease models including arthritis, liver damage, atherosclerosis, 
myocardial ischemia, and cancer by reducing the inflammatory cascades associated with 
these conditions73,77,79,80,121,134,144,146,147. Recent investigations have indicated emodin can 
reduce activation of pro-inflammatory signaling NF-κB, STAT6, Erk1/2, and 
P3872,77,122,148. However, the direct mechanism of action of emodin has yet to be 
discovered. Emodin may have a potential target in the P2X7 receptor75,79,87,145,149. The 
P2X7 receptor is found the central and peripheral nervous systems, in microglia, 
macrophages, and the retina75,149. The P2X7 receptor has also been shown to serve as a 




regulation of receptor trafficking, mast cell degranulation, and inflammation145,149 and is 
therefore of interest as a therapeutic target. 
In the present study, we aimed to establish the efficacy of emodin as a 
complementary therapeutic to attenuate the non-selective toxicity of 5FU chemotherapy. 
We utilized a previously established protocol of 5FU treatment which was paired with 
complementary emodin treatment given three-times per week. We performed chronic and 
acute studies of 5FU toxicity investigating the benefits of complementary emodin. 
Investigating the chronic effects, we observed a 100% survival rate in mice treated with 
5FU + Emodin. This was complemented by reduced pain sensitivity, improved grip 
strength, and reduced fatigability. We observed increased M2-type macrophages (MRC1) 
and reduced neutrophils (Ly6g) in the small intestine but not in the colon. However, we 
did report a decrease in dysplasia inducing Muc5ac in the colon. Acutely, we observed 
improved body weight in 5FU + Emodin treated mice and a maintained peripheral 
lymphocyte count. Utilizing 16S rRNA FISH we observed a dose dependent response of 
maintained structural integrity of the proximal and distal colon in emodin treated mice. 
We saw increased macrophages in the bone marrow and expression of the 
proinflammatory markers which was paralleled by drastic cell death and cell cycle arrest 
with 5FU. Interestingly, we observed increased cells inG2/M phase in the bone marrow 
and decreased CD11c expression of Emodin treated mice. Overall, we believe that 
emodin may be protecting the hematopoietic system during 5FU treatment, leading to a 







Male and female C57BL/6 mice were purchased from Jackson Laboratories (Bar 
Harbor, ME) and were cared for in the animal facility at the University of South Carolina. 
Mice were randomized upon arrival to the animal facility to prevent litter biases in 
microbiome data and were housed five per cage, maintained on a 12:12-h light-dark cycle 
in a low-stress environment (220C, 50% humidity, low noise). Mice were kept in a room 
isolated from all other ongoing animal experiments and were only handled by the primary 
investigators. All mice were habituated to the AIN-76A diet prior to any interventions 
and were given food and water ad libitum through the course of the study. All methods 
were in accordance with the American Association for Laboratory Animal Science, and 
the Institutional Animal Care and Usage Committee of the University of South Carolina 
approved all experiments.  
5.3.2 Experimental Design 
 Mice were acclimated to the animal facility at the University of South Carolina 
for 6 weeks prior to the start of experiments. In the chronic study (Fig 5.1A), N=50 mice 
were randomly assigned into 4 groups: Control (n=5), Emodin (n=5), 5FU + Vehicle 
(n=20), and 5FU + 40 mg/kg Emodin (n=20). In the acute study (Fig 5.4A): N=80/sex 
mice were randomly assigned into 4 groups; 5FU + Vehicle (n=20/sex), 5FU + 20 mg/kg 







5.3.3 Emodin Preparation 
Emodin was purchased from Nanjing Zelang Medical Technology Co., Ltd, 
(Nanjing, China). Emodin was independently analyzed by the Mass Spectrometry Center 
at the University of South Carolina prior to the initiation of the experimental study. LC-
UV-MS and NMR was performed to confirm the purity of Emodin and the molecular 
structure (Fig S1A). Emodin was delivered via oral gavage to mice using 20ga 30mm 
flexible plastic tubing oral gavage needles (Instech, #FTP-20). Emodin was prepared 
fresh, daily, in a 24mg/mL stock solution using pure propylene glycol (VWR) and mixed 
for 6-8 hours at room temperature protected from light prior to gavage. The 24mg/mL 
solution was used for 80 mg/kg dosing; 12mg/mL and 6mg/mL dilutions were also 
prepared for 40 mg/kg and 20 mg/kg doses, respectively. Pure propylene glycol was used 
as a vehicle control in all experiments.  
5.3.4 5FU and Emodin treatment regime 
5FU (Sigma Chemical Co., St. Louis, MO) was dissolved in sterile phosphate 
buffered saline (PBS), pH7.4 and then sterile filtered through a 0.2μm syringe filter. 5FU 
was administered in 3 (chronic, Fig 5.1A) or 1 (acute, Fig 5.4A) cycles of a 35 mg/kg 
dosage and was administered via intraperitoneal injection. Each cycle consisted of 5 
consecutive days of injections followed by 9 days of recovery. 5FU was prepared fresh at 
the beginning of each cycle. Sterile filtered PBS alone was used as the vehicle control. To 
avoid potential drug interactions Emodin and 5FU were administered separately. 5FU 
was given in the AM time slot of the light cycle and Emodin was given in the PM time 
slot of the light cycle. The t1/2 of 5FU is 15 minutes and we have previously determined 




5.3.5 Peripheral Neuropathic Nociception 
All experimental mice were utilized to evaluate the effects of 5FU treatment on 
peripheral neuropathic nociception. After a brief habituation to the testing apparatus, 
right hind-paws were tested for neuropathic nociception by a single experimenter blinded 
to experimental conditions using Von Frey filaments (North Coast Medical, Morgan Hill, 
CA). Each Von Frey filament was tested for 5 consecutive measurements, data was 
calculated as the paw withdrawal threshold in grams of force. Threshold was determined 
by 3 consecutive reactions to the stimulus. Measurements were performed by the same 
investigators through the entirety of the study (ATS). Total stimuli were also summed to 
interpret total sensitivity to the touch test. 
5.3.6 Grip strength assessment 
All experimental mice were utilized to evaluate the effects of 5FU treatment on 
grip strength. Grip strength was measured prior to 5FU administration and during the 
recovery period of the second cycle. Briefly, holding the mice by the tail, the front and 
back feet were allowed to grip the grate. Mice were then pulled from the grate, generating 
a force that was measured by the force transducer. Five measurements were taken 
consecutively, with 2 min rest between sets until a total of 15 measurements were taken 
for each mouse. The averages of the 15 measurements were used in the data analysis. 
Measurements were performed by the same investigator through the entirety of the study 
(ATS). 
5.3.7 Run-to-fatigue assessment 
To determine the effect of 5FU on fatigability, all experimental mice were 




period of the second cycle (chronic) or in the night cycle after the final 5FU 
administration (acute). After 3 consecutive days of habituation during the night cycle, 
mice were subjected to the following run-to fatigue protocol: 20 m/min for 30 min and 25 
m/min following a 15-min warm-up. Fatigue was defined as the time at which mice were 
no longer able or willing to keep up with the treadmill despite hand prodding for at least 
1 minute. All treadmill performances were performed during the night cycle by the same 
investigators through the entirety of the study (ATS and BNV). Data were analyzed as 
percent performance change from baseline (week -1) to post treatment (week 1 – acute, 
week 4 – chronic).  
5.3.8 Tissue collection 
Mice were euthanized by isoflurane overdose and blood was collected from the 
inferior vena cava. Tissues were removed, weighted and immediately snap-frozen in 
liquid nitrogen and stored at -800C or fixed in 10% formalin until further analysis. The 
colon was carefully dissected distal to the cecum and proximal to the anus. Mesentery 
adipose tissue was removed with forceps. The colon was flushed with PBS, opened 
longitudinally, and flattened with a cotton swab. Colon length was measured using 
calipers. A 5-mm piece of the distal portion of the colon was cut and fixed in 10% 
buffered formalin (Fisher Scientific, Pittsburg, PA) for morphological analysis. The 
remaining colon was hemi-sectioned longitudinally and snap-frozen for further analysis. 
The distal portion of the ileum was cut and fixed in 10% buffered formalin for 
immunohistochemical and morphological analysis, the remining distal-middle portion of 





5.3.9 Anemia markers 
A complete blood panel analysis was performed using the VetScan HMT (Abaxis, 
Union City, CA) for determination of WBCs, LYM, MON, NEU, PLT, RBCs, Hct, and 
Hb. Neutrophil/Lymphocyte ratio (NLR) was calculated from obtained values. 
5.3.10 Histopathology 
Hematoxylin and eosin (H&E) staining of the colon and small intestines were 
performed as previously described132. All images were obtained using a Nikon E600. 
Intestinal mucositis was assessed via measurement of the epithelial architecture of the 
villi (small intestine) using ImageJ. Goblet cells were identified by Alcian blue staining 
and counterstained with nuclear fast red as previously described94. All histopathological 
analyses were performed by a board-certified pathologist blinded to the experimental 
conditions (I.C.). All tissue morphological measurements were performed in triplicate 
and the coefficient of variance was determined to be less than 5%. 
5.3.11 Gene expression 
Quantification of colonic expression of EMR-1, MRC1, ITGAX, Ly6G, IL10, 
NOS2, TNFα, MCP1, OCLN, MUC2, and MUC5ac were performed as previously 
described132. Briefly, RNA was extracted using TRIzol reagent (Life Technologies, 
GIBCO-BRL, Carlsbad, CA) and chloroform procedures. RNA sample quality and 
quantities were verified using an Agilent Bioanalyzer and determined to be of good 
quality based on A260/A280 values (>1. 8) prior to cDNA synthesis using QuantiTect 
Reverse Transcription kit (Qiagen 205313). Quantitative RT-PCR analysis was carried 
out as per the manufacturer’s instructions (Applied Biosystems) using Taq-Man Gene 




five reference targets (B2M, TBP, HPRT, HMBS, and H2AFV), which were evaluated 
for expression stability using GeNorm algorithm.98,99 
5.3.12 Bone Marrow Flow Cytometry and Cell Cycle Analysis 
Bone marrow was taken from both femoral shafts by flushing with saline and 
passing the resulting extracts through a 70μm filter. Red blood cell lysis was performed 
with 20 second hypotonic solution (0.2% NaCl) treatment followed by hypertonic (1.6% 
NaCl) cessation. Bone marrow isolates were blocked with FC block and stained with 
CD11b – APC, F4/80 – FITC, and CD45 – PE/Cy7 (Biolegend, San Diego, CA) 
antibodies for 1hr at 40C. Lymphocytes were identified by gating for CD45+ cells. 
Macrophages were determined to be CD11b+F4/80+ cells. Aliquots of bone marrow 
isolates were also fixed in 70% ethanol for 24h at -200C before staining with Ki67 – APC 
and propidium iodide – PE-Texas Red (Biolegend San Diego, CA) according to standard 
protocols. Data were acquired using a BD FACS Aria II cell sorter and analyzed by 
FlowJo v10.6.2. 
5.3.13 Western Blotting 
 Briefly, bone marrow extracts were homogenized in Mueller Buffer containing 
protease inhibitor cocktail (Sigma Aldrich, St. Louis, MO). Total protein concentrations 
were determined by the Bradford method. Equal amounts of crude protein homogenates 
(10ug) were separated on hand-casted SDS-polyacrylamide gels and electrophoretically 
transferred to a PVDF membrane using a Royal Genie Blotter (IDEA Scientific, 
Minneapolis, MN). Membranes were blocked for 1hr at room temperature with 5% non-
fat milk in tris-buffered saline with 0.1% tween (TBST). Western blots were performed 




1-Ig), and CD11c (Cell Signaling #97585). An anti-rabbit (Cell signaling: #7047) IgG 
horseradish peroxidase conjugated secondary antibody was diluted 1:2000 in 5% milk-
TBST and incubated for one hour at room temperature. An enhanced chemiluminescent 
substrate for detection of horseradish peroxidase (Thermo Scientific, Watham, MA) was 
used to visualize the antibody-antigen interaction. Autoradiography films were scanned, 
and blots were quantified using scientific imaging software ImageJ (NIH Bethesda, MD). 
After completion of the western blot, all membranes were stained with Amido black 
(VWR #AAJ66798-14) and the densitometry of each lane was calculated using ImageJ 
allowing for total protein normalization as previously described150. 
5.3.14 16S rRNA FISH 
 A subset of mice (n=3) were used to observe the bacterial spatial organization 
present in the colon. Briefly, colons were excised whole from the rectum to the anus, 
opened longitudinally without disturbing opened tissue, and fixed for 24hrs in Carnoy’s 
solution (6:6:1 – Ethanol:Acetic Acid:Chloroform) then processed and embedded into 
paraffin blocks by standard techniques. 5μm section were placed on SuperFrost slides for 
FISH studies. The oligonucleotide probe (EUB338: 5’-GCTGCCTCCCGTAGGAGT-3’) 
was purchased from EuroFins synthesized with carbocyanite dye (Cy3) added to the 5’-
end. In-Situ Hybridizations were performed according to previously published 
protocols117,151,152. Fluorescent images were taken using a Leica DM2500 fluorescent 
microscope.  
5.3.15 Statistical analyses 
All data were analyzed using commercial software (SigmaStat V3.5, SPSS, 




treatment) for the chronic treatment investigation and a one-way ANOVA for the acute 
investigation. A Student-Newman-Keuls test was used for all post-hoc analyses. A 
student’s t-test was used to analyze Ly6G expression during the chronic study due to only 
two groups (of four total) have detectable levels of expression. Survival curve analysis 
was conducted by Log-rank (Mantel-Cox) test. Any data that were not normally 
distributed or did not display equal variance were logarithmically transformed so that 
those criteria were met. Statistical significance was set with an alpha value of p<0.05. 
Data are presented as mean ± SEM. 
5.4 Results 
5.4.1 Complementary emodin delays weight loss and improves survival and quality of life 
during chronic 5FU. 
 
A 3-cycle 5FU regimen caused significant body weight loss through the entire 
duration of the treatment period (Fig 5.1A,B; p<0.05). A main effect of 5FU and emodin 
therapy exists at various points through the course of treatment (Day 2, 4, 6, 8, 10, 28, 30, 
32, and 34); within control mice there was no effect of emodin therapy throughout the 
treatment period. However, there was a significant interaction detected within 5FU, in 
which emodin treated mice had significantly greater body weight at days 7, 8, 10, 11, 12, 
13, and 14 (Fig 5.1B; p<0.05). n=3/20 mice in the 5FU+Vehicle group did not survive the 
first cycle of 5FU chemotherapy, a Mantel-Cox test indicated that there was no 
significant risk for this group; regardless, no other experimental groups had decreased 
survival (Fig 5.1C). At necropsy, there were no significant differences detected for liver 
and spleen weight (Table 1). A main effect of 5FU was detected for decreasing 




was found. Interestingly, a main effect of emodin treatment was detected in increasing 
colon length; however, there was no interaction detected with 5FU (Table 5.1). 
5.4.2 Complementary emodin improves functional measures of fatigue associated with 
chronic 5FU. 
 
We have previously established a battery of functional tests that can detect 
differences in performance associated with 5FU toxicity132. We find a main effect of 5FU 
on increasing touch sensitivity (p<0.05), a trending effect of emodin treatment (p=0.051), 
and a trending interaction (p=0.051) between 5FU and emodin treatment (Fig 5.1D). 
Despite these results, two-way ANOVA indicated a difference between treatment groups 
within 5FU in which emodin treated mice showed reduced pain sensitivity (p<0.05). This 
result is likely from the ceiling effect inherent of this assay which does not allow for main 
effects to be elucidated from the data collection. To further our analysis of peripheral 
neuropathy, we summed the total responses of each mouse throughout the peripheral 
neuropathy assay (see methods). Two-way ANOVA of these summed responses 
indicated a main effect of both 5FU and emodin treatment (Fig 1E; p<0.05). Again, we 
report a trending interaction (p=0.058) between emodin and vehicle treated groups within 
5FU mice. Despite this, emodin treated 5FU mice showed significantly reduced total 
responses during the peripheral neuropathy assay compared to 5FU alone (Fig 5.1E; 
p<0.05).  
A grip strength test was used to measure absolute (N) and relative (N/kg) front 
limb strength. We found no main effects of 5FU or emodin treatment in absolute grip 
strength (Fig 5.1F); however, vehicle treated 5FU mice showed significantly lower 




was a significant interaction (Fig 5.1F; p<0.05) within 5FU in which emodin treated mice 
showed increased absolute grip strength compared to 5FU alone, however, were still 
lower than control mice. Relative grip strength showed no significant main effects of 
either 5FU or emodin treatment; further, there was no significant interaction detected (Fig 
5.1G).  
To investigate the fatiguability induced by 5FU treatment we analyzed run-to-
fatigue data as a percent performance change from baseline (see methods). We report a 
main effect of both 5FU and emodin treatment on percent performance change (Fig 5.1H; 
p<0.05). 5FU mice treated with vehicle had significantly lower performance compared to 
control mice. Interestingly, 5FU mice treated with emodin showed significantly less 
performance deficits compared to 5FU alone, however, were still lower than control mice 
(Fig 5.1H; p<0.05).  
5.4.3 Complementary emodin does not rescue 5FU-induced anemia and 
lymphocytopenia. 
 
We have previously reported that 5FU treatment causes significant cytopenia.132 
As expected, we observe a main effect of 5FU on decreasing WBC, LYM, NEU, RBC, 
HGB, and HCT; however, we do not detect an interaction of 5FU with emodin treatment 
(Table 5.2; p<0.05). Further, we find a main effect of 5FU for increasing PLT counts; 
however, we also do not find a significant interaction of 5FU with emodin treatment 
(Table 5.2; p<0.05). Interestingly we do not report any significant effects of 5FU or 








5.4.4 Complementary emodin reduces inflammation and protects small intestine tissue 
during chronic 5FU treatment. 
 
One of the most significant effects of 5FU is non-selective toxicity targeted 
towards the small intestine tissue. Measuring the villus length of small intestine tissue, 
we find a significant main effect of 5FU treatment in decreasing villus length (Fig 
5.2A,B; p<0.05); further, we find a significant interaction with emodin treatment within 
the 5FU group which had greater villus length compared to 5FU treatment alone, but 
lower length compared to control mice (Fig 5.2A,B; p<0.05). We performed gene 
expression analysis to observe any differences select pro-inflammatory cytokines in 
addition to macrophage (F4/80) and neutrophil (Ly6g) populations. Interestingly, mice 
treated with 5FU had decreased NOS2 expression in the small intestine but increased 
TNFα and MCP-1 (Fig 5.2C; p<0.05). Emodin treatment only seemed to interact 
significantly with TNFα leading to reduced levels compared to mice treated with 5FU 
alone (Fig 5.2C; p<0.05). We further report no difference in total macrophages (EMR1) 
or M1-like macrophages (Itgax) but increased M2-like macrophages (Mrc1) in mice 
treated with 5FU+Emodin compared to 5FU alone (Fig 5.2D; p<0.05). Neutrophils are 
minimally expressed in the small intestine and are not usually detected with conventional 
qPCR. Within 5FU treated mice, however, we detect Ly6g expression in the small 
intestine which was trending (p=0.12) decrease in emodin treated mice when normalized 
back to 5FU+Vehicle treated mice and analyzed via a student’s t-test (Fig 5.2E).  
5.4.5 Emodin improves colon health during chronic 5FU treatment. 
 We performed a similar analysis in the colon as reported above. Interestingly, we 
find a significant increase in NOS2, TNFα, and MCP1 in mice treated with 5FU alone 




significant interaction with emodin only in NOS2 expression (p<0.05) but not in TNFα or 
MCP1 (Fig 5.3A) We assessed macrophage markers EMR1, Itgax, and Mrc1 but found 
no changes across all groups (Fig 3B). We found a main effect of neutrophil marker Ly6g 
in 5FU treated mice but no interaction between 5FU and emodin (Fig 5.3C). To assess 
gut health, we measured OCLN expression and report a main effect of 5FU to decrease 
OCLN expression but there was no significant interaction with emodin (Fig 5.3D). 
Interestingly, we show an increase in Muc5ac expression in 5FU treated mice with a 
trending decrease (p=0.05) in 5FU+Emodin mice. Despite this, we report no difference in 
Muc2 expression across all groups. We stained distal colon biopsies with hematoxylin 
and eosin and Alcian blue but found no significant histopathological differences between 
all groups (Fig 5.3E). 
5.4.6 Complementary emodin delays weight loss during an acute bout of 5FU in male 
and female mice and reduces fatigability. 
To study the acute benefits of emodin on reducing 5FU toxicity, we investigated 
male and female mice treated with 5 consecutive days of 5FU and complementary 
emodin given at 20 mg/kg, 40 mg/kg, or 80 mg/kg (Fig 5.4A). All three dosing groups of 
emodin lost significantly less weight compared to mice treated with 5FU alone (Fig 
5.4B,C; p<0.05). Specifically, male mice treated with 20 mg/kg, 40 mg/kg, and 80 mg/kg 
had significantly lower weight loss compared to vehicle treated controls on days 3, 4, 5, 
6, and 7 (Fig 5.4B; p<0.05). Female mice treated with 20 mg/kg had significantly lower 
weight loss compared to vehicle treated controls on days 5, 6, and 7, female mice treated 
with 40 mg/kg had significantly lower weight loss compared to vehicle treated controls 
on day 7 only, and female mice treated with 80 mg/kg had significantly lower weight loss 




A subset of mice (n=10) were utilized to assess the same functional tests used in 
the chronic phase of the study. Male and female mice functional test performances were 
pooled for analysis. We saw no noticeable differences between or within all groups in 
peripheral nociception (Fig 5.4D,E) or grip strength (Fig 5.4F,G) tests. Interestingly, we 
found a dose dependent response to improvement in run-to-fatigue performance change 
(Fig 5.4G; p<0.05), with the benefits beginning to show in the 40mg/kg dose and 
improving in the 80 mg/kg dose.  
Weighing the major organs, we found no significant differences between groups 
(Table 5.3). Interestingly, male mice treated with 5FU + 20 mg/kg emodin had a 
significantly greater (Table 5.3; p<0.05) spleen weights compared to all other groups. 
However, this weight was not indicative of significant pathology and is expected to be a 
type I error. 
5.4.7 Increasing dosage of emodin rescues peripheral blood lymphocytopenia associated 
with acute 5FU treatment in males only. 
 In both male and female mice, 5FU decreases total WBC count, of which is 
mostly attributed to loss in circulating LYM. In male mice only, we found a dose 
dependent increase in total WBC with increasing emodin dosage which was attributed 
primarily to increased total LYM counts (Table 5.4; p<0.05). There was no difference in 
MON, NEU, RBC, HGB, HCT, or PLT measures between sex or treatment dosage. 
Interestingly, we found a significant decrease in NLR in male mice treated with 80 mg/kg 
emodin. This was also seen in female mice treated with both 40 mg/kg and 80 mg/kg 





5.4.8 Emodin reduces inflammation to small intestines and benefits gut architecture. 
 To investigate the acute benefits of emodin on small intestine health, we 
performed villus measurements on male mice as described in our chronic experiment. 
Interestingly, each treatment group had significantly different measurements compared to 
all other groups with mice treated with 80mg/kg emodin recording the greatest relative 
villus length compared to mice treated with 5FU alone (Fig 5.5 A,B; p<0.05). Gene 
expression analysis indicates no significant differences in pro-inflammatory cytokines 
NOS2, TNFα, or MCP1 (Fig 5.5C). However, we do show a significant decrease in IL10 
expression in mice treated with 40 mg/kg and 80 mg/kg emodin compared to mice treated 
with 5FU alone (Fig 5.5C; p<0.05). This trend was paralleled by a significant decrease in 
M2-like macrophages (MRC1) (p<0.05) but no decrease in total macrophages (EMR1) 
and M1-like macrophages (Itgax) (Fig 5.5D). Interestingly, we also show a decrease in 
neutrophil marker Ly6G expression in mice treated with 40 mg/kg and 80 mg/kg emodin 
compared to mice treated with 5FU alone (Fig 5.5E; p<0.05). 
5.4.9 Emodin does not alter immune status of the colon acutely but, may benefit bacterial 
spatial arrangement and gut integrity. 
 We performed an immune cell panel analysis on the colon tissue of male mice 
treated acutely with 5FU + emodin. Analyzing NOS2, TNFα, MCP1, and IL10 
expression we only report a significant increase in NOS2 in mice treated with 40 mg/kg 
(Fig 5.6A;p<0.05), however we believe this to be a type-I error and not attributed to 
pathology associated with emodin treatment at 40 mg/kg.  We analyzed macrophage 
markers EMR1, MRC1, and ITGAX in addition to neutrophil marker Ly6g, however, we 




performing markers for gut integrity, as in out chronic investigation, we did not notice 
any difference in OCLN, Muc5ac, and Muc2 between groups (Fig 5.6D). 
 To further our analysis of the colon, we used a subset of male mice to assess gut 
bacterial spatial arrangement using 16S rRNA FISH. Because of the landscape 
differences between the distal and proximal portions of the colon we separated our 
analysis to include each region. Within the proximal colon, we notice a thin mucous layer 
separating the bacteria (yellow) and epithelial cells (blue). When assessing 5FU treated 
mice, we noticed significant disposition of the mucosal layer and bacterial organization 
(arrow). We also observed invasion of bacteria within the crypts (arrow). We saw 
reduction of this phenotype when emodin is introduced into the treatment regime. In the 
20mg/kg emodin treated mice we observed a reduced incidence of crypt invading bacteria 
and a complete elimination of this phenotype in the 40 mg/kg and 80 mg/kg doses (Fig 
6A). Interestingly, we see that mice treated with 5FU + Vehicle also have significant 
bacterial invasion in the distal portion of the colon. As seen in the proximal portion of the 
colon, the 20 mg/kg emodin treated mice have a slight reduction of this characteristic and 
a complete elimination of this exists in the 40 mg/kg and 80 mg/kg emodin treated mice 
(Fig 5.6B). 
5.4.10 Emodin reduces bone marrow inflammation and may work to maintain actively 
cycling cells.  
 In a separate cohort of male mice, we performed an acute analysis of 5FU + 40 
mg/kg emodin treatment to analyze bone marrow health. We isolated bone marrow and 
assessed the macrophage content using flow cytometry. Interestingly, we found a 




however this was not decreased with emodin treatment (Fig 5.7A,B). The severity of 
cytopenia caused discrepancies on whether more inflammation was present in 5FU mice. 
Therefore, we isolated protein content of bone marrow and assessed protein expression of 
the CD11c, P2X7 receptor, and TNFα. Paralleling the trends seen in macrophage content, 
we see that 5FU treated mice had a significantly increased CD11c (p<0.05), P2X7 
receptor (p<0.05), and TNFα (p<0.05) expression but only CD11c was significantly 
lower (p<0.05)  in emodin treated mice compared to 5FU alone (Fig 5.7C-E). 
Interestingly, when normalizing to total protein content using amido black staining, we 
observed a significant banding difference between control and 5FU treated mice. 
Although total protein content was the same according to Bradford assay, this finding 
indicates that there are substantial perturbations to the cellular environment of the bone 
marrow in 5FU treated mice.  
We performed a cell cycle analysis of the bone marrow content and observed that 
5FU treated mice have fewer total cells compared to controls (Fig 5.8A). Further, we 
found that emodin treated mice have a lower percentage of cells in G1/G0 phase 
compared to control and 5FU+Vehicle treated mice. Interestingly, there was a greater 
percentage of cells in S phase in emodin treated mice compared to 5FU alone (Fig 
5.8A,B; p<0.05). Following this pattern, emodin treated mice had a trending increase in 
G2/M phase cells (Fig 5.8A,B; p=0.07). Although total cell content is lower in 5FU 
treated mice compared to controls, this finding indicates more cells are proliferating in 







5FU chemotherapy is widely used in the treatment of CRC. However, common 
side effects including fatigue, peripheral neuropathy, and diarrhea can lead to a reduced 
quality of life24,31,153. Emerging evidence has shown that natural anthraquinone emodin 
can be used as a safe and effective anti-inflammatory compound to reduce such 
physiological perturbations77,78,121. Therefore, in the current study, we aimed to 
investigate the ability for emodin to reduce the common side effects and inflammation 
associated with 5FU treatment. Despite significant weight loss, complementary emodin 
treatment improved survival in cancer-free mice and reduced severity of sensitive 
peripheral nociception, muscular weakness, and fatigability. Select intestinal markers of 
inflammatory cells indicate cite specific benefits of emodin and a reduction of 
pathological perturbations to the small intestine and colon barrier. Further, bone marrow 
analysis indicated a mitigation of the toxic effects of 5FU to the bone marrow and an 
attenuation of associated lymphocytopenia. 
We report here an important first step in establishing emodin as a safe and 
effective complementary therapeutic in clinical oncology. In the chronic study, we 
observe 100% survival in mice treated with emodin compared to 84% survival in mice 
treated with 5FU alone during a 3-cycle regimen. Previous investigations by our lab have 
shown that 5FU can cause significant toxicities in the presence of cancer132. However, 
this previous investigation utilized a different dosing regimen (40, 20, 20 mg/kg) 
compared to the present study. In the present study, we utilized a consistent 35 mg/kg 
dosing regimen which caused significant physiological perturbations in a cancer-free 




associated with chronic 5FU treatment. We report here that chronic 5FU given at 35 
mg/kg can increase peripheral nociception sensitivity, reduce muscular strength, and 
cause significant fatiguability; each of which can be rescued with complementary emodin 
treatment. The mechanisms of these 5FU-associated perturbations have not yet been fully 
elucidated. However, several hypotheses have been proposed including serotonin 
dysregulations, HPA dysfunction, circadian disruptions, depression, anemia/cytopenia, 
and central/local inflammation.27,88,154 Arguably, the strongest of these are inflammation 
and anemia. In our acute phase investigation, in male mice only, we observe significant 
increases in WBC and LYM counts with complementary emodin compared to 5FU alone. 
In our chronic phase investigation, however, we do not see significant recovery of 
systemic anemia and cytopenia with complementary emodin. However, we do report 
increased hemoglobin and reduced platelet count in mice treated with emodin compared 
to 5FU alone. This indicating that preventing the drastic lymphocytopenic effects early in 
5FU treatment might be sufficient to prolong survival and improve quality of life. 
Incidentally, where these mitigated effects may contribute to performance and quality of 
life improvements, it does not explain the full benefits of emodin. 
One of the most documented 5FU-induced toxicities involves inflammatory 
damage to the gastrointestinal barrier or ‘mucositis.’ We report here that the 
characteristic shortening of the villi in the small intestine typically seen with 5FU can be 
ameliorated with complementary emodin treatment both acutely and chronically. Where 
the mechanisms of mucositis remain elusive, our findings here indicate that 5FU causes 
an increase in neutrophil marker Ly6g which is attenuated with complementary emodin. 




(F4/80) expression with 5FU but an increase in M2-type macrophage marker MRC1 
(CD206) in mice receiving complementary emodin. M2-type macrophages are more anti-
inflammatory type macrophages and are characterized as resident ‘repair’ cells53. 
Interestingly, we see that M2-type macrophages are reduced acutely with complementary 
emodin. It is likely that this response is indicative of gut resilience during 5FU. Acutely, 
emodin may be working to reduce tissue damaging neutrophil infiltration to the gut and, 
in result, reduces the severity of mucositis leading to less activation of M2-type 
macrophages. Chronically, however, emodin may be benefiting the homeostatic balance 
that exists in the gut leading to an improved immune response through activation of M2-
type macrophages. This, in turn, would lead to maintained turnover of tissue and repair of 
5FU-induced damage to the intestinal villi. Interestingly, when we assay the colon for the 
same markers, we do not find increased MRC1 expression or reduced Ly6g expression 
with complementary emodin treatment. This indicates that despite an overall benefit to 
gastrointestinal physiology, it appears that emodin might be playing a site-specific role in 
the small intestine leading to the observed overall benefits to quality of life. 
The degree of mucositis varies through the GI system, we have previously shown 
that low dose 5FU can disrupt immune homeostasis and cause severe small intestine and 
colon inflammation132. In the present study, we show that there is no increase in colon 
macrophages with both acute and chronic 5FU treatment, but there is a pathological 
response causing increased Muc5ac expression. Muc5ac is transiently expressed in the 
colon and is increased in situations of dysplasia and colon dysfunction155. Here we show 
that chronic 5FU increases Muc5ac expression 7-fold and that emodin can reduce this 




expression. Interestingly, we did not see any increased inflammation or alterations in 
Muc5ac or OCLN in our acute phase analysis but a decrease in NOS2 expression when 
mice are treated chronically with 5FU and emodin. To our knowledge, there is no body of 
literature linking NOS2 expression with Muc5ac perturbations. However, we believe that 
5FU-induced overexpression of Muc5ac may be increasing tissue/location dependent 
increases in NOS2 which would cause gut barrier dysfunction and reduced gut integrity 
during 5FU treatment. This further suggests that initial exposure to 5FU might not 
elucidate these toxic mechanisms and that repeated 5FU exposure might be contributing 
to the chronic toxicities associated with chemotherapy. Where these findings require 
further investigation, we believe we have uncovered a significant mechanism of intestinal 
mucositis in the colon which can be attenuated with complementary emodin at a dose of 
40 mg/kg. 
The role of the microbiome has been implicated in many pathologies40,94,116-118,150. 
We have previously shown that 5FU can cause significant perturbations to the gut 
microbiota which might be exacerbating associated non-specific toxicities132. In the 
present study, we aimed to investigate the spatial arrangement and homeostatic 
environment of the colon. Swidsinski et. al. 2016152, describes the colon as a bacterial 
bioreactor that has evolutionarily been developed to house the commensal relationship 
between bacteria and humans. In taking with these ideals, we examined the spatial 
arrangement of bacteria within the colon using 16S rRNA FISH. We observe that 5FU, 
when given acutely, can cause significant perturbations to the bacterial environment. We 
observe pockets of significant invasion of bacteria to the mucous layer and the epithelia 




we observe a dose dependent reduction of this phenotype with emodin and a re-
established mucous barrier. Where emodin may not be altering the immune environment 
of the colon, we show here that significant alteration in bacterial spatial arrangement may 
have implications on the gut-immune system axis and may be contributing to the overall 
benefit to quality of life seen with our functional testing.  
We further aimed to investigate the hematopoietic benefits of emodin when given 
acutely. As a thymidylate synthase inhibitor, 5FU will target any actively proliferating 
tissue. It has been well established that 5FU causes significant lymphocytopenia and 
anemia when given acutely and chronically27,30,36. We investigated the inflammatory 
status of the bone marrow via flow cytometry and found that despite systemic cytopenia, 
there was an increase in total macrophages counts in the bone marrow. This indicating 
that local inflammation might be present in the bone marrow leading to exacerbated 
effects of 5FU toxicity. Interestingly, we show that a 40 mg/kg dose of emodin does not 
ameliorate the total macrophage count in the bone marrow but may reduce CD11c 
expressing M1-type macrophages. This reduction in M1-type macrophages may signify 
the mechanism of emodin in ameliorating the toxicities associated with 5FU. Previous 
investigations have shown macrophages specific ‘depolarizing’ effects of emodin in-
vitro80, a mechanism that may be occurring in the bone marrow with 5FU treatment in-
vivo. To further investigate the mechanism of emodin, we assayed the expression of the 
P2X7 receptor in the bone marrow. Interestingly, we did not find similar trends to CD11c 
expression. However, it is important to note that despite no difference in protein 
expression, emodin might be reducing activity of this Ca2+ ATPase receptor. Further 




to these findings, we also show that 40 mg/kg emodin is sufficient to cause increased 
percentage of S phase and G2/M phase cells according to Ki67/PI staining. This provides 
further evidence that emodin may be acting directly on the hematopoietic system to 
ameliorate 5FU-induced cytopenia. Further investigations on specific types of myeloid 
precursor cells would be needed to find specific mechanisms associated with the benefits 
of complementary emodin.  
In summary, we show here that natural anthraquinone emodin is a safe and 
effective complementary therapeutic which can be used to ameliorate the toxic side-
effects of 5FU both acutely and chronically. We report improved quality of life measures 
through reduced pain sensitivity, improved grip strength, and reduced fatigability. We 
show improved gut resilience to 5FU-induced mucositis through reduced Ly6g 
expression and a M2-type macrophage dependent maintenance of gut homeostasis. This 
was complemented by a reduction of perturbations to gut bacterial spatial arrangement 
and bacterial invasion to crypts within the proximal and distal colon. Finally, we report a 
potential mechanism of emodin which might reduce bone marrow inflammation and 
reduce systemic lymphocytopenia. Despite the benefits described here, further studies are 
necessary to determine the exact mechanisms of emodin before moving to clinically 








5.6 Figures & Legends 
 
Figure 5.1. Complementary emodin improves survival and quality of life during a 3-
cycle regimen of 5FU. A. Study design. B. Relative change in body weight measured as 
percent (%) from baseline. * indicates statistical significance at indicated time point from 
two-way ANOVA between 5FU + Emodin and 5FU alone. C. Percent survival. D. Pain 
threshold measured in grams (gr). 1 gr was maximal pressure tested using VonFrey 
Filaments. E. Pain threshold measured as a sum of scores during VonFrey filament test. 
F. Absolute grip strength measured in Newtons (N). G. Relative grip strength measured 
as Newtons per kilogram (N/Kg) H. Percent (%) performance change in run-to-fatigue 
test from pre-5FU treatment to post-5FU treatment. Groups not containing the same 








Table 5.1. The effect of chronic 5FU and emodin on major organs. Liver, spleen, epididymal fat, mesenteric fat, and colon length 
weights at euthanization. Groups not containing the same letters (a, b, ab) indicate statistical significance between groups (p < 0.05) 
from two-way ANOVA, n = 5–20/group. 
Group Liver (mg) Spleen (mg) 
Mesenteric 
Fat (mg) 






1143 ± 87.47 91.80 ± 13.86 165.0 ± 11.70 a 672.0 ± 99.77 a 72.75 ± 4.15 
Control + 
Emodin 
1166 ± 39.86 74.80 ± 7.42 146.2 ± 33.61 a 619.6 ± 86.16 a 79.20 ± 3.33 
5FU + 
Vehicle 
1216 ± 29.04 81.41 ± 5.94 123.1 ± 10.88 b 398.6 ± 17.77 b 78.12 ± 1.34 
5FU + 
Emodin 







Table 5.2. The effect of chronic 5FU and emodin on blood profile in mice. White blood cells (WBC), Lymphocytes (LYM), 
Monocytes (MON), Neutrophils (NEU), Neutrophil:Lymphocyte Ratio (NLR), Red Blood Cells (RBC), Hemoglobin (HGB), 
Hematocrit (HCT), and Platelets (PLT). Groups not containing the same letters (a-c) indicate statistical significance between groups 




































































































Figure 5.2. Emodin improves small intestine morphology and promotes M2-
macrphage polarization during 5FU treatment. A. Representative H&E images of 
small intestine biopsies at 4X. B. Measurement of villus length in small intestine, 
measurements are normalized to vehicle treated controls and represented as arbitrary 
units (A.U.). C. qPCR analysis of NOS2, TNFα, and MCP1 inflammatory cytokines. D. 
qPCR analysis of macrophage markers EMR1, MRC1, and ITGAX. E. qPCR analysis of 
neutrophil marker Ly6G. Data were normalized to vehicle treated controls and compared 
to five reference targets (B2M, TBP, HPRT, HMBS, and H2AFV), which were evaluated 
for expression stability using GeNorm. Groups not containing the same letters (a-c) 






Figure 5.3. Emodin does not reduce colon inflammation but may improve gut 
resilience during 5FU treatment. A. qPCR analysis of NOS2, TNFα, and MCP1 
inflammatory cytokines. B. qPCR analysis of macrophage markers EMR1, MRC1, and 
ITGAX. C. qPCR analysis of neutrophil marker Ly6G. D. qPCR analysis of gut health 
markers OCLN, Muc5ac, and Muc2. E. Representative H&E and Alcian Blue images of 
colon biopsies at 4X, insets are 20X. Data were normalized to vehicle treated controls 
and compared to five reference targets (B2M, TBP, HPRT, HMBS, and H2AFV), which 
were evaluated for expression stability using GeNorm. Groups not containing the same 








Figure 5.4. Emodin benefits quality of life during a single cycle 5FU treatment. A. 
Study design. B. Relative change in body weight measured as percent (%) from baseline 
in male mice. C. Relative change in body weight measured as percent (%) from baseline 
in male mice. *,#, and $ indicate statistical significance (p<0.05) between 20 mg/kg, 40 
mg/kg, and 80 mg/kg groups, respectively, compared to vehicle treated controls from 
one-way ANOVA at each time point, n=25/group. D. Pain threshold measured in grams 
(gr). 1 gr was maximal pressure tested using VonFrey Filaments. E. Pain threshold 
measured as a sum of scores during VonFrey filament test. F. Absolute grip strength 
measured in Newtons (N). G. Relative grip strength measured as Newtons per kilogram 
(N/Kg) H. Percent (%) performance change in run-to-fatigue test from pre-5FU treatment 
to post-5FU treatment. * indicates statistical significance between groups (p < 0.05) from 








Table 5.3. The effect of acute 5FU and emodin on major organs. Liver, spleen, epididymal fat, mesenteric fat, and colon length 
weights at euthanization. Groups not containing the same letters (a, b, ab) indicate statistical significance between groups (p < 0.05) 
from one-way ANOVA, n = 5–20/group.  









1148 ± 29.30 59.5 ± 1.34 a 229 ± 17.20 396 ± 27.80 7.50 ± 0.10 
Male 
5FU+20mg/kg 
1140 ± 47.20 66.2 ± 1.64 b 201 ± 12.20 368 ± 21.10 7.75 ± 0.10 
Male 
5FU+40mg/kg 
1253 ± 32.00 62.6 ± 1.36 a 235 ± 19.40 403 ± 27.00 7.94 ± 0.09 
Male 
5FU+80mg/kg 
1177 ± 46.40 62.3 ± 1.75 a 202 ± 11.80 355 ± 20.90 7.79 ± 0.11 
Female 
5FU+Vehicle 
1105 ± 39.50 60.6 ± 1.49 202 ± 21.60 221 ± 26.20 7.63 ± 0.12 
Female 
5FU+20mg/kg 
1101 ± 39.90 60.9 ± 1.24 180 ± 17.60 266 ± 28.8 7.59 ± 0.13 
Female 
5FU+40mg/kg 
1147 ± 50.60 63.1 ± 2.54 200 ± 22.00 234 ± 21.40 7.66 ± 0.10 
Female 
5FU+80mg/kg 








Table 5.4. The effect of acute 5FU and emodin on blood profile in male and female mice. White blood cells (WBC), Lymphocytes 
(LYM), Monocytes (MON), Neutrophils (NEU), Neutrophil:Lymphocyte Ratio (NLR), Red Blood Cells (RBC), Hemoglobin (HGB), 
Hematocrit (HCT), and Platelets (PLT). Groups not containing the same letters (a-c) indicate statistical significance between groups 























































































































































































Figure 5.5. Emodin protects small intestine morphology and reduces neutrophil and 
M2-macrphage expression during 5FU treatment. A. Representative H&E images of 
small intestine biopsies at 4X. B. Measurement of villus length in small intestine, 
measurements are normalized to vehicle treated controls and represented as arbitrary 
units (A.U.). C. qPCR analysis of NOS2, TNFα, MCP1, and IL10 inflammatory 
cytokines. D. qPCR analysis of macrophage markers EMR1, MRC1, and ITGAX. E. 
qPCR analysis of neutrophil marker Ly6G. Data were normalized to vehicle treated 
controls and compared to five reference targets (B2M, TBP, HPRT, HMBS, and 
H2AFV), which were evaluated for expression stability using GeNorm. Groups not 
containing the same letters (a-c) indicates statistical significance between groups 





Figure 5.6. Emodin does not reduce colon inflammation acutely but may improve 
gut microbial spatial arrangement during 5FU treatment. A. qPCR analysis of NOS2, 
TNFα, MCP1, and IL10 inflammatory cytokines. B. qPCR analysis of macrophage 
markers EMR1, MRC1, and ITGAX. C. qPCR analysis of neutrophil marker Ly6G. D. 
qPCR analysis of gut health markers OCLN, Muc5ac, and Muc2. E. Representative 16S 
rRNA FISH images hybridized with EUB338 probe in proximal and distal colons. 
Images are at 20X. Arrows indicate invasion of bacteria to crypts and mucus layer. Data 
were normalized to vehicle treated controls and compared to five reference targets (B2M, 
TBP, HPRT, HMBS, and H2AFV), which were evaluated for expression stability using 
GeNorm. Groups not containing the same letters (a-c) indicates statistical significance 





Figure 5.7. 5FU causes local bone marrow inflammation which may be ameliorated 
acutely with emodin. A. Representative flow plots of bone marrow isolates indicating 
relative macrophage content (CD11b+F4/80+). B. Counted events of total macrophages 
per 10000 events collected. C. Representative western blots of CD11c, P2X7, and TNFα 
and amido black staining of bone marrow protein extracts. 10 μg of protein was added to 
each well. Healthy whole mouse brain was used to identify P2X7+ control. D-F. 
Quantification of western blots for (D) CD11c, (E) P2X7 Receptor, and (F) TNFα. Data 
were normalized to vehicle treated controls. All western blots were normalized to amido 
black (total protein) content. Groups not containing the same letter (a-c) indicates 





Figure 5.8. Emodin increases S phase cells during 5FU treatment. A. Representative 
flow plots of bone marrow isolates stained with Ki67 and Propidium Iodide. B. 
Quantification of G1/G0, S, and G2/M phase cells as percent of 100,000 cells collected. 
Groups not containing the same letter (a-c) indicates statistical significance between 






ANTHRAQUINONE EMODIN REDUCES TUMOR BURDEN AND DECREASES PRO-























Emodin, a natural anthraquinone, has shown potential as an effective therapeutic agent in 
the treatment of many diseases including cancer. We sought to investigate the utility of 
emodin as a dietary agent used in the prevention of intestinal/colorectal cancer using the 
Apcmin/+ and AOM/DSS mouse models. Emodin was given 3x/week orally in both studies 
dissolved in pure propylene glycol. 16 Apcmin/+ mice were randomized into two groups; 
Apcmin/+ + Vehicle and Apcmin/+ + 80 mg/kg emodin. 60 C57BL/6 were randomized into 
three groups; Control (n=5), AOM/DSS+Vehicle (n=20), AOM/DSS+40 mg/kg (n=20), 
AOM/DSS+80 mg/kg (n=20). CRC was induced chemically by a single 10 mg/kg 
injection of azoxymethane (AOM) followed by two cycles (2% and 1%) of dextran 
sodium sulfate (DSS). Oral emodin treatment began at the initiation of DSS (Week 2). At 
the conclusion of both studies, emodin reduced total polyp count in Apcmin/+ mice treated 
with 80 mg/kg (p<0.05) and in both 40 mg/kg (p<0.05) and 80 mg/kg (p<0.05) 
AOM/DSS mice. We found that emodin reduces M2-type macrophages in the colonic 
lamina propria of AOM/DSS mice at both 40 mg/kg (p<0.05) and 80mg/kg (p<0.05) 
doses. Further we see that emodin reduces the pro-inflammatory environment of the bone 
marrow in AOM/DSS mice by reducing the number of M1-type macrophages (p<0.05). 
In evaluating bone protein expression; we observe that emodin reduces the expression of 
the P2X7 Receptor and the phosphorylation of STAT3 at Y705 with both 40 mg/kg and 
80 mg/kg doses. Taken together, we provide vital evidence of anti-tumorigenic and anti-
inflammatory potential for emodin to be used as an effective therapeutic in the prevention 






Colorectal cancer (CRC) is the third most common malignancy for men or 
women. Preventative interventions, such as exercise and improving dietary patterns  
has been shown to improve outcome. However, as CRC progresses, treatment options 
become more limited and some patients select a no treatment option. Therefore, there is a 
critical need to develop new preventative strategies that improve outcome and can be 
administered safely. 
 There has been a recent increase in the clinical utility of herb-derived compounds 
due to evidence of the anti-inflammatory properties of many of these compounds. 
Emodin is a trihydroxy-anthraquinone that is found in several Chinese herbs, including 
Rheum palmatum and Polygonum multiflorum. Emodin has been shown to attenuate the 
severity of multiple experimental disease models including arthritis, liver damage, 
atherosclerosis, myocardial ischemia, and cancer by reducing the inflammatory cascades 
associated with these conditions. The mechanism of action of emodin has yet to be 
discovered. However, an investigation by Jelassi et al 2013 suggested the P2X7 receptor 
as a potential target of emodin79. The P2X7 receptor is a Ca2+ channel receptor that it is 
found the central and peripheral nervous systems, in microglia, macrophages, and the 
retina.75 The P2X7 receptor has also been shown to serve as a pattern recognition 
receptor for extracellular ATP-mediated apoptotic cell death, regulation of receptor 
trafficking, mast cell degranulation, and inflammation.145,149 
 Macrophages have been demonstrated to represent the majority of immune cells 




in the blood and are recruited to the tumor by chemokines such as MCP-1 and TGFβ. 
Once recruited to the tissue, monocytes will mature into macrophages. It is generally 
understood that the recruitment of macrophages to the tumor contribute to the 
maintenance of the tumor microenvironment and exert pro-tumoral functions. Pro-
tumoral macrophages are characterized as M2-type macrophages, which are polarized 
from exposure to cytokines such as TGFβ and IL-10. The presence of M2-type 
macrophages in the tumor microenvironment have been shown to promote proliferation, 
invasion and metastasis, angiogenesis, and tissue remodeling. Further, high counts of 
tumor associated macrophages (TAMs) have been associated with poor prognosis and 
therapeutic outcome in CRC. Therefore, therapeutic interventions targeting TAMs and 
reducing the M2-type/M1-type ratio within the tumor microenvironment might contribute 
to improved survival and subsequent success of further therapeutic outcome.  
In the present study, we aimed to establish the efficacy of emodin as a 
preventative therapeutic in two models of colorectal/intestinal cancer. Giving emodin as a 
preventative therapeutic to at-risk patients might contribute to prolonged survival and 
improved immune-based therapeutic outcome. We utilized a chemically induced model 
of CRC (AOM/DSS) and a genetic model of intestinal cancer (Apcmin/+). In both models, 
mice develop tumors and present with chronic inflammation and anemia with increasing 
tumor burden. We utilized oral emodin administration at a dose of 40 mg/kg and 80 
mg/kg given orally 3x/week to observe the preventative effects in both these models. Our 
data indicate that emodin is able to reduce total polyp count and size in both models. 
Within the polyps of AOM/DSS mice, emodin reduced the presence of M2-type 






Male WT C57BL/6 and male Apcmin/+ mice were purchased from Jackson 
Laboratories (Bar Harbor, ME) and were cared for in the animal facility at the University 
of South Carolina. Mice were randomized upon arrival to the animal facility to prevent 
litter biases in microbiome data and were housed four-five per cage, maintained on a 
12:12-h light-dark cycle in a low-stress environment (220C, 50% humidity, low noise). 
Mice were kept in a room isolated from all other ongoing animal experiments and were 
only handled by the primary investigators. All mice were habituated to the AIN-76A diet 
prior to any interventions and were given food and water ad libitum through the course of 
the study. All methods were in accordance with the American Association for Laboratory 
Animal Science, and the Institutional Animal Care and Usage Committee of the 
University of South Carolina approved all experiments.  
6.3.2 Apcmin/+ protocol 
Fig 1A illustrates the protocol used to treat Apcmin/+ mice with emodin. Briefly, 16 
male Apcmin/+ mice randomly divided into 2 groups: Apcmin/+ + Vehicle (n=8) and 
Apcmin/+ + 80 mg/kg emodin (n=8). Mice arrived at the animal facility at the University of 
South Carolina at 4 weeks of age and were immediately placed n=4/cage and given AIN-
76A diet and drinking water ad libitum. After one week of habituation, mice were started 
on either Vehicle or emodin intervention. 
6.3.3 AOM/DSS protocol 
Fig 2A illustrates the protocol used to chemically induce colorectal cancer with 




randomly divided into four groups: Control + Vehicle (n=5), AOM/DSS + Vehicle 
(n=20), AOM/DSS + 40 mg/kg emodin (n=20), and AOM/DSS + 80 mg/kg emodin 
(n=20). At 12 wk of age (baseline week 0) mice received either an intraperitoneal 
injection of the carcinogen156, AOM (10 mg/kg) (Sigma, St. Louis, MO), diluted in PBS 
(AOM/DSS) or PBS alone (Control). Mice receiving the AOM injection were subjected 
to two cycles of DSS (36-50 kDa) (MP Biomedical, Solon, OH)-supplemented water at 
final concentrations of 2% and 1% at weeks 1 and 4, respectively. Each DSS cycle lasted 
for a 1-wk period.  
6.3.4 Symptom monitoring and score calculation 
Both Apcmin/+ and AOM/DSS mice underwent the same symptom monitoring and 
score calculation. Body weights and symptom scores were determined semi-weekly along 
with food and water measurements. Calculation of symptom score was performed as 
previously described94, taking into account percent body weight loss, stool consistency, 
and rectal bleeding. Briefly, fresh colonic evacuates were smeared onto “Hemoccult” 
tape to assess severity of diarrhea and were tested with developer (Beckman Coulter, 
Brea, CA) to assess rectal bleeding. Bleeding was scored; no positive detection of blood 
(0), detection of blood but not grossly visible (2), and gross visibility of blood (4). 
Diarrhea was scored; solid cylinder (0), soft cylinder and easily spreadable (2), and non-
cylindrical or runny (4). Body weight was calculated as percent body weight loss; 0-5% 
(0), 6-10% (1), 11-15% (2), 15-20% (3), 20-25% (4), and >25% (5). Scores of all three 






6.3.5 Emodin Preparation 
Emodin was purchased from Nanjing Zelang Medical Technology Co., Ltd, 
(Nanjing, China). Emodin was independently analyzed by the Mass Spectrometry Center 
at the University of South Carolina prior to the initiation of the experimental study. LC-
UV-MS and NMR was performed to confirm the purity of Emodin and the molecular 
structure. Emodin was delivered via oral gavage to mice using flexible plastic tubing oral 
gavage needles (Instech, #FTP-20). Emodin was prepared fresh in a 24mg/mL stock 
solution using pure propylene glycol (VWR) and mixed for 6-8 hours at room 
temperature protected from light prior to gavage. The 24mg/mL solution was used for 80 
mg/kg dosing and was used to prepare a 12mg/mL dilution for delivering the 40 mg/kg 
dose. Pure propylene glycol was used as a vehicle control in all experiments.  
6.3.6 Tissue collection 
Mice were euthanized 24 hr post final treatment with emodin and blood was 
collected from the inferior vena cava. Tissues were removed, weighted and immediately 
snap-frozen in liquid nitrogen and stored at -800C or fixed in 10% formalin until further 
analysis. The colon was carefully dissected distal to the cecum and proximal to the anus. 
Mesentery adipose tissue was removed with forceps. The colon was opened 
longitudinally, and polyps were counted and measured using a dissecting microscope. 
Colon length was measured using calipers. A subset of mice (n=4) was used for flow 
cytometry analysis in which the colon was placed in ice cold PBS until digestion. The 
remaining mice were used for qPCR analysis, polyps were removed from normal 
appearing tissue and both were snap frozen until further analysis. In a subset of mice, 




embedded in paraffin blocks. Within the same subset of mice, contralateral femurs and 
both tibias and fibulas were snap frozen in liquid nitrogen and stored at -800C until 
further analysis. 
6.3.7 Polyp counting and measurements 
At the conclusion of each study polyps were counted and measured using a 
dissecting microscope. For Apcmin/+ mice, whole colons and small intestines were opened 
longitudinally, laid flat on filter paper, and fixed in 10% formalin overnight. Tissues were 
then stained in 0.1% methylene blue to visualize polyps. Polyps were counted by the 
same investigator who was blinded to the treatments. Polyps were counted under a 
dissecting microscope, using forceps to pick through the intestinal villi and identify 
polyps. Polyps were categorized as small (< 1 mm), medium (1-2 mm), or large (> 2 
mm). After polyps were counted, intestinal sections were washed with 70% ethanol and 
embedded in paraffin for further analysis.  
 For AOM/DSS mice, freshly dissected colons were opened longitudinally, and 
polyps were counted and measured under a dissecting microscope. Polyps were counted 
to obtain total numbers and were also categorized as small (< 1 mm), medium (1-2 mm), 
or large (> 2 mm) as in Apcmin/+ mice. Further, colons were segmented into proximal, 
middle, and distal regions to record location of polyps. After polyps were counted, mice 
that were not used for flow cytometry had polyps removed from healthy appearing tissue 
and flash frozen in liquid nitrogen and stored at -80oC until further analysis. 
6.3.8 Blood Panel Analysis 
A complete blood panel analysis was performed using the VetScan HMT (Abaxis, 




Hb. Neutrophil/lymphocyte ratio (NLR) was calculated from obtained values. Briefly, 
whole blood was placed in an EDTA coated microtube and analyzed on the VetScan 
HMT according to the manufacturer’s instructions. 
6.3.9 Lymphocyte Isolation and Flow Cytometry 
Colons were removed and digested to obtain single cell suspensions using the 
Miltenyi Biotech Lamina Propria Dissociation Kit (#130-097-410). Bone marrow was 
taken from both femoral shafts by flushing with saline. Red blood cell lysis was 
performed with 20 second hypotonic solution (0.2% NaCl) treatment followed by 
hypertonic (1.6% NaCl) cessation. All isolates were passed through a 70 μm filter prior to 
antibody staining. Bone marrow and lamina propria isolates were stained with 
macrophage panel (CD11b – FITC, F4/80 – PE, CD206 - APC, CD11c – APC/Cy7, Ly6c 
– PerCP/Cy5.5, and CD45 – PE/Cy7). All antibodies were purchased from Biolegend 
(San Diego, CA). Cell suspensions were blocked with CD16/32 FC Block and staining 
was performed for 1hr at 40C. Lymphocytes were identified by gating for CD45+ cells. 
Active monocytes were identified as Ly6C+ cells. Data were acquired using a BD FACS 
Aria II cell sorter and analyzed by FlowJo v10.6.2. 
6.3.10 Gene expression 
Quantification of colonic expression of IFN-γ, TNFα, MCP-1, IL4, IL-6, IL-10, 
IL-1β, and P2RX7 were performed as previously described132. Briefly, RNA was 
extracted using TRIzol reagent (Life Technologies, GIBCO-BRL, Carlsbad, CA) and 
chloroform procedures. Because DSS has been shown to inhibit polymerase and reverse 
transcriptase activity, lithium chloride was used to purify the RNA as described in detail 




Agilent Bioanalyzer and determined to be of good quality based on A260/A280 values 
(>1. 8) prior to cDNA synthesis using QuantiTect Reverse Transcription kit (Qiagen 
205313). Quantitative RT-PCR analysis was carried out as per the manufacturer’s 
instructions (Applied Biosystems) using Taq-Man Gene Expression Assays. Data were 
normalized to vehicle treated controls and compared to five reference targets (B2M, TBP, 
HPRT, HMBS, and H2AFV), which were evaluated for expression stability using the 
GeNorm algorithm.98,99  
6.3.11 Histopathology 
Hematoxylin and eosin (H&E) staining of the bone tissue was performed as 
previously described132. All images were obtained using a Nikon E600. All 
histopathological analyses were performed by a board-certified pathologist blinded to the 
experimental conditions (I.C.).  
6.3.12 Bone Protein Isolation and Western Blot 
Frozen bone femurs, tibias, and fibulas were pulverized using a mortar and pestle 
while kept frozen at liquid nitrogen. Protein was purified by further homogenizing 
pulverized products in Mueller buffer containing protease inhibitor cocktail (Sigma 
Aldrich, St. Louis, MO). Total protein concentrations were determined by the Bradford 
method. Equal amounts of crude protein homogenates (20ug) were separated on hand-
casted SDS-polyacrylamide gels and electrophoretically transferred to a PVDF 
membrane using a Royal Genie Blotter (IDEA Scientific, Minneapolis, MN). Membranes 
were blocked for 1hr at room temperature with 5% non-fat milk in tris-buffered saline 
with 0.1% tween (TBST). Western blots were performed using primary antibodies P2X7 




#8690). An anti-rabbit (Cell signaling: #7047) IgG horseradish peroxidase conjugated 
secondary antibody was diluted 1:2000 in 5% milk-TBST and incubated for one hour at 
room temperature. An enhanced chemiluminescent substrate for detection of horseradish 
peroxidase (Thermo Scientific, Watham, MA) was used to visualize the antibody-antigen 
interaction. Autoradiography films were scanned, and blots were quantified using 
scientific imaging software ImageJ (NIH Bethesda, MD). After completion of the 
western blot, all membranes were stained with Amido black (VWR #AAJ66798-14) and 
the densitometry of each lane was calculated using ImageJ allowing for total protein 
normalization as previously described150. 
6.3.13 Statistical analyses 
All data were analyzed using commercial software (SigmaStat V3.5, SPSS, 
Chicago, IL). All outcomes were analyzed using a one-way ANOVA. A Student-
Newman-Keuls test was used for all post-hoc analyses. Survival curve analysis was 
conducted by Log-rank (Mantel-Cox) test. Any data that were not normally distributed or 
did not display equal variance were logarithmically transformed so that those criteria 
were met. Statistical significance was set with an alpha value of p<0.05. Data are 
presented as mean ± SEM. 
6.4 Results 
6.4.1 Emodin reduces polyp load in Apcmin/+ mice. 
There was no difference in body weight or calculated symptom score between 
Apcmin/+ mice treated with vehicle or 80 mg/kg emodin (Fig 6.1B,C). After 11 weeks of 
treatment, mice were euthanized, and the entire small intestines were stained with 




reduced total polyps in Apcmin/+ mice (Fig 6.1D; p<0.05). Further, emodin reduced the 
number of large (>2mm) and medium (1-2mm) sized polyps in the small intestine 
compared to vehicle treated controls (Fig 6.1E; p<0.05). There was no difference in small 
polyp count (<1mm) with emodin treatment (Fig 6.1E). 
6.4.2 Emodin does not alter organ weight but might improve immune health in Apcmin/+ 
mice. 
 Splenomegaly, anemia/cytopenia, and cachexia are hallmarks of advanced 
colorectal/intestinal cancer; therefore, reduced spleen size/weight, maintenance of healthy 
major organ weight, and improved circulating blood cell counts can indicate improved 
prognosis and a successful therapy. At the conclusion of the study, there was no 
detectable difference in liver, spleen, epididymal fat, or mesenteric fat pad weight (Table 
6.1) between vehicle and emodin treated mice. However, it is important to note that 
splenomegaly was achieved at this stage with both groups having average spleen weights 
greater than 200mg (Splenomegaly in mice is described as spleen weight >100mg). We 
also observe no difference small intestine or colon length (Table 6.1).  We performed a 
comprehensive blood panel analysis at the conclusion of the study. Although not 
statistically significant, we detected trending increases in total WBC count (p=0.149) and 
MON count (p=0.137) and a trending decrease in NLR (p=0.081) with emodin treatment 
(Table 2). Supplemental to these findings, there were no differences in LYM, NEU, RBC, 
HGB, HCT, or PLT counts with emodin treatment. 
6.4.3 Emodin reduces polyp load in AOM/DSS mice. 
All mice injected with AOM had significantly lower body weight loss compared 




vehicle only; 40 mg/kg of emodin yielded a smaller change in body weight at Week 4.5, 
and 80 mg/kg of emodin yielded a smaller change in body weight at Week 2, Week 4.5, 
and Week 5 (Fig 6.2AB; p<0.05). Within AOM/DSS mice treated with emodin there was 
a significantly smaller difference in body weight change between 40m/kg treatment and 
80 mg/kg treatment at Week 2 (Fig 6.2AB; p<0.05). There was a significantly lower 
symptom score calculation in 40 mg/kg and 80 mg/kg mice compared to vehicle treated 
mice at Week 5, Week 8, Week 9, and Week 10 (Fig 6.2AC; p<0.05). Survival was 
monitored through the course of the study. No mice expired due to complications from 
oral gavage treatment. Mice that were found dead in cage (FDIC) were counted as part of 
survival measurements. Although not statistically significant, through the course of study 
there were three deaths in the AOM/DSS + Vehicle group (17/20 survival), two deaths in 
the AOM/DSS + 40 mg/kg group (18/20 survival), and no deaths in the AOM/DSS + 80 
mg/kg group (20/20 survival) (Fig 6.2A,D).  
At the conclusion of the study colons were excised and polyps were counted 
under a dissecting microscope. There was a statistically significant difference between 
vehicle treated mice and mice treated with 40 mg/kg and 80 mg/kg (Fig 6.2E; p<0.05). 
Similar to our Apcmin/+ study, we categorized polyp counts by size. This revealed that 
both 40 mg/kg and 80 mg/kg emodin treatment significantly reduced medium sized (1-
2mm) (p<0.05) polyps but not small (<1mm) and large (>2mm) polyps (Fig 2F). The 
location of polyps within the colon has been shown to be important in the prognosis of 
colorectal cancer with more distal polyps indicating worse outcome. With this 
understanding we analyzed colon polyps in distal, middle, and proximal sections of the 




of distal or proximal polyps but does significantly reduce the presence of polyps in the 
middle portion of the colon (Fig 6.2G; p<0.05).  
6.4.4 Emodin improves liver weight in AOM/DSS mice but does associate with other 
organ weight changes. 
As described in the Apcmin/+ section; splenomegaly, anemia/cytopenia, and 
cachexia are hallmarks of advanced colorectal/intestinal cancer. We observed 
splenomegaly in all AOM/DSS mice (p<0.05) but this was not changed with emodin 
treatment (Table 6.3). Advanced CRC causes organ wasting which is observed 
experimentally through decreased major organ weight. We observe decreased epididymal 
fat and mesenteric fat weight in all AOM/DSS mice (Table 6.3; p<0.05). Interestingly we 
found that mice treated with 80 mg/kg emodin had lower epididymal fat pad weight 
compared to mice treated with 40 mg/kg emodin (p<0.05) but not vehicle treated controls 
(Table 6.3). There was no difference in mesenteric fat pad weight with emodin treatment 
(Table 6.3). Liver weight has also been shown to decrease with progressed CRC. We 
show that vehicle treated AOM/DSS mice had significantly lower liver weights on 
average (Table 6.3; p<0.05). Interestingly, although not statistically significant from 
vehicle treated AOM/DSS mice, we found that both 40 mg/kg and 80 mg/kg had 
increased liver weight compared to vehicle treated AOM/DSS mice which yielded a non-
statistically significant difference between emodin treated mice and healthy controls 
(Table 6.3).  
6.4.5 Emodin reduces pro-tumoral M2-macrophage count in colon lamina propria of 
AOM/DSS mice. 
Tumor associated macrophages are understood to play an essential role in the 




here that colon cancer increases total lamina propria macrophages (Gated from: 
CD45+/CD11b+/Ly6C+/F480+ cells). Compared to healthy controls, total macrophages 
were significantly greater in AOM/DSS mice treated with vehicle (Fig 6.3A,B; p<0.05). 
However, both 40 mg/kg and 80 mg/kg emodin treated mice did not have different total 
macrophages compared to vehicle treated AOM/DSS mice or healthy controls (Fig 
6.3A,B).  
We characterize CD11c expressing macrophages as M1-type macrophages and 
CD206 expressing macrophages as M2-type macrophages. Double expressing CD11c and 
CD206 macrophages are characterized as cells undergoing transition and not completely 
polarized M1- or M2-type macrophages. Further, cells not expressing CD11c or CD206 
are characterized as M0-type macrophages. As expected, we observed a significant 
increase in M2-type macrophages in the lamina propria of AOM/DSS mice treated with 
vehicle (Fig 6.3C,D; p<0.05). Both 40 mg/kg and 80 mg/kg emodin treatment decreased 
the abundance of CD206+ M2-type macrophages in the lamina propria (Fig 6.3C,D; 
p<0.05). There was a similar trend in CD11c-/CD206- M0-type macrophages (Fig 
6.3C,D; p<0.05), however, emodin treated mice did not have significantly lower M0-type 
macrophages compared to mice treated with vehicle (Fig 6.3C,D). There was no 
significant difference between groups in the presence of M1-type or transitioning 
macrophages (Fig 6.3C,D).  
M1-type macrophages are described as having anti-tumor properties and M2-type 
macrophages are described as having pro-tumor properties. To observe the general pro-
vs. anti-tumor niche we show the ratio of M2 vs. M1 macrophages within the lamina 




the ratio of M2/M1 macrophages which is ameliorated with 40 mg/kg and 80 mg/kg 
emodin treatment (Fig 6.3E; p<0.05).  
6.4.6 High dose emodin increases intra-polyp NOS2 expression. 
Polyps were removed from normal appearing tissue and RNA was extracted for 
inflammatory cytokine analysis via RT-PCR. Interestingly, despite reduced polyp load, 
mice treated with 40 mg/kg and 80 mg/kg emodin do not have differences in MCP1, IL6, 
TNFα, IL1β, IFNγ, IL10, IL4, or Tgfb1 (Fig 6.4). However, there was a significant 
increase in NOS2 expression of mice treated with 80 mg/kg emodin compared to vehicle 
treated controls and mice treated with 40 mg/kg emodin (Fig 6.4; p<0.05).  
6.4.7 Emodin does not ameliorate cancer associated anemia but does reduce bone 
marrow associated inflammation. 
Hematological perturbations are a significant hallmark of advanced CRC. We find 
here that all AOM/DSS mice had significantly greater monocyte counts compared to 
healthy controls (Table 6.4; p<0.05). Although not statistically significant, there was a 
trending decrease in monocyte counts (p=0.121) in 80 mg/kg mice compared to vehicle 
treated mice. Further, there was a significant decrease in RBC counts, HGB, and HCT in 
all AOM/DSS mice (p<0.05), but no difference was detected in mice treated with emodin 
(Table 6.4). In parallel, there was a significant decrease in PLT counts in AOM/DSS 
mice treated with vehicle and 40 mg/kg emodin (Table 6.4; p<0.05). Interestingly, 
AOM/DSS mice treated with 80 mg/kg emodin had increased PLT counts but was not 
statistically different from AOM/DSS mice treated with vehicle and 40 mg/kg or healthy 
controls (Table 6.4). There were no significant differences detected in WBC, LYM, 




Bone marrow macrophages were analyzed by flow cytometry from a subset of 
mice (n=2-4). Interestingly, mice treated with both 40 mg/kg and 80 mg/kg had 
significantly lower total macrophages (CD45+/CD11b+/Ly6C+/F480+ cells) compared to 
control and AOM/DSS alone (Fig 6.5A,B; p<0.05). Upon further analysis, we found that 
AOM/DSS mice had increased M1-type macrophages (CD11c+ cells) compared to 
control mice (Fig 6.5C,D; p<0.05). Interestingly, 40 mg/kg and 80 mg/kg emodin 
treatment reduced M1-type macrophage counts to similar values as control mice (Fig 
6.5C,D; p<0.05). In all AOM/DSS groups there was a significant decrease in M2-type 
(CD206+ cells) and M0 (CD11c-/CD206- cells) compared to controls (Fig 6.5C,D; 
p<0.05). There was no difference in CD11c+/CD206+ cells between all groups. We 
confirm this increase in M1-type macrophages by reporting a significant increase in the 
M1/M2 ratio of AOM/DSS mice compared to controls (Fig 6.5E; p<0.05). Interestingly, 
we show a dose response decrease in this ratio with increasing emodin treatment in which 
40 mg/kg emodin is not different from control or AOM/DSS alone but 80 mg/kg emodin 
is significantly lower (p<0.05) than AOM/DSS alone but not different than control (Fig 
6.5E). 
6.4.8 Emodin reduces expression of P2X7 and STAT3 signaling in bone tissue of 
AOM/DSS mice. 
To further observe the effects of emodin on bone and bone marrow health, we 
performed western blot analysis on frozen distal limb bones (femur, tibia, fibula). We 
observe a significant increase in P2X7 expression in AOM/DSS mice which was reduced 
with 40 mg/kg and 80 mg/kg emodin treatment (Fig 6.6A,B; p<0.05). STAT3 activation 
by phosphorylation at Y705 was significantly increased in AOM/DSS mice treated with 




6.6A,C; p<0.05). Interestingly, there was a significant increase in total STAT3 protein 
expression in all AOM/DSS mice which was not changed with emodin treatment but 
caused a significant decrease in the ratio of phospho/total STAT3 protein expression (Fig 
6.6A,C; p<0.05). We found a significant increase in phospho-ERK1/2 (T202/Y204) in all 
AOM/DSS mice (p<0.05) which was not changed with emodin treatment (Fig 6.6A,D; 
p<0.05). Further, we found no increase in total ERK1/2 expression which caused the 
phospho/total ERK1/2 ratio to have the same trends as the phospho-ERK1/2 expression 
(Fig 6.6A,D; p<0.05). We also detected a significant increase in phospho-P38 in 
AOM/DSS mice which trended towards a decrease in mice treated with 80mg/kg emodin 
(Fig 6.6A,E; p=0.117). There was no difference in the expression of total P38 which 
caused a similar trend in the phospho/total P38 ratio to have the same trends as the 
phospho-P38 expression (Fig 6.6A,E; p<0.05). 
6.5 Discussion 
There is overwhelming evidence supporting the use of natural compounds as 
preventative therapeutics in the treatment and prevention of colorectal cancer. We utilize 
two models (Apcmin/+ and AOM/DSS) of intestinal/colorectal cancer to examine the 
ability for dietary emodin to reduce tumor burden. In both models, we observe a 
significant decrease in colon polyps. Mice treated with emodin exhibited lower pro-
tumorigenic M2-type macrophages and had reduced the ratio of M2/M1 macrophages 
within the colon. Despite this decrease in M2-type macrophages, we did not observe any 
change in M2 associated cytokines IL10, IL4, and Tgfb1 within excised polyps. Further, 
we did not see changes in M1 associated cytokines IL6, TNFα, IL1β, and IFNγ, but we 




emodin. Emodin treatment also decreased total macrophage content within the bone 
marrow and reduced activation of M1-type macrophages compared to vehicle treated 
controls. Further analysis showed decreased P2X7 receptor expression in whole bone 
homogenates compared to vehicle treated AOM/DSS mice which presented with 
increased P2X7 expression compared to healthy controls. Taken together, these data 
suggest that emodin reduces pro-tumorigenic macrophages in the colon in the presence of 
colon cancer and can ameliorate the pro-inflammatory consequences of colorectal cancer 
by potentially targeting the P2X7 receptor. 
 The tumor microenvironment consists of a heterogenous population of immune 
cells that can act to reduce or promote tumor growth. TAMS are conditioned by the 
tumor microenvironment and exert pro-tumoral properties. Cytokines such as TGF-β, IL-
10, and IL-4 polarize monocytes recruited to the tumor microenvironment into M2-type 
macrophages which act to promote proliferation, invasion and metastasis, angiogenesis, 
and matrix deposition and remodeling. 157 TAMs have been shown to be directly 
associated with poor prognosis and therapeutic outcome in CRC.46,158 Emodin has been 
shown to act as a macrophage deactivator in-vitro, but has never been tested in-vivo. We 
show that emodin treatment decreases polyp count and size in both Apcmin/+ and 
AOM/DSS models of intestinal/colorectal cancer. This was partially explained by the 
reduced M2-type macrophage (CD206+) counts within the colons of AOM/DSS mice 
treated with emodin which resulted in a more balanced M2/M1 ratio of macrophages. 
Interestingly, this was not elicited by reduced expression of M2-promoting cytokines 
TGF-β, IL-10, and IL-4. The only change in cytokine expression detected was an increase 




promote M1-type macrophage polarization, but in the case of emodin, might be 
promoting depolarization of M2-type macrophages. A study by Iwanowycz et al 2016 
demonstrated that emodin promotes TNFα release from IL-4 induced M2-type 
macrophages in-vitro and depolarized M2-type macrophages. Although not the same 
mechanism, this suggests that emodin may be promoting M2-type macrophage 
depolarization by increasing M1-promoting cytokines in a tissue dependent manner. It is 
important to note that flow cytometry was performed in whole colons and not specifically 
polyps; therefore, this altered macrophage phenotype may not completely represent the 
tumor microenvironment.  
 Systemic inflammation is a hallmark characteristic of advanced colorectal cancer. 
Where wo do not see alterations in the blood profile of Apcmin/+ mice, we do see a 
trending decrease in circulating monocyte counts of AOM/DSS mice treated with 80 
mg/kg emodin, a value which is increased with advanced CRC as indicated by 
AOM/DSS mice treated with vehicle. This finding was complemented by reduced total 
macrophage counts and M1-type (CD11c+) macrophages in the bone marrow of mice 
treated with emodin. We identified that there were no gross histological indications of 
metastasis to the bone in AOM/DSS mice (Fig 6.7), and therefore the increase of M1-
type macrophages in the bone marrow is likely attributed to extraneous factors from CRC 
burden. However, this finding does not explain the complete benefits of emodin. The 
physiological effects of this change in macrophage count needs to also be considered. We 
observe a drastic decrease in total macrophage count in 40 mg/kg and 80 mg/kg emodin 
treated mice that falls well below healthy control mice (2,490 and 2,380 cells vs. 9,031 




this loss in macrophage count solely attributed to the reduction of CD11c+ (M1-type) 
macrophages. Beyond this finding, AOM/DSS mice presented with a drastic decrease in 
CD206+ (M2-type) macrophages and CD11c-/CD206- (M0-type) macrophages 
compared to healthy controls, which was not altered with emodin treatment. Therefore, it 
is imperative to provide further investigations into the physiological consequences of this 
drastic macrophage reduction in the bone marrow to understand the benefits associated 
with emodin treatment. 
The mechanism of action of emodin has yet to be discovered; however, it has 
been suggested that emodin may inhibit the activity and expression of the P2X7 receptor. 
The P2X7 receptor is found the central and peripheral nervous systems, in microglia, 
macrophages, and the retina75,149. The P2X7 receptor has also been shown to serve as a 
pattern recognition receptor for extracellular ATP-mediated apoptotic cell death, 
regulation of receptor trafficking, mast cell degranulation, and inflammation.145,149 We 
demonstrate in the present study that the expression of P2X7 receptor is increased in mice 
receiving AOM/DSS mice alone and decreased with increasing emodin dosage. Previous 
investigations have also showed that emodin can change the expression of P38 and 
ERK1/2 MAP Kinases, however these findings have been inconsistent.72,81-84 
Interestingly, although we see increased activation of P38 and ERK1/2 in the bone tissue 
of AOM/DSS mice, there is no change associated with emodin treatment. Emodin has 
also been shown to antagonize STAT3 signaling in-vitro. We confirm this mechanism in 
the bone marrow environment where we see that AOM/DSS mice treated with vehicle 
have increased STAT3 signaling, which was decreased with both 40 mg/kg and 80 mg/kg 




receptor would suggest that emodin is working to antagonize the P2X7 receptor, which is 
present on activated pro-inflammatory immune cells, and therefore contributes to the 
decreased expression of STAT3 signaling. However, this mechanism needs further 
investigation. 
Overall, our findings indicate the efficacy of emodin as a primary therapeutic to 
be used in the prevention of intestinal/colon-based cancers. The in-vivo mechanisms of 
emodin have proven to be elusive and have not been explored in the presence of CRC. 
We provide evidence that emodin can decrease pro-tumorigenic M2-type macrophages in 
the colon of AOM/DSS by increasing NOS2 expression within the polyp environment. 
We further demonstrate that emodin ameliorates the increased systemic monocyte counts 
and bone marrow M1-type macrophages likely by inhibiting the activity of the P2X7 
receptor. Although these findings do not definitively indicate the mechanism of action of 
emodin, we are the first to show evidence of anti-cancer and anti-inflammatory 
mechanisms of emodin in-vivo. These findings indicate that the benefit of emodin is 
highly tissue specific and warrants further investigation to confirm the mechanisms 
discussed here.  
In conclusion, the present study confirms that emodin is an effective primary 
therapeutic against the onset of genetic and chemically induced sporadic 
intestinal/colorectal cancer. We established that emodin reduces the M2-type pro-
tumorigenic macrophages within the colon of AOM/DSS mice. Further, we provide 
evidence that emodin may be acting to antagonize the P2X7 receptor within the bone 
tissue of with advanced CRC and decrease the activation of macrophages within the bone 




inflammatory and anti-cancer therapeutic and provide insight into the tissue specific 
mechanisms in which this novel drug might benefit longevity of patients at risk for 
chronic diseases. 
6.5 Figures and Legends 
Figure 6.1. 80 mg/kg emodin reduces polyp count in Apcmin/+ mice. A. Experimental 
design. B. Absolute body weight measurements during the experiment. C. Symptom 
score calculation during the experiment. D. Total polyp count in the entire small intestine. 









Table 6.1. Emodin does not alter organ weight in Apcmin/+ mice. Liver, spleen, epididymal fat, mesenteric fat, small intestine, and 
colon length weights at the conclusion of the study. Milligrams (mg), centimeters (cm). 
























613.7 ± 106.5 201.2 ± 20.7 32.9 ± 0.9 8.2 ± 0.1 
 
Table 6.2. Emodin does not alter hematological perturbations in Apcmin/+ mice. White blood cells (WBC), lymphocytes (LYM), 
monocytes (MON), neutrophils (NEU), neutrophil:lymphoctye ration (NLR), red blood cells (RBC), hemoglobin (HGB), hematocrit 
































































Figures 6.2. Emodin reduces polyp count in AOM/DSS mice. A. Experimental design. 
B. Percent (%) change in body weight from start of experiment (W1). C. Symptom score 
calculation. D. Survival curve. E. Total polyp count. F. Polyp size. G. Polyp location. # 
indicates statistical significance (p<0.05) between 40 mg/kg and vehicle treated mice, $ 
indicates statistical significance (p<0.05) between 80 mg/kg and vehicle treated mice, % 
indicates statistical significance (p<0.05) between 40 mg/kg and 80 mg/kg treated mice 







Table 6.3. Emodin treatment does not alter organ weight in AOM/DSS mice. Liver, spleen, epididymal fat, mesenteric fat, small 
intestine, and colon length weights at the conclusion of the study. Milligrams (mg), centimeters (cm), millimeters (mm). 



















































Figure 6.3. Emodin reduces pro-tumorigenic M2-type Macrophages within the 
AOM/DSS mouse colon lamina propria. A. Flow plots identifying mature macrophages 
(CD45+/CD11b+/Ly6C+/F480+ cells). B. Quantification of mature macrophages. C. 
Flow plots identifying M1-type (CD11c+) vs. M2-type (CD206+) macrophages. 
CD11c/CD206+ cells are considered transitioning cells and CD11c-/CD206- cells are 
considered M0-type macrophages. D. Quantification of M1, transition, M2, and M0 
macrophages. E. Ratio of M2/M1 macrophage counts.  Groups not containing the same 





Figure 6.4. 80 mg/kg emodin increases NOS2 expression within polyps of AOM/DSS 
mice. qPCR analysis of MCP-1, IL6, TNFα, IL1b, IFNg, NOS2, IL10, IL4, and Tgfb1 
genes. Data were normalized to vehicle treated controls and compared to five reference 
targets (B2M, TBP, HPRT, HMBS, and H2AFV), which were evaluated for expression 
stability using GeNorm. Groups not containing the same letters (a,b) indicates statistical 








Table 6.4. Emodin does not significantly alter hematological parameters within AOM/DSS mice. White blood cells (WBC), 
lymphocytes (LYM), monocytes (MON), neutrophils (NEU), neutrophil:lymphoctye ration (NLR), red blood cells (RBC), hemoglobin 



































































































Figure 6.5. Increasing dose of emodin reduces pro-inflammatory macrophage 
environment within the bone marrow of AOM/DSS mice. A. Flow plots identifying 
mature macrophages (CD45+/CD11b+/Ly6C+/F480+ cells). B. Quantification of mature 
macrophages. C. Flow plots identifying M1-type (CD11c+) vs. M2-type (CD206+) 
macrophages. CD11c/CD206+ cells are considered transitioning cells and CD11c-
/CD206- cells are considered M0-type macrophages. D. Quantification of M1, transition, 
M2, and M0 macrophages. E. Ratio of M1/M2 macrophage counts.  Groups not 
containing the same letter (a-c) indicates statistical significance between groups (p<0.05) 




Figure 6.6. Increasing dose of emodin reduces P2X7 receptor expression and STAT3 
phosphorylation/activation within the bone tissue of AOM/DSS mice. A. 
Representative western blots of P2X7, p-STAT3 (Y705), t-STAT3, p-ERK1/2 (), t-
ERK1/2, p-P38 (), t-P38, and amido black stain. B-E. Quantification of relative 
expression of B) P2X7 receptor, C) STAT3, D) ERK1/2, E) P38. Groups not containing 
the same letter (a-b) indicates statistical significance between groups (p<0.05) from one-
way ANOVA, n=2(control)-4(AOM/DSS)/group. 
6.6 Supplemental Material
 
Figure 6.7. No histological evidence of metastasis to bone in AOM/DSS mice. A. 










When used in the treatment of colorectal cancer, it is reported that 5 Fluorouracil 
has a 10-15% success rate. However, many patients present with multiple side effects 
associated with 5FU treatment, the most common including fatigue, loss of appetite, 
diarrhea, increased pain sensitivity, and anemia, all of which can lead to a reduced quality 
of life. Furthermore, 7.5% of cancer patients treated with chemotherapy die prematurely 
as a result of non-selective chemotherapy toxicity rather than the cancer itself. Natural 
anthraquinone emodin, found in several Chinese herbs, has been shown to attenuate the 
severity of multiple disease models including, arthritis, liver damage, atherosclerosis, and 
cancer and thus presents an excellent subject for use as a complementary therapeutic 
against 5FU toxicity and colorectal cancer. In the present document, I describe the pro-
inflammatory consequences of 5FU treatment and identify the gut microbiome as a 
potential target for amelioration of these symptoms. I further demonstrate the safety of 
emodin and show its efficacy as a complementary therapeutic to ameliorate the toxicities 
associated with 5FU. Finally, I show that emodin can be given as a preventative 
therapeutic against colorectal cancer and demonstrate in-vivo evidence for a potential 
mechanism of action of emodin to ameliorate inflammation and cancer cell survival.  
In Chapter 3 I present my first study describing the mechanisms of 5FU toxicity. 
In this study, I provide evidence showing 5FU causes significant perturbations to the 
hematopoietic and gastrointestinal systems which correlate to reduced quality of life, as 
demonstrated by reduced muscular strength and fatigability, all of which may be 
associated with perturbations in the gut microbiota. In cancer-free mice we show that 
5FU causes significant anemia and systemic lymphocytopenia and reduces the presence 




phenotype is likely controlled, in part, by alterations in the gut microbial 
microenvironment and may be a targetable system against 5FU-induced toxicities.  
Chapter 4 introduces the natural anthraquinone emodin (1,3,8-trihydroxy-6-
methylanthraquinone). It was imperative to establish the safety and pharmacodynamics of 
emodin in mice prior to initiating any interventional investigations. In Chapter 4 I show 
that emodin is poorly absorbed through the gut when given orally and when given 
systemically. I further demonstrate that emodin is rapidly metabolized to its active form 
(glucuronidated-emodin) within one hour of dosing and is cleared from the plasma within 
12 hours; but does not differ between peritoneal and oral routes of administration. 
However, I did uncover a significant difference in the bioavailability of emodin between 
male and female mice, in which female mice have significantly higher plasma emodin 
concentrations 1 hour after dosing. We also show that emodin does not cause any 
noticeable pathological indications in major organ systems when given through the diet 
continuously for 12 weeks at relative doses of 20 mg/kg, 40 mg/kg, and 80 mg/kg. This 
culminated into an understanding that emodin is a safe compound to be used in both male 
and female mice. 
The pairing of emodin with 5FU was the major focus of the novelty of this 
dissertation. In Chapter 5 I demonstrate that emodin improves survival and quality of life 
in mice both after an acute and chronic regime of 5FU. This primarily involved 
amelioration of pro-inflammatory cytokines TNFα and NOS2 within the gastrointestinal 
system leading us to suggest that emodin, while not well absorbed, is able to improve gut 
resilience during 5FU therapy. Where the cytokine profile of the colon did not mirror the 




preservation of colon integrity and reduced infiltration of bacteria to the crypts. This 
finding further illustrating the likelihood that the benefits of emodin are partially due to 
mechanisms involving benefits to the gut microbial environment. Taken together, we 
show that emodin treatment improves gut resilience during 5FU treatment. I further 
demonstrate that acutely, emodin reduces the severity of lymphocytopenia caused by 5FU 
and improves cell cycling in the bone marrow at a moderate dose (40 mg/kg). This 
finding was also complemented with evidence showing that 5FU causes infiltration of 
pro-inflammatory macrophages to the bone marrow which is partially ameliorated with a 
40 mg/kg dose of emodin. Together, Chapter 4 and 5 demonstrate the safety and efficacy 
of emodin as a complementary therapeutic and provide vital evidence for further 
investigation of emodin in models of chemotherapy toxicity.  
My final aim was to demonstrate that emodin can be used as primary therapeutic 
against the onset of colorectal cancer. In Chapter 6, I utilize two models of sporadic 
intestinal/colorectal cancer development (Apcmin/+ and AOM/DSS) to show that emodin 
reduces tumor burden by up to 50% when given as a dietary supplement. I focused my 
mechanistic investigations on the AOM/DSS mouse because it is a more translatable 
model to the development of colorectal cancers in humans. I show using flow cytometry 
that emodin diminishes the pro-tumorigenic niche in the colon by reducing the presence 
of M2-type macrophages. This was complemented by an increase in NOS2 expression 
within the polyps which is known to induce differentiation of anti-tumor M1-type 
macrophages. Stemming from my findings in Chapter 5, I analyzed the bone marrow 
inflammatory environment. I show that emodin significantly reduces the presence of total 




This was complemented by whole bone tissue reductions in the expression of the P2X7 
receptor and decreased activation of STAT3, giving further evidence to a specific 
mechanism of action of emodin. 
Taken together, the evidence presented in this document illustrate the utility of 
emodin as both a safe and effective complementary and primary therapeutic. Our data 
specifically shows essential evidence for the use of emodin as a complementary 
therapeutic to reduce 5FU induced toxicities. Additionally, we show evidence that 
emodin is an effective preventative therapeutic which can reduce tumor associated pro-
tumorigenic macrophages. Due to the increasing prevalence of CRC and the hampered 
clinical utility of 5FU chemotherapy, any potential complementary and alternative 
therapeutic that shows promise is important to the field of biomedicine. Although further 
studies are needed, the data presented here provide an essential first step towards bringing 










The data presented in this document pave the way for the next step in the 
progression of emodin to clinical trials. Where I have provided evidence on the efficacy 
of emodin, there is still much to learn mechanistically before the next steps are taken.  
In Chapter 3, we uncovered a significant role of the microbiome-immune axis 
involved in the non-specific toxicities associated with chemotherapy treatment. I am 
confident in this data but urge the expansion of these research designs into a cancer 
model. Utilizing FMT from 5FU treated AOM/DSS mice to observe the direct role of the 
microbiome in the presence of cancer will provide vital evidence towards the 
understanding the role of the microbiome-immune axis in the treatment and progression 
of colorectal cancer. 
In Chapters 4 and 5 I revealed promising evidence towards the clinical utility for 
emodin to be used as a complementary therapeutic to reduce the toxicities associated with 
5FU. However, as stated above, now these investigations need to be performed in cancer 
burdened mice in order to fully appreciate the clinical utility of emodin as a 
complementary therapeutic to ameliorate 5FU-induced toxicity.  
Finally, I am excited for the continuation of data gathering from the studies 
presented in Chapter 6. Our results indicate emodin is a safe and effective drug that can 
be used to prevent the onset of CRC in at-risk populations. I hope this in-vivo evidence 
provided can be utilized to return to in-vitro mechanistic investigations to further our 
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Specific Aim #1 will evaluate the effect of 5 fluorouracil chemotherapy on 
inflammation, functional parameters, and gut microbiota.  
Rationale: It has been previously established that 5FU chemotherapy causes 
severe adverse reactions and non-selective toxicities in cancer patients. Side effects 
include fatigue, loss of appetite, and diarrhea among others, all of which can lead to a 
reduced quality of life and premature death. Identifying strategies to increase efficacy and 
reduce toxicity of chemotherapy are of significant public health importance. Further, 5FU 
has been reported to cause disturbances in the gut microbiome, which can further 
influence the outcome of cancer therapy. Thus, the goal of this aim is to perform a 
comprehensive analysis of the physiological effects of 5FU therapy on inflammation, 
functional parameters, and gut microbiota. 
Experimental design for specific aim #1. Experiment 1 will contain two separate 
animal experiments to test the effect of 5FU on inflammation, functional parameters and 
gut microbiota. 
Primary Outcomes 
Functional Testing: Functional tests will be employed to evaluate the effect of 5FU on 
quality of life measures associated with non-specific toxicities attributed to 5FU toxicity. 
Inflammation: The inflammatory response to 5FU will be evaluated systemically and in 
major organs. 
Microbiome: The effect of 5FU on the gut microbiome and microbial ecosystem will be 






Polyp count and size: To confirm the anti-tumor response to 5FU we will evaluate colon 
polyp count and size after 5FU treatment.  
Specific Methodology Aim #1: 
Animals: At approximately 12 weeks of age, C57BL/6J mice were randomized into four 
groups: Control + Vehicle (n=10), Control + 5FU (n=10), AOM/DSS + Vehicle (n=15), 
and AOM/DSS + 5FU (n=15). Control mice received a 200μl dose of sterile PBS and 
AOM/DSS mice received a 10 mg/kg dose of AOM prepared in sterile PBS. After one 
week, AOM/DSS mice received 2% DSS drinking water ad libitum for one week 
followed by two weeks of recovery. After two weeks of recovery, AOM/DSS mice 
received 1% DSS drinking water ad libitum for one week followed by 2 weeks of 
recovery. After two weeks of recovery all groups were subjected to a battery of 
functional tests (peripheral nociception, grip strength, and run-to-fatigue) over the course 
of one week. After recovery from functional tests, all mice commenced a three-cycle 
regime of PBS or 5FU treatment; cycle 1: 40 mg/kg, cycle 2 and 3: 20 mg/kg via 
intraperitoneal injection. Each cycle consisted of 5 consecutive days of injection followed 
by 9 days of recovery. The treatment period lasted for 5 weeks and mice were sacrificed 
24 hr after the final injection of the third cycle.  
The second animal study contained two phases; a donor phase and a recipient 
phase. The donor phase contained two groups of C57BL/6J mice that received either 
Vehicle (n=5) or 40 mg/kg 5FU (n=5). Treatments lasted for five consecutive days and 




from mice via mucosal scrape and pellet collection from the anus to the cecum. Fecal 
matter was suspended in sterile 10% glycerol/PBS, allowed to settle by gravity for 10 
min, and aliquoted into daily requirements for delivery as fecal microbial transplants to 
their respective recipient groups. Recipient mice were separated into two groups; Vehicle 
FMT (n=10) and 5FU FMT (n=15). Prior to receiving fecal microbial transplantation, 
recipient mice initially received an antibiotic cocktail which consisted of: Vancomycin 
(50 mg/kg), Neomycin (100 mg/kg), Metronidazole (100 mg/kg), and Amphotericin-B (1 
mg/kg) via oral gavage and was supplemented with Ampicillin (1 mg/kg) in the drinking 
water given ad libitum. Antibiotic treatment lasted 10 days and mice were treated every 
12 hours with gavage boluses. A few days prior to cessation of antibiotic treatment, all 
mice were subjected to functional tests (grip strength and run-to-fatigue). 12 hours after 
final antibiotic treatment all mice began a 14-day FMT protocol which involved 150 μl of 
















Table A.1 Animal treatment groups for experiment #1. 
Strain Treatment Age (Weeks) N 
C57BL/6J Control + Vehicle 12 10 
C57BL/6J Control + 5FU 12 10 
C57BL/6J AOM/DSS + Vehicle 12 15 
C57BL/6J AOM/DSS + 5FU 12 15 
C57BL/6J Donor Vehicle 10 5 
C57BL/6J Donor 5FU 10 5 
C57BL/6J Recipient Vehicle 12 10 
C57BL/6J Recipient 5FU 12 15 
 
Table A.2 Animal clinical score guidelines. 
Body Weight Loss Fecal Hemoccult Diarrhea 
5% = 0 No blood = 0 Hard stool  
6-10% = 1 Positive test = 2 Soft stool = 2 
11-15% = 2 Visible blood = 4 Runny stool = 4 
16-20% = 3   
>20% = 4   
 
Functional Testing: 
Grip strength assessment 
All experimental mice were utilized to evaluate the effects of 5FU treatment on 
grip strength. Grip strength was measured prior to 5FU administration (week 8) and 




antibiotic treatment (week 0) and fecal transplantation (week 2) in experiment 2. The 
assay was performed as follows: Holding the mice by the tail, the front and back feet 
were allowed to grip a grate attached to a force transducer (Aurora Scientific, Ontario, 
Canada). Mice were then pulled from the grate, generating a force that was measured by 
the force transducer. Five measurements were taken consecutively, with at least 2 min 
rest between sets until a total of 15 measurements were taken for each mouse. The 
averages of the 15 measurements were used in the data analysis. Measurements were 
performed by the same investigator through the entirety of the study. Body weight was 
measured immediately prior to the administration of the grip strength test and used to 
calculate relative (N/kg) grip strength.  
Run-to-fatigue assessment 
To determine the effect of 5FU on fatigability, mice were subjected to a run-to-
fatigue test prior to 5FU administration (week 8) and during the recovery period of the 
second cycle (week 11) in experiment 1 and following antibiotic treatment (week 0) and 
fecal transplantation (week 2) in experiment 2. After 3 consecutive days of habituation 
during the night cycle, mice were subjected to the following run-to fatigue protocol: 15-
min warm-up, 20 m/min for 30 min, and 25 m/min thereafter until fatigue was reached. 
Fatigue was defined as the time at which mice were no longer able or willing to keep up 
with the treadmill despite hand prodding for at least 1 min. All treadmill tests were 
performed during the night cycle by the same investigators through the entirety of the 
study. 
Blood Panel Analysis: Blood panel analysis was performed using the VetScan HMT 




the inferior vena cava of mice that were overdosed with isoflurane. Tubes were mixed by 
inverting multiple times and stored on ice until transported to the School of Medicine for 
analysis. Tubes were places in the VetScan HMT apparatus, and the following counts 
were obtained: WBC, LYM, MON, NEU, PLT, RBC, Hct, and Hb. 
Neutrophil/Lymphocyte ratio (NLR) was calculated from obtained values. 
Polyp count: At tissue collection the colon was carefully dissected distal to the cecum and 
proximal to the anus. Mesentery adipose tissue was removed with forceps. The colon was 
opened longitudinally, and polyps were counted and measured using a dissecting 
microscope. 
RNA isolation and qPCR: Tissue samples were homogenized in 1 mL TRIzol reagent 
(Life Technologies, GIBCO-BRL, Carlsbad, CA) reagent using mechanical bead beating. 
After incubating for 5 min at room temperature, 200μl of ultrapure chloroform was 
added, samples were mixed, and then incubated at room temperature for 5 minutes. 
Samples were then centrifuged at 14,000g for 15 min at 40C and the resulting supernatant 
was removed and mixed with equal volume (~500 μl) ultrapure isopropanol to precipitate 
RNA. After precipitation at room temperature for 5 minutes, samples were centrifuged at 
14,000g for 15 min at 40C to pellet RNA. After pellets were obtained, the supernatant 
was discarded, and pellets were washed twice with 70% ultrapure ethanol. Samples were 
centrifuged at 7,500g for 6 min between washes. After washes, pellets were dried and 
dissolved in 100 μl ultrapure RNase free water. To further purify RNA, samples were 
incubated twice with 10 μl of 8M Lithium Chloride on ice for 1 hr and centrifuged at 
14,000g for 20 min between incubations. After the final incubation, pellets were 




Sodium Acetate and 200 μl ultrapure ethanol. After precipitation, samples were 
centrifuged at 14,000g for 20 min at 40C. After centrifugation, the supernatant was 
discarded and the resulting pellet was washed with 800 μl of 75% ultrapure ethanol and 
recentrifuged at 14,000g for 10 min at 40C. Pellets were then dried and dissolved in 80 μl 
ultrapure RNase free water. RNA sample quality and quantities were verified using a 
Nanodrop One Microvolume Spectrophotometer (Thermofisher, San Diego, CA) and 
determined to be of good quality based on A260/A280 values (>1. 8) prior to cDNA 
synthesis using QuantiTect Reverse Transcription kit (Qiagen 205313). Quantitative RT-
PCR analysis was carried out as per the manufacturer’s instructions (Applied 
Biosystems) using Taq-Man Gene Expression Assays. We utilized groups of 3 color gene 
expression assays consisting of FAM, VIC, and JUN fluorophores. Data were normalized 
to vehicle treated controls and compared to five reference targets (B2M, TBP, HPRT, 
HMBS, and H2AFV), which were evaluated for expression stability using the GeNorm 
algorithm.98,99  
Histopathology:  
Hematoxylin & Eosin staining (H&E) 
Transverse sections (~5μm) were cut from the paraffin embedded tissues on a 
rotary microtome. Cut tissues will be allowed to expand on a 400C -450C water bath and 
then attached to (+) charged saline coated microscope slides. Excess paraffin is removed 
by placing slides in a 650C oven for 1hr and then stored at 40C until staining. Sections 
were warmed to room temperature for 5-10 min. In cases of polyp analysis, tissue 
morphology was analyzed by observation and comparison to healthy tissue control 




xylene washes, 2x5min 100% EtOH, 1x3min 95% EtOH, and 1x3min 70% EtOH. 
Sections were then washed for 5min in dH2O, stained with filtered hematoxylin for 5min, 
then again washed 6x5 in dH2O. Sections were washed in acid alcohol mix (160mL 
100% EtOH, 1mL acetic acid, and volumed to 200mL with dH2O) for 6 dips then again 
washed in dH2O for 4 dips. Sections are then washed in Ammonia H2O (0.6mL 
Ammonium OH volumed to 200mL with dH2O) for 6 dips and then again washed in 
dH2O for 10min. The sections were then be stained with Eosin for 2min and dehydrated 
in the following alcohol progression; 1x2min 70% EtOH, 1x2min 95% EtOH, 2x3min 
100% EtOH, and 2x5min xylene. Sections were allowed to air dry for 30min and then 
mounted for viewing with Permount mounting media. Digital photographs will be taken 
from each section at 4x, 10x, 20x and 40x with a Nikon E600 Widefield Epifluorescence 
and Darkfield Microscopy System at the University of South Carolina School of 
Medicine, and morphology examined. All histopathological analyses were performed by 
a board-certified pathologist at the University of South Carolina School of Medicine (Dr. 
Ioulia Chatzistamou, M.D. Ph.D.). 
Immunohistochemistry: Transverse sections (~5μm) were cut from the paraffin 
embedded tissues on a rotary microtome. Cut tissues will be allowed to expand on a 400C 
-450C water bath and then attached to (+) charged saline coated microscope slides. 
Excess paraffin is removed by placing slides in a 650C oven for 1hr and then stored at 
40C until staining. Sections were warmed to room temperature for 5-10 min. Sections 
were deparaffinized using the following washing progression; 3x5min xylene washes, 
2x5min 100% EtOH, 1x3min 95% EtOH, 1x3min 70% EtOH, and finally washed for 




solution (Vector Labs) for 30 min at 950C and then cooled for 20min at room 
temperature. Sections were then washed in PBS for 5 min then blocked in 10% serum 
from the host species of the dedicated secondary antibody (i.e. Goat serum) in a humid 
chamber. After blocking, primary antibodies were diluted 1:100 in 5% goat serum and 
incubated overnight at 40C. The next day, sections were washed with PBS for 5 min and 
then incubated with an HRP-conjugated secondary antibody for 1 hour at room 
temperature in a humid chamber and finally washed in PBS. DAB solution was used to 
develop HRP-conjugated secondary antibodies. After DAB development, sections were 
washed with dH2O and counterstained with acidic Harris Hematoxylin solution for 30s -1 
min. After briefly washing in dH2O, sections were dehydrated quickly through 95% 
EtOH and 100% EtOH. Sections were allowed to air dry for 30min and then mounted for 
viewing with Permount mounting media. Immunohistochemistry stains were imaged at 
4x, 10x, 20x and 40x with a Nikon E600 Widefield Epifluorescence and Darkfield 
Microscopy System at the University of South Carolina School of Medicine.  
Fecal transplantation: For the fecal transplantation experiment (Fig. 1B), 35 mice were 
randomly divided into four groups: Donor Vehicle, Donor 5FU, Recipient Vehicle 
(Vehicle FMT), Recipient 5FU (5FU FMT) (n=5 per Donor group and n=10–15 per 
Recipient group). The Donor 5FU group was injected with 40 mg/kg 5FU for 5 
consecutive days as described earlier. All Donor mice were sacrificed 9 days after initial 
injection and a mucosal scrape was performed of the distal enteric tract (cecum to anus) 
to harvest the microbiota for fecal transplantation. Fecal materials were suspended in 
sterile 10% glycerol/PBS, allowed to settle by gravity for 10 min, and aliquoted into daily 




Reikvam et al. 201195. Recipient mice were pretreated with the following antibiotic 
cocktail every 12 h for 10 days prior to FMT: Vancomycin (50 mg/kg), Neomycin (100 
mg/kg), Metronidazole (100 mg/kg), and Amphotericin-B (1 mg/kg) via oral gavage 
supplemented with Ampicillin (1 mg/ml) in the drinking water given ad libitum. All 
antibiotics were purchased from ACROS Organics, New Jersey. FMT was administered 
via oral gavage for 14 days with 150 μl respective fecal suspension from PBS or 5FU 
injected mice. 
Microbiota sequencing and PICRUSt analysis: All Microbiome analysis and sequencing 
was performed by the University of North Carolina Microbiome Core. Fecal evacuates 
were collected from each mouse at the conclusion of the study and were chosen at 
random for 16S rRNA sequencing, at least one sample from each cage was used to 
prevent a cage effect in the data. A final n=5/group was obtained and used for 16S rRNA 
sequencing. DNA was isolated from fecal evacuates homogenized with bead-beating 
using the Qiagen Qiamp Fast DNA Stool Mini Kit (Qiagen #51604) and was used for 
16S rRNA gene targeted sequencing using the V4 region on an Illumina MiSeq 
sequencer100,101. Amplification of the 16S rRNA V4 hypervariable region was carried out 
using the 16S V4 515F forward (5′ TCGTCGGCAGCGTCAGATGTGTATAAGAGAC 
AGGTGCCAGCMGCCGCGGTAA 3′) and V4 806R reverse primer (5′ GTCTCGTGG 
GCTCGGAGATGTGTATAAGAGACAGGGACTACHVGGGTWTCTAAT 3′) with 
added Illumina adapter overhang nucleotide sequences. The PCR conditions used were 
initial denaturing step at 95 °C for 3 min, followed by a cycling of denaturing of 95 °C 
for 30 s, annealing at 55 °C for 30 s and a 30 s extension at 72 °C (25 cycles), a 5 min 




AMPure XP reagent (Beckman Coulter, Indianapolis, IN). In the next step each sample 
was amplified using a limited cycle PCR program, adding Illumina sequencing adapters 
and dual index barcodes (index 1(i7) and index 2(i5)) (Illumina, San Diego, CA) to the 
amplicon target. The thermal profile for the amplification of each sample had an initial 
denaturing step at 95 °C for 3 min, followed by a denaturing cycle of 95 °C for 30 s, 
annealing at 55 °C for 30 s and a 30 s extension at 72 °C (8 cycles), a 5 min extension at 
72 °C and a final hold at 4 °C. The final libraries were again purified using the AMPure 
XP reagent (Beckman Coulter), quantified and normalized prior to pooling. The DNA 
library pool was then denatured with NaOH, diluted with hybridization buffer and heat 
denatured before loading on the MiSeq reagent cartridge (Illumina) and on the MiSeq 
instrument (Illumina). 
Automated cluster generation and paired–end sequencing with dual reads were 
performed according to the manufacturer’s instructions. Multiplexed paired-end fastq 
files were produced from the sequencing results of the Illumina MiSeq using the Illumina 
software configure BclToFastq. The paired-end fastq files were joined into a single 
multiplexed, single-end fastq using the software tool fastq-join. Demultiplexing and 
quality filtering was performed on the joined results. Quality analysis reports were 
produced using the FastQC software. Bioinformatics analysis of bacterial 16S amplicon 
sequencing data was conducted using the Quantitative Insights Into Microbial Ecology 
(QIIME) software102. Operational taxonomic units (OTUs), an operational definition used 
to classify groups of closely related individuals103, were picked from the quality filtered 
results using pick_de_novo_otus.py. Chimeric sequences were detected and removed 




data set using the QIIME routines: alpha_rarefaction.py and beta_diversity_-
through_plots.py, respectively. Summary reports of taxonomic assignment by sample and 
all categories were produced using QIIME summarize_taxa_through_plots.py and 
summarize_otu_by_cat.py103. Samples were rarefied at 10,000 reads/sample. FastTree2 
(Price MN, Dehal PS, Arkin AP FastTree 2- approximately maximum-likelihood tress for 
large alignments) to build the phylogenetic tree. Finally, we used an open reference 
method for OTU picking. Phylogenetic Investigation of Communities by Reconstruction 
of Unobserved States (PICRUSt) was used to predict the functional gene content in the 
fecal microbiota based on taxonomy obtained from the Greengenes reference database. 
PICRUSt and LefSe were performed online in the Galaxy workflow framework. 
Specific Aim #2 will determine the safety and efficacy of dietary emodin on reducing 
toxicity of 5 fluorouracil chemotherapy. 
Rationale: Emodin is a natural anthraquinone found in various Chinese medicinal 
herbs. Recent evidence has demonstrated that emodin has many health benefits, including 
anti-inflammatory, anti-viral, and anti-bacterial properties, among others. In this aim, we 
will first characterize the safety and pharmacodynamics of emodin and then use emodin 
as a complementary therapeutic to attenuate the toxicities of 5FU. 
Experimental design for specific aim #2.  
Primary Outcomes 
Pharmacodynamics: Emodin will be measured in the plasma of male and female mice 
given a 20 mg/kg and 40 mg/kg dose at specific time points to determine the peak 




Histopathology and Toxicology: A broad tissue analysis will be performed to evaluate the 
systemic toxicity of emodin after 3 months of continuous feeding. 
Functional Testing: Functional tests will be employed to evaluate the effect of 5FU on 
quality of life measures associated with non-specific toxicities attributed to 5FU toxicity. 
Inflammation: The inflammatory response to 5FU will be evaluated systemically and in 
major organs. 
Secondary outcomes: 
Microbiome: The effect of 5FU on the gut microbiome and microbial ecosystem will be 
evaluated by 16S rRNA sequencing. 
Specific Methodology Aim #2: 
Animals: For experiment 1; we performed a subchronic (12 week) toxicity study using 3 
different doses of emodin (~20 mg/kg, 40 mg/kg, and 80 mg/kg) infused into the AIN-
76A diet of male and female mice (n=5/group/sex).  
For experiment 2; we evaluated chronic (n=5-20/group) and acute (n=20/group/sex) 
interventions to 5FU. 
Emodin Preparation: Emodin was purchased from Nanjing Zelang Medical Technology 
Co., Ltd, (Nanjing, China). Emodin was independently analyzed by the Mass 
Spectrometry Center at the University of South Carolina prior to the initiation of the 
experimental study. LC-UV-MS and NMR was performed to confirm the purity of 
Emodin and the molecular structure. Emodin was delivered intraperitoneally (I.P.) or by 




was made in a large batch, aliquoted, and stored at -200C until used for injections. It was 
subsequently diluted in PBS (1% DMSO) and administered to mice I.P. at doses of 20 
mg/kg (0.5mg/mL) or 40 mg/kg (1mg/mL). To deliver emodin P.O., we utilized a 20G 
30-mm flexible plastic tubal oral gavage needle (Instech, #FTP-20). To prevent aspiration 
of the emodin bolus, mice were briefly anesthetized with 2% isoflurane prior to gavage 
and held upright until consciousness was regained. Emodin was prepared fresh on the day 
of administration. Briefly, emodin was mixed in pure propylene glycol (VWR, #97061) 
for 6-8 hours at room temperature while protected from light. The emodin solution was 
delivered to mice at 20 mg/kg (6 mg/mL) and 40 mg/kg (12 mg/mL) doses. We used 1% 
DMSO in PBS (I.P.) or pure propylene glycol (P.O.) for vehicle controls. 
Specific Aim #2: will determine the safety and efficacy of dietary emodin on 
reducing toxicity of 5 fluorouracil chemotherapy. 
Table A.3 Animal treatment groups for experiment #1. 
Strain Treatment Age (Weeks) N 
C57BL/6J AIN Diet 10 5/sex 
C57BL/6J Low Emodin Diet 10 5/sex 
C57BL/6J Medium Emodin Diet 10 5/sex 











Table A.4 Animal treatment groups for experiment #2. 
Strain Treatment Age (Weeks) N 
C57BL/6J Control + Vehicle 10 5 
C57BL/6J Control + 40 mg/kg Emodin 10 5 
C57BL/6J 5FU + Vehicle 10 20 
C57BL/6J 5FU + 40 mg/kg Emodin 10 20 
C57BL/6J 5FU + Vehicle 10 20/sex 
C57BL/6J 5FU + 20 mg/kg 10 20/sex 
C57BL/6J 5FU + 40 mg/kg 10 20/sex 
C57BL/6J 5FU + 80 mg/kg 10 20/sex 
 
Solid Phase Extraction and LC-MS/MS Analysis: 
Whole blood was collected in EDTA coated tubes from the inferior vena cava and 
centrifuged at 4,000 RPM for 10 min. Plasma was aliquoted and stored at -200C until 
solid phase extractions. For free emodin quantification, 50 μl plasma was mixed with 
equal 0.2M sodium acetate buffer with 1% ascorbic acid (pH 5.0). For emodin 
glucuronide quantification, 50 μl plasma was mixed with half volume of 0.2M sodium 
acetate buffer with 1% ascorbic acid and 1000 units of β-glucuronidase (Millipore Sigma 
#G2174). D4-emodin (1 ng/μl) was used as an internal standard (Santa Cruz #218302). 
Both tubes were then incubated at 370C for 2hr. After incubation, the mixture was 
extracted with 600 μl ethyl acetate three times. The ethyl acetate layer was evaporated 
under N2 gas to dryness and reconstituted in 5% ammonia water. Solid phase extraction 
was performed using a vacuum manifold (Supelco #SU57250-U) with Oasis MCX 




After elution, the eluent was evaporated under N2 gas to dryness and reconstituted in 400 
μl 5% ammonia methanol.  
Emodin samples were analyzed and quantified by LC-MS/MS using electrospray 
ionization in negative ion mode. Chromatorgraphic separation was performed on a 
Waters Acquity UPLC system using a binary solvent gradient. Solvent A was water 
containing 0.1% formic acid and solvent B was methanol. The LC column was a Waters 
XBridge C18 reversed phase column (2.1mm X 100mm containing 3.5um particles) 
running at a flow rate of 0.2 mL/min. The solvent gradient started at 50%B, ramped to 
95%B over 10 minutes and was maintained at 95%B until 14 minutes. The gradient then 
returned to initial conditions. The mass spectrometer was a Waters Premier XE triple 
quadrupole instrument. Data was collected in multiple reaction monitoring (MRM) mode. 
Two precursor/product ion pairs were monitored; one pair for emodin (269 daltons > 225 
daltons) and one pair for the internal standard deuterium labeled emodin (273 daltons > 
229 daltons). According to the standard curve of emodin in 5% ammonia methanol, the 
concentration of emodin was calculated relative to the D4-emodin internal standard. Total 
emodin was measured from the tube containing the β-glucuronidase, free emodin was 
measured from the tube without β-glucuronidase, and glucuronidated emodin was 
calculated as the difference between total emodin and free emodin.  
Histopathology:  
Hematoxylin & Eosin staining (H&E) 






Alcian Blue staining 
Goblet cells were observed using Alcian blue staining. Transverse sections 
(~5μm) were cut from the paraffin embedded tissues on a rotary microtome. Cut tissues 
will be allowed to expand on a 400C -450C water bath and then attached to (+) charged 
saline coated microscope slides. Excess paraffin is removed by placing slides in a 650C 
oven for 1hr and then stored at 40C until staining. Sections were warmed to room 
temperature for 5-10 min. Sections were deparaffinized using the following washing 
progression; 3x5min xylene washes, 2x5min 100% EtOH, 1x3min 95% EtOH, 1x3min 
70% EtOH, and finally washed for 5min in dH2O. Sections were then stained with Alcian 
Blue solution (1% Alcian blue, 3% acetic acid) for 30 min and then washed with tap 
water, then dH2O. After washing, sections were counterstained with Nuclear Fast Red 
solution (0.1% nuclear fast red, 5% aluminum sulfate) for 5 minutes and then washed in 
tap water. Sections were then washed with dH2O and dehydrated quickly through 95% 
EtOH and 100% EtOH. Sections were allowed to air dry for 30min and then mounted for 
viewing with Permount mounting media. Digital photographs will be taken from each 
section at 4x, 10x, 20x and 40x with a Nikon E600 Widefield Epifluorescence and 
Darkfield Microscopy System at the University of South Carolina School of Medicine. 
Trichrome staining 
Transverse sections (~5μm) were cut from the paraffin embedded tissues on a 
rotary microtome. Cut tissues will be allowed to expand on a 400C -450C water bath and 
then attached to (+) charged saline coated microscope slides. Excess paraffin is removed 
by placing slides in a 650C oven for 1hr and then stored at 40C until staining. Sections 
were warmed to room temperature for 5-10 min. Sections were deparaffinized using the 




95% EtOH, 1x3min 70% EtOH, and finally washed for 5min in dH2O. Sections were 
then re-fixed in Bouin’s solution for 1 hr at 560C and then washed in dH2O for 10 min. 
Sections were then stained in Biebrich scarlet-acid fuchsin solution for 10-15 minutes and 
then washed in dH2O. Sections then were differentiated in phosphomolybdic-
phosphotungstic acid solution for 10-15 minutes. Sections were then placed directly 
(without rinsing) into aniline blue solution for 5-10 minutes, rinsed briefly in dH2O and 
differentiated in 1% acetic acid solution for 2-5 minutes. Sections were then washed with 
dH2O and dehydrated quickly through 95% EtOH and 100% EtOH. Sections were 
allowed to air dry for 30min and then mounted for viewing with Permount mounting 
media. Digital photographs will be taken from each section at 4x, 10x, 20x and 40x with 
a Nikon E600 Widefield Epifluorescence and Darkfield Microscopy System at the 
University of South Carolina School of Medicine, and morphology examined. All 
histopathological analyses were performed by a board-certified pathologist at the 
University of South Carolina School of Medicine (Dr. Ioulia Chatzistamou, M.D. Ph.D.). 
Plasma Cytokine Analysis: Plasma was analyzed for common markers of major organ 
toxicity/physiological impairment including ALT (Cayman Chemical, 700260) and 
creatinine (Cayman Chemical, 700460) and according to manufacturer’s instructions. 
Functional Testing: 
Peripheral nociception assessment 
All experimental mice were utilized to evaluate the effects of 5FU treatment on 
peripheral neuropathic nociception. After 3 consecutive days of habituation to the testing 
apparatus, right hind-paws were tested for neuropathic nociception by a single 
experimenter blinded to experimental conditions using Von Frey filaments (North Coast 




measurements, data was calculated as the paw withdrawal threshold in grams of force. 
Threshold was determined by 3 consecutive reactions to the stimulus. Measurements 
were performed by the same investigators through the entirety of the study (A. 
Sougiannis). Total stimuli were also summed to interpret total sensitivity to the touch 
test. 
Grip strength assessment 
Grip strength assessment was performed as described in Aim 1. 
Run-to-fatigue assessment 
Run-to-fatigue assessment was performed as described in Aim 1. 
Blood Panel Analysis: Blood panel analysis was performed as described in Aim 1. 
RNA isolation and qPCR: RNA isolation and qPCR were performed as described in Aim 
1. 
16S rRNA in-situ hybridization: Colons were excised whole from the rectum to the anus, 
opened longitudinally without disturbing opened tissue, and fixed for 24hrs in Carnoy’s 
solution (6:6:1 – Ethanol:Acetic Acid:Chloroform) then processed and embedded into 
paraffin blocks by standard techniques. 5μm section were placed on SuperFrost slides for 
FISH studies. The oligonucleotide probe (EUB338: 5’-GCTGCCTCCCGTAGGAGT-3’) 
was purchased from EuroFins synthesized with carbocyanite dye (Cy3) added to the 5’-
end. Sections were deparaffinized and dehydrated with 4x3 min washes in xylene 
followed by 4x3 min washes in 100% EtOH. Bacterial cell walls were opened by 
washing sections in ultrapure chloroform for 15 min, air dried for 1 min, then put in a 
500C oven for 30 min. Hybridization buffer was prepared with 1% formamide and 
prewarmed before hybridizations. 2 mL preparations were as follows: 20μl, 1,580 μl 




incubated with EUB338 probe diluted 1:100 in buffer for 1 hr at 500C in a humid 
chamber. After incubation, samples were washed with dH2O and incubated for 5 min at 
room temperature with 1 μg/mL DAPI solution and washed again. Diluted hybridization 
buffer was used as a mounting media and imaged immediately using a Leica DM2500 
fluorescent microscope.  
Western Blotting: Whole cell protein extracts were obtained by homogenizing bone 
marrow isolates in 300μl Mueller Buffer. Homogenates were centrifuged at 14,000 RPM 
for 15 min and then supernatants were aliquoted to new microcentrifuge tubes. Total 
protein per μl was quantified using the Bradford method. Tissue homogenates were 
separated on had casted 10-12% SDS-PAGE gels and transferred to nitrocellulose 
membranes. The gels are transferred to nitrocellulose membranes for 1hr at 12V in room 
temperature transfer buffer. After transfer, membranes were washed with dH2O and 
stained with ponceau S to ensure equal loading and proper transfer. Membranes were 
then blocked with TBS with 0.1% Tween 20 and 5% non-fat milk (5% TBST) for 1 hr at 
room temperature and then placed in primary antibody at dilutions of 1:600-1:1000 
overnight at 40C. The next day, after 3x10 min wash with TBST, secondary anti-rabbit 
IgG-conjugated secondary antibodies were incubated with the membranes at 1:2000 for 1 
hr in 5% TBST at room temperature. Enhanced chemiluminescence was used to visualize 
the antibody-antigen interactions and develop the blot using autoradiography. 
Autoradiographs were scanned to digital files and were analyzed by measuring the 
integrated optical density of each band using Image J software (NIH, Bethesda, MD). 




determined by quantification of each lane after membranes were stained with Amido 
Black solution and scanned to digital files.  
Flow Cytometry: Flow cytometry was performed using the BD FACS ARIA II machine 
located and operated by the UofSC School of Medicine Instrument Resource Facility. 
Bone marrow was flushed from both left and right femurs of mice using PBS and passed 
through 70μm cell strainers. An aliquot of cells was fixed in 70% EtOH for 24hr at-200C 
prior to staining with Ki67 and Propidium Iodide (PI) for cell cycle analysis. Remaining 
unfixed cells were resuspended in flow buffer (PBS with 5% FBS) and blocked with FC 
block (anti-CD16/CD32) for 30min at 40C. After blocking cells were stained with 
macrophage panel (CD11b – FITC, F4/80 – PE, and CD45 – PE/Cy7) for 1hr at 40C. 
Cells were then washed twice with sterile PBS and then resuspended in 1mL PBS for 
flow cytometric analysis. Analysis was performed using FlowJo_v10.6.2 software by 
identifying CD45+ immune cells, then gating for CD11b+ monocytes and F4/80+ to 
identify double positive cells as mature macrophages.  
Specific Aim #3 will determine the efficacy of dietary emodin on preventing 
colorectal cancer. 
Rationale: There is emerging evidence that emodin may have anti-tumor 
properties. We will use the AOM/DSS and Apcmin/+ models of colorectal cancer to 
investigate the potential for emodin to be administered as a preventative agent to patients 
at risk for developing colorectal cancer.   
Experimental design for specific aim #3. Aim 3 will contain two separate animal 
experiments to test the efficacy of emodin as a preventative agent against the 





Polyp Count: The total polyp number will be evaluated. 
Inflammation: The inflammatory response to 5FU will be evaluated systemically and in 
major organs. 
Secondary outcomes: 
Microbiome: The effect of emodin on the gut microbiome and microbial ecosystem will 
be evaluated by 16S rRNA sequencing. 
Specific Methodology Aim #3: 
Animals: Apcmin/+ mice were purchased from Jackson Laboratories at 4 weeks of age and 
were habituated to AIN-76A diet for 1 week prior to the start of the experiment. At 5 
weeks of age mice were randomized into two groups: Apcmin/+ + Vehicle (n=8) and 
Apcmin/+ + 80 mg/kg emodin (n=8). Mice were euthanized at 16 weeks of age and tissues 
were collected. For chemical induction of CRC (AOM/DSS model) C57BL/6J mice from 
Jackson Laboratories were randomized into four groups at approximately 12 week of age: 
Control (n=5), AOM/DSS + Vehicle (n=20), AOM/DSS + 40 mg/kg emodin (n=20), and 
AOM/DSS + 80 mg/kg emodin (n=20). Control mice received a 200μl dose of sterile 
PBS and AOM/DSS mice received a 10 mg/kg dose of AOM prepared in sterile PBS. 
After one week, AOM/DSS mice received 2% DSS drinking water ad libitum for one 
week followed by two weeks of recovery. After two weeks of recovery, AOM/DSS mice 




recovery. Mice were euthanized after 12 weeks of treatment and tissues were collected. 
Symptom scores were determined using the same method as in Aim 1. 
Emodin Preparation: 
Emodin was prepared as described in Aim 2 and administered orally. 
Specific Aim #3: will determine the efficacy of dietary emodin on preventing 
colorectal cancer. 
Table A.4 Animal treatment groups for experiment #2. 
Strain Treatment Age (Weeks) N 
C57BL/6J Control + Vehicle 10 5 
C57BL/6J AOM/DSS + Vehicle 10 20 
C57BL/6J AOM/DSS + 40 mg/kg Emodin 10 20 
C57BL/6J AOM/DSS + 80 mg/kg Emodin 10 20 
Apcmin/+ Vehicle 4 8 
Apcmin/+ 80 mg/kg Emodin 4 8 
 
Genotyping: All Apcmin/+ mice were genotyped using a tail snip and DNA PCR. At 4-5 
weeks of age; animals will be weaned, numbered, and a small tail snip (~1-2mm) 
collected. The tail snip is digested in 200μL of tail digest buffer and 5μL of proteinase K. 
Tails are incubated overnight in a water bath set at 55OC. After incubation, samples are 
heat shocked at 95OC in a dri-bath for 10 minutes. Heterozygosity of the Apc gene will 
be determined via a PCR reaction (Apc forward 5' TGAGAAAGACAGAAGTTA 3', 




polyacrylamide gel and exposed to UV light. Presence of a band indicates heterozygosity 
of the Apc gene. 
Polyp count: Intestinal polyps from Apcmin/+ mice were counted by staining in methylene 
blue. Formalin fixed intestinal sections from all Apcmin/+ mice were rinsed in deionized 
water, briefly stained in 0.1 % methylene blue, and counted by the same investigator who 
was blinded to the treatments. Polyps from AOM/DSS mice were counted during surgical 
resection without methylene blue. Polyps were counted under a dissecting microscope, 
using forceps to pick through the villi and crypts to identify polyps. Polyps were 
categorized as small (< 1 mm), medium (1-2 mm), or large (> 2 mm). After polyps were 
counted, methylene blue stained intestinal sections were washed with 70% ethanol and 
embedded in paraffin for further analysis.  
Flow Cytometry: Flow cytometry was performed using the BD FACS ARIA II machine 
located and operated by the UofSC School of Medicine Instrument Resource Facility. 
Bone marrow was flushed from both left and right femurs of mice using PBS and passed 
through 70μm cell strainers. Cells were resuspended in flow buffer (PBS with 5% FBS) 
and blocked with FC block (anti-CD16/CD32) for 30min at 40C. Lamina propria was 
isolated from whole excised colons using the Miltenyi Biotech Lamina Propria 
Dissociation Kit, Mouse (Miltenyi# 130-097-410). After blocking, cells were stained 
with macrophage panel (CD11b – FITC, F4/80 – PE, CD206 - APC, CD11c – APC/Cy7, 
Ly6C – PerCP/Cy5.5, and CD45 – PE/Cy7) for 1hr at 40C. Cells were then washed twice 
with sterile PBS and then resuspended in 1mL PBS for flow cytometric analysis. 
Analysis was performed using FlowJo_v10.6.2 software by identifying CD45+ immune 




cells as mature macrophages. Mature macrophages were then gated and analyzed for 
CD11c and CD206 expression to identify M1- and M2-type macrophages, respectively. 
RNA isolation and qPCR: 
RNA isolation and qPCR were performed as described in Aim 1. 
Histopathology:  
Hematoxylin & Eosin staining (H&E) 
H&E staining was performed as described in Aim 1. 
Western Blotting: 










Principal Investigator: Alexander T. Sougiannis 
Re: 1 F31 AT009820-01 
Product Information: Emodin  
 
D. Refined Products 
D1. Name the supplier of the product. * 
 Nanjing Zelang Medical Technology Co., Ltd. 
D2. Present data on the characterization of the product (e.g., chemical profile or 
fingerprint) as thoroughly as the state of the science allows. 
a. Indicate the purity if the product is a single component. 
b. Provide concentration of major and minor components if the product is a 
mixture. 
c. Information from suppliers MUST be confirmed through independent 
analysis either by a third-party lab or by the investigator (if they have 
appropriate facilities and expertise). Provide conformational data (e.g. 
chromatograms and/or spectra) or a plan regarding how this will be 
obtained. 
Purity: Emodin is a single component with >98% purity. 
Independent verification: Nanjing Zelang Medical Technology Co., Ltd. will perform 
preliminary identification of Emodin sample using in-house LC-UV-MS techniques. 
Nanjing Zelang Medical Technology Co., Ltd. will provide a certificate of analysis 
(see Appendix, documents in Chinese and English) with identity and impurity test 
results and source information. Emodin will be independently analyzed by the Mass 
Spectrometry Center at the University of South Carolina prior to the initiation of any 
experimental study (see Appendix). LC-UV-MS and NMR will be performed to 
confirm the purity of Emodin and the molecular structure (see Appendix). All 
chemicals and reagents used for standardization at the University of South Carolina 




D3. Provide data on the analysis of the product for contaminants/impurities such as 
pesticides, heavy metals, and residual solvents. 
Product information: Nanjing Zelang Medical Technology Co., Ltd. follows the 
guidelines of the China Food and Drug Administration (CFDA) which includes 
testing of heavy metals, impurities, and other toxins (see Appendix). 
Independent verification: After receiving Emodin, I will send the Emodin powder to 
be tested for microbial aflatoxin, heavy metal, and pesticide presence to NP 
Analytical Laboratories (St. Louis, MO, USA). Microbial analysis will detect the 
presence of total microbial counts, yeast and most counts, gram-negative bacteria, E. 
coli, and salmonella. Emodin will also be tested for aflatoxin B1 presence. The 
presence of arsenic, cadmium, lead, and mercury heavy metals will be verified. 
Additionally, a pesticide screen will be performed. 
D4. Provide data on batch-to-batch reproducibility. These data may be required 
separately for the agent alone, the vehicle alone, and the final products as 
appropriate. 
I will use the same batch of Emodin for the entire study, thus I do not expect to 
have any problems with batch-to-batch reproducibility. In the case that I need a 
new batch of Emodin, special attention will be given to the lot number. Further, I 
will perform NMR and LC-UV-MS to confirm the purity and molecular structure 
of the new batch.  Data presented in the appendix indicates our streamlined 
ability to validate the Emodin extract (see NMR and MS appendix).  
D5. Present a plan to monitor stability of product samples from all batches used 
during the study. The plan should include: 
a. How you plan to store the test agents, vehicle, and/or final product 
b. What analyses will be conducted, the methods to be used, and how frequently 
and by whom the analyses will be done 
c. Investigator’s tolerances for chemical and/or biological variability, and what 
will be done if variability exceeds those limits. In addition, sufficient material 
must be retained from each batch to allow independent analysis, should 
NCCIH request samples. Samples should be maintained a minimum of 1 
year after all results arising from the study have been published.  
Storage: Emodin will be stored at -20 degrees Celsius as a dry powder once it arrives 
from the Nanjing Zelang Medical Technology Co., Ltd. Solutions of Emodin extracts 





Stability Testing: Before conducting a new experiment, or every 3 months, 27 mg/ml 
of Emodin powder will be dissolved in DMSO, aliquoted, and stored at -20 degrees 
Celsius. An aliquot will be used for Emodin stability testing (anti-inflammatory 
capacity) against a freshly prepared aliquot. Remaining aliquots will be stored at -20 
degrees Celsius.  
After confirming the stability of Emodin using LC-UV-MS, I will verify the anti-
inflammatory capacity of Emodin utilizing freshly harvested bone marrow derived 
macrophages. Briefly, bone marrow derived macrophages will be harvested and 
allowed to grow in the presence of 15% L929 conditioned media for 7 days. Cells will 
be plated on a 12-well cell culture plate at a density of 0.5x106 cell/ well for 24 hours 
to allow for adherence. Then, cells will be treated with Emodin at 0, 50, 100, and 200 
μg/ml for 24 hours. After Emodin treatment, cells will be stimulated with LPS at 100 
ng/ml for 24 hours. Media and cells will be harvested and assayed for TNFα, IL-6, 
IL-1β, IFNγ, and CXCL2 RT-PCR assays. Results should show a dose-response of 
Emodin’s ability to decrease TNFα, IL-6, IL-1β, and IFNγ expression in bone marrow 
derived macrophages stimulated with LPS. CXCL2 expression will be used as a 
negative control, as Emodin does not change CXCL2 expression after LPS treatment. 
The PI, Alexander Sougiannis, will perform all stability and cell culture experiments 
(see attached paper from Fan laboratory (dissertation committee member)). 
Tolerances and Contingency for Variability: Emodin aliquots that show less than 
10% variability in anti-inflammatory capacity test will be used for experimental 
studies. If Emodin aliquots fail to reduce TNFα, IL-6, IL-1β, and IFNγ expression, 
shows greater than 10% variability, or does not show a dose response curve, these 
aliquots will not be used in any of the experiments and new Emodin aliquots will be 
analyzed prior to any experiments and a new LC-UV-MS fingerprint will be 
compared to the original chromatogram. In the event the Emodin fingerprint is not 
comparable to the original chromatogram, new Emodin will be ordered from the 
Nanjing Zelang Medical Technology Co., Ltd. and the stability protocols will be 
performed as described above prior to any experimentation.  
Voucher samples: We will store voucher specimens of Emodin, and any new orders 
of Emodin (2 x 100g). Emodin will be stored at -20 degrees Celsius as previously 
described. The raw material will be confirmed taxonomically by Nanjing Zelang 
Medical Technology Co., Ltd. A voucher specimen will be submitted to the University 
of South Carolina A.C. Moore Herbarium (http://herbarium.biol.sc.edu//). The A.C. 
Moore Herbarium at the University of South Carolina, founded in 1907, contains 
over 100,000 specimens making the herbarium the largest in the state of South 
Carolina. The majority of material stored is native to the Southeastern United States 




D6. Provide information relevant to the manufacturing process assuring reasonably 
consistent material suitable for scientific study (including process control, as well as 
chemical standardization of ingredients). 
a. Provide information on the formulation of the final product (e.g. excipients, 
solvents, buffers, chow/feed composition). 
b. Provide documentation to show product was manufactured under GMP 
guidelines. 
Final Product Formulation: Nanjing Zelang Medical Technology Co., Ltd. uses 
crude material from Rheum palmatum to extract Emodin. As described above 
(sections D2, D3, and D5), we will confirm the chemical fingerprint (LC-UV-MS and 
NMR) and characterize Emodin upon arrival to ensure we have received a purified 
compound. 
GMP guidelines: Nanjing Zelang Medical Technology Co., Ltd. follows the 
guidelines of the China Food and Drug Administration (CFDA). The Emodin extract 
to be used in our studies will be purchased from the Nanjing Zelang Medical 
Technology Co., Ltd. and will only be used in animal studies. The extract will be well 
characterized (see section D2, D3 and D5) to allow similar human studies to be 
performed in a GMP compliant laboratory in the future.  
D7. When the product is combined with a diet, a Certificate of Analysis and 
specifications for the vehicle will also be necessary to assure purity, consistency, 
absence of bioactive components and/or reproducibility of the vehicle. Furthermore, 
analysis of the formulated diet may be required to assess consistency, stability, etc., 
of the product in this matrix. 
Not applicable. Emodin will be given by oral gavage and will be prepared fresh 
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Immunity. 
Obtained from https://www.elsevier.com/about/our-business/policies/copyright#Author-
rights. 
